var title_f28_28_29120="P falciparum gametocyte";
var content_f28_28_29120=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Blood smear of falciparum malaria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Giemsa- stained thin smear of blood showing the characteristic banana-shaped gametocyte of Plasmodium falciparum (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen B Calderwood, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_28_29120=[""].join("\n");
var outline_f28_28_29120=null;
var title_f28_28_29121="Calculator: Child Pugh classification for severity of liver disease (SI units)";
var content_f28_28_29121=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"ChildPughScore_SI_form\" name=\"ChildPughScore_SI_form\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Child Pugh classification for severity of liver disease (SI units)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Encephalopathy",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"ChildPughScore_SI_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         None (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"ChildPughScore_SI_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Grade 1: Altered mood/confusion (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"ChildPughScore_SI_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Grade 2: Inappropriate behavior, impending stupor, somnolence (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"ChildPughScore_SI_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Grade 3: Markedly confused, stuporous but arousable (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"ChildPughScore_SI_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Grade 4: Comatose/unresponsive (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Ascites",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"ChildPughScore_SI_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Absent (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"ChildPughScore_SI_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Slight (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"ChildPughScore_SI_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Moderate (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Bilirubin",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc3\" onclick=\"ChildPughScore_SI_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         &lt; 34.2 mcmol/L (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc3\" onclick=\"ChildPughScore_SI_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         34.2-51.3 mcmol/L (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc3\" onclick=\"ChildPughScore_SI_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         &gt; 51.3 mcmol/L (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Albumin",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc4\" onclick=\"ChildPughScore_SI_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         &gt; 35 g/L (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc4\" onclick=\"ChildPughScore_SI_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         28-35 g/L (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc4\" onclick=\"ChildPughScore_SI_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         &lt; 28 g/L (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Prothrombin time prolongation",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc5\" onclick=\"ChildPughScore_SI_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Less than 4 seconds above control/INR &lt; 1.7 (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc5\" onclick=\"ChildPughScore_SI_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         4-6 seconds above control/INR 1.7-2.3 (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc5\" onclick=\"ChildPughScore_SI_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         More than 6 seconds above control/INR &gt; 2.3 (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontCCTabBold\">",
"     Total Criteria Point Count:",
"    </span>",
"    <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Child Pugh Score Interpretation",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"      <tr id=\"rr1_1\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         5-6 points:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Child class A",
"        </span>",
"       </td>",
"      </tr>",
"      <tr id=\"rr1_2\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         7-9 points:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Child class B",
"        </span>",
"       </td>",
"      </tr>",
"      <tr id=\"rr1_3\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         10-15 points:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Child class C",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"   <span class=\"medCalcFontOneBold\">",
"    Notes",
"   </span>",
"   <ul class=\"medCalcFontOne\">",
"    <li>",
"     In cases of Primary Biliary Cirrhosis,",
"     <b>",
"      Bilirubin",
"     </b>",
"     point values are sometimes considered differently:",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       17-68 mcmol/L --&gt; 1 point",
"      </li>",
"      <li>",
"       68-171 mcmol/L --&gt; 2 points",
"      </li>",
"      <li>",
"       &gt; 171 mcmol/L --&gt; 3 points",
"      </li>",
"     </ul>",
"    </li>",
"    <li>",
"     Please see appropriate UpToDate topic reviews for further information.",
"    </li>",
"   </ul>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"   <span class=\"medCalcFontRef\">",
"    <b>",
"     References",
"    </b>",
"   </span>",
"   <ol>",
"    <li>",
"     <span class=\"medCalcFontRef\">",
"      Pugh RN, Murray-Lyon IM, Dawson JL, et. al. Transection of the oesophagus for bleeding oesophageal varices.",
"      <i>",
"       Br J Surg",
"      </i>",
"      . 1973; 60:646.",
"     </span>",
"    </li>",
"    <li>",
"     <span class=\"medCalcFontRef\">",
"      Child CG, Turcotte JG. The Liver and Portal Hypertension.",
"      <i>",
"       Philadelphia, WB Saunders Co",
"      </i>",
"      . 1964.",
"     </span>",
"    </li>",
"    <li>",
"     <span class=\"medCalcFontRef\">",
"      Trey C, Burns DG, Saunders SJ. Treatment of hepatic coma by exchange blood transfusion.",
"      <i>",
"       NEJM",
"      </i>",
"      . 1966; 274:473.",
"     </span>",
"    </li>",
"   </ol>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    /* &lt;![CDATA[ */",
"",
";",
"ChildPughScore_SI_fx();",
"/* ]]&gt; */",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_28_29121=[" /* <![CDATA[ */",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function ChildPughScore_SI_fx() {",
"with(document.ChildPughScore_SI_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1[0].checked){",
"Score = Score + 1;",
"}",
"if (cc1[1].checked){",
"Score = Score + 2;",
"}",
"if (cc1[2].checked){",
"Score = Score + 2;",
"}",
"if (cc1[3].checked){",
"Score = Score + 3;",
"}",
"if (cc1[4].checked){",
"Score = Score + 3;",
"}",
"if (cc2[0].checked){",
"Score = Score + 1;",
"}",
"if (cc2[1].checked){",
"Score = Score + 2;",
"}",
"if (cc2[2].checked){",
"Score = Score + 3;",
"}",
"if (cc3[0].checked){",
"Score = Score + 1;",
"}",
"if (cc3[1].checked){",
"Score = Score + 2;",
"}",
"if (cc3[2].checked){",
"Score = Score + 3;",
"}",
"if (cc4[0].checked){",
"Score = Score + 1;",
"}",
"if (cc4[1].checked){",
"Score = Score + 2;",
"}",
"if (cc4[2].checked){",
"Score = Score + 3;",
"}",
"if (cc5[0].checked){",
"Score = Score + 1;",
"}",
"if (cc5[1].checked){",
"Score = Score + 2;",
"}",
"if (cc5[2].checked){",
"Score = Score + 3;",
"}",
"cctotal.value = Score;",
"",
"if (doCalc){",
"",
"rrclr();",
"if ((Score >= 5) && (Score <= 6)){ document.getElementById('rr1_1').bgColor = \"#cccccc\";",
"}",
"if ((Score >= 7) && (Score <= 9)){ document.getElementById('rr1_2').bgColor = \"#cccccc\";",
"}",
"if ((Score >= 10) && (Score <= 15)){ document.getElementById('rr1_3').bgColor = \"#cccccc\";",
"}",
"",
"",
"",
"}",
"}",
"}",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"}",
"",
"",
"/* ]]> */"].join("\n");
var outline_f28_28_29121=null;
var title_f28_28_29122="Patient information: Pyoderma gangrenosum (The Basics)";
var content_f28_28_29122=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/85634\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/7/6256\">",
"         Colostomy",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"          Colonoscopy",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/8/9350\">",
"           Pyoderma gangrenosum sore",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?4/60/5058\">",
"         Patient information: Blisters (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/56/10115\">",
"         Patient information: Crohn's disease in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/31/16883\">",
"         Patient information: Rheumatoid arthritis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/17/42258\">",
"         Patient information: Ulcerative colitis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?23/40/24196\">",
"         Patient information: Crohn's disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/61/21463\">",
"         Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/39/10869\">",
"         Patient information: Ulcerative colitis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Pyoderma gangrenosum (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/pyoderma-gangrenosum-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H30389323\">",
"      <span class=\"h1\">",
"       What is pyoderma gangrenosum (PG)?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Pyoderma gangrenosum (called &ldquo;PG&rdquo; here) is a rare skin disease that causes painful sores. It can happen at any age, but is most common in people between 40 and 60. It is more common in women than in men. &nbsp; &nbsp;",
"     </p>",
"     <p>",
"      PG is more common in people with certain conditions. These include: &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Digestive system diseases, such as Crohn&rsquo;s disease and ulcerative colitis",
"       </li>",
"       <li>",
"        Blood diseases and blood cancers",
"       </li>",
"       <li>",
"        Arthritis, such as rheumatoid arthritis and ankylosing spondylitis",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Healthy people can also get PG.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30389338\">",
"      <span class=\"h1\">",
"       What are the symptoms of PG?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The first symptom is usually a raised bump or blister. It might be filled with fluid or pus. It can spread out and form an open sore (",
"      <a class=\"graphic graphic_picture graphicRef85576 \" href=\"UTD.htm?9/8/9350\">",
"       picture 1",
"      </a>",
"      ). The edges sometimes look purple. PG blisters and sores can be very painful.",
"     </p>",
"     <p>",
"      The symptoms of PG are most common on the legs. But bumps, blisters, and sores can also happen on other parts of the body. A person who had a colostomy can get PG around the opening called the &ldquo;stoma&rdquo; (",
"      <a class=\"graphic graphic_figure graphicRef57774 \" href=\"UTD.htm?6/7/6256\">",
"       figure 1",
"      </a>",
"      ) where bowel movements leave the body. A few people get PG inside the body, but this is very rare.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30389353\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if you have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Painful bumps or blisters",
"       </li>",
"       <li>",
"        Open sores that do not heal quickly",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30389368\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. It can be hard to tell for sure if someone has PG without doing tests. That&rsquo;s because many other conditions cause similar symptoms. The doctor or nurse will learn about your symptoms, do an exam, and order tests. The tests can check for diseases people with PG often have, or show if you have a condition that is not PG.",
"     </p>",
"     <p>",
"      Tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A test called a &ldquo;biopsy&rdquo; &ndash; In this test, a doctor takes a sample of tissue from the area with a blister or sore. Another doctor looks at the tissue under a microscope for signs of PG.",
"       </li>",
"       <li>",
"        Blood tests &ndash; These can show if you have 1 of the conditions that people with PG often have. &nbsp; &nbsp;",
"       </li>",
"       <li>",
"        A chest X-ray &ndash; This can show PG inside the body and any infections.",
"       </li>",
"       <li>",
"        A test called a &ldquo;colonoscopy&rdquo; (",
"        <a class=\"graphic graphic_figure graphicRef52258 \" href=\"UTD.htm?4/46/4834\">",
"         figure 2",
"        </a>",
"        ) &mdash; During a colonoscopy, the doctor inserts a tube and a tiny camera into your anus and up to your colon. He or she can check your colon for signs of Crohn&rsquo;s disease or ulcerative colitis.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30389394\">",
"      <span class=\"h1\">",
"       How is PG treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Prescription creams",
"       </li>",
"       <li>",
"        Pills you take by mouth - If 1 medicine does not work, your doctor can try something else.",
"       </li>",
"       <li>",
"        An injection (shot) of medicine around the area with PG",
"       </li>",
"       <li>",
"        Surgery to remove dead skin and tissue &ndash; Doctors do not often do surgery for PG because it sometimes makes the condition worse. But it can help some people with severe symptoms.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with PG might need more than 1 treatment at a time. For example, doctors might prescribe a cream to put on the area and pills to take by mouth. Or a person might take 2 different types of pills.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30389409\">",
"      <span class=\"h1\">",
"       Can PG be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors do not yet know how to prevent PG. But if you already have it, avoiding cuts or scrapes could help prevent new blisters or sores.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30389423\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;PG takes several months or years to go away completely, so you might need treatment for a long time. When PG heals, it usually leaves scars. It can also come back later. Be sure to tell all of your doctors and nurses that you had PG. If you find new sores, bumps, or blisters, talk to a doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30389438\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/60/5058?source=see_link\">",
"       Patient information: Blisters (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=see_link\">",
"       Patient information: Crohn's disease in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=see_link\">",
"       Patient information: Rheumatoid arthritis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/17/42258?source=see_link\">",
"       Patient information: Ulcerative colitis in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"       Patient information: Crohn's disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=see_link\">",
"       Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"       Patient information: Ulcerative colitis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?28/28/29122?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 85634 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-3FB984B900-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_28_29122=[""].join("\n");
var outline_f28_28_29122=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30389323\">",
"      What is pyoderma gangrenosum (PG)?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30389338\">",
"      What are the symptoms of PG?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30389353\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30389368\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30389394\">",
"      How is PG treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30389409\">",
"      Can PG be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30389423\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30389438\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/85634\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/7/6256\">",
"      Colostomy",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"       Colonoscopy",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/8/9350\">",
"        Pyoderma gangrenosum sore",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/60/5058?source=related_link\">",
"      Patient information: Blisters (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=related_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=related_link\">",
"      Patient information: Crohn's disease in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=related_link\">",
"      Patient information: Rheumatoid arthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=related_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=related_link\">",
"      Patient information: Ulcerative colitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/17/42258?source=related_link\">",
"      Patient information: Ulcerative colitis in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_28_29123="Methylcellulose: Drug information";
var content_f28_28_29123=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methylcellulose: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/14/14564?source=see_link\">",
"    see \"Methylcellulose: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F194960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Citrucel&reg; [OTC];",
"     </li>",
"     <li>",
"      Soluble Fiber Therapy [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F194981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Fiber Supplement;",
"     </li>",
"     <li>",
"      Laxative;",
"     </li>",
"     <li>",
"      Laxative, Bulk-Producing",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F194961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Constipation:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Citrucel&reg; caplet:",
"     </i>",
"     2 caplets up to 6 times/day; maximum: 12 caplets/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Citrucel&reg; powder:",
"     </i>",
"     2 g (1 heaping tablespoon) in 8 oz of cold water increase as needed by 1 heaping tablespoon up to 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Citrucel&reg; powder (sugar free):",
"     </i>",
"     2 g (1 rounded tablespoon) in 8 oz of cold water; increase as needed by 1 rounded tablespoon up to 3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F194970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Constipation:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-11 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Citrucel&reg; caplet:",
"     </i>",
"     1 caplet up to 6 times/day; (maximum: 6 caplets/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Citrucel&reg; powder:",
"     </i>",
"     1 g (2.5 level teaspoons) in 8 oz of cold water; increase as needed by 2.5 level teaspoons up to 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Citrucel&reg; powder (sugar free):",
"     </i>",
"     1 g (2 level teaspoons) in 8 oz of cold water; increase as needed by 2 level teaspoons up to 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F194962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F194954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Citrucel&reg;: 500 mg [gluten free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Citrucel&reg;: 2 g/scoop (454 g, 850 g, 1843 g) [gluten free; contains potassium 105 mg/scoop, sodium 3 mg/scoop; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Soluble Fiber Therapy: 2 g/scoop (454 g) [orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, oral [sugar free formulation]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Citrucel&reg;: 2 g/scoop (479 g, 907 g, 1190 g) [gluten free, sugar free; contains phenylalanine 52 mg/scoop; orange flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F194945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Powder",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11515522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Follow each dose with 8 oz of water to prevent choking.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F194955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct in treatment of constipation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F194985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Citrucel&reg; may be confused with Citracal&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F194948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): Prior to self-medication, patients should contact healthcare provider if they have abdominal pain, nausea, vomiting, or a sudden change in bowel habits lasting 2 weeks.  Patients should stop use and call healthcare provider right away if they experience rectal bleeding, chest pain, vomiting, difficulty breathing or swallowing, or if no bowel movement after use. All doses must be taken with 8 ounces of water to prevent choking; patients who have difficulty swallowing should not use. Do not use for longer than 1 week unless directed by healthcare provider.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14446373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered with adequate fluids, use is considered safe for the treatment of occasional constipation during pregnancy (Wald, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F194957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain phenylalanine, potassium, and/or sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Methylcellulose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (100 mL): $22.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (100 mL): $27.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3% (100 mL): $31.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Citrucel Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (164): $20.53",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bulk (AT);",
"     </li>",
"     <li>",
"      Celevac (GB, IE);",
"     </li>",
"     <li>",
"      Cellulone (AU);",
"     </li>",
"     <li>",
"      Citrucel (BE, LU);",
"     </li>",
"     <li>",
"      Cologel (GB);",
"     </li>",
"     <li>",
"      Dacryolarmes (FR);",
"     </li>",
"     <li>",
"      Davilose (PT);",
"     </li>",
"     <li>",
"      Lacril (BR, DK);",
"     </li>",
"     <li>",
"      Lacrisyn (CZ);",
"     </li>",
"     <li>",
"      Methylcellulose-Bournonville (LU);",
"     </li>",
"     <li>",
"      Muciplasma (ES);",
"     </li>",
"     <li>",
"      Oftan MC (FI);",
"     </li>",
"     <li>",
"      Tear cell (IN)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Wald A, \"Constipation, Diarrhea, and Symptomatic Hemorrhoids During Pregnancy,\"",
"      <i>",
"       Gastroenterol Clin North Am",
"      </i>",
"      , 2003, 32(1):309-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/28/29123/abstract-text/12635420/pubmed\" id=\"12635420\" target=\"_blank\">",
"        12635420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10153 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-3BFBD2B80D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_28_29123=[""].join("\n");
var outline_f28_28_29123=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194960\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194981\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194961\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194970\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194962\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194954\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194945\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11515522\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194955\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194985\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194948\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299697\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221629\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14446373\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194957\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323390\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539893\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10153\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10153|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/14/14564?source=related_link\">",
"      Methylcellulose: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_28_29124="Pagets dis with carcinoma2";
var content_f28_28_29124=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extramammary Paget disease of the vulva with adenocarcinoma-2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_28_29124=[""].join("\n");
var outline_f28_28_29124=null;
var title_f28_28_29125="Bumetanide: Patient drug information";
var content_f28_28_29125=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bumetanide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/9/43158?source=see_link\">",
"     see \"Bumetanide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/15/40182?source=see_link\">",
"     see \"Bumetanide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F142835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Burinex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10015740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700616",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is a strong water pill. Sometimes too much water and major elements (potassium) in the blood may be lost. Your doctor will follow you closely to change the dose to match your body's needs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691367",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to get rid of extra fluid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help a weak heart.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bumetanide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703484",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Coma from liver disease, trouble passing urine, kidney disease, liver disease, low calcium levels, low magnesium levels, or low potassium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697799",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may need extra potassium. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698616",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in hearing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11478 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C070ECA3F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_28_29125=[""].join("\n");
var outline_f28_28_29125=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142835\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015740\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015742\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015741\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015746\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015747\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015749\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015744\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015745\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015750\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015751\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/9/43158?source=related_link\">",
"      Bumetanide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/15/40182?source=related_link\">",
"      Bumetanide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_28_29126="Treatment of sphincter of Oddi dysfunction";
var content_f28_28_29126=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of sphincter of Oddi dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/28/29126/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/28/29126/contributors\">",
"     Lyndon V Hernandez, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/28/29126/contributors\">",
"     Marc F Catalano, MD, FACP, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/28/29126/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/28/29126/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/28/29126/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/28/29126/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/28/29126/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sphincter of Oddi (SO) is a muscular structure that encompasses the confluence of the distal common bile duct and the pancreatic duct as they penetrate the wall of the duodenum (",
"    <a class=\"graphic graphic_figure graphicRef78786 \" href=\"UTD.htm?27/17/27924\">",
"     figure 1",
"    </a>",
"    ). The term \"sphincter of Oddi dysfunction\" has been used to describe a clinical syndrome of biliary or pancreatic obstruction related to mechanical or functional abnormalities of the sphincter of Oddi. The terms papillary stenosis, sclerosing papillitis, biliary spasm, biliary dyskinesia, and postcholecystectomy syndrome have been used synonymously.",
"   </p>",
"   <p>",
"    The treatment of sphincter of Oddi dysfunction (SOD) will be reviewed here. The clinical manifestations and diagnosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sphincter of Oddi dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51501198\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have addressed the long-term natural history of SOD. The available data suggest that the clinical course is variable depending in part upon the initial biliary classification. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=see_link&amp;anchor=H16565707#H16565707\">",
"     \"Clinical manifestations and diagnosis of sphincter of Oddi dysfunction\", section on 'Classification systems'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a one-year follow-up study, seven type II patients (biliary pain and either abnormal liver tests or a dilated common bile duct) with abnormal SO pressure treated by a sham procedure continued to have symptoms, which resolved only after subsequent sphincterotomy. All patients continued to do well four years later. Five other type II patients with abnormal SO pressure refused sphincterotomy. At four-year follow-up, three were unimproved, while two had \"fair\" improvement.",
"   </p>",
"   <p>",
"    The clinical course is unpredictable after a sham or endoscopic sphincterotomy in patients with type III biliary pain (biliary pain but normal liver tests and common bile duct). In one report, 11 such patients were followed for two years after sphincterotomy. Four improved symptomatically while seven had no change. Eleven other patients had a sham procedure, of whom five improved, while six had no change in symptoms during two years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT GOALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of treating patients with symptomatic sphincter of Oddi dysfunction is to eliminate pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recurrent pancreatitis by improving the impaired flow of biliary and pancreatic secretions into the duodenum, which can be accomplished by pharmacologic, endoscopic, and surgical approaches. Successful treatment depends upon a secure diagnosis. A variety of other disorders, such as irritable bowel syndrome and functional dyspepsia, can cause symptoms that may be confused with SOD. In addition, other causes of pain in patients with postcholecystectomy syndrome or recurrent pancreatitis should be investigated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs that cause smooth muscle relaxation may be beneficial in patients with SOD. Calcium channel blockers and nitrates have been best studied, although the data are sparse. Although calcium channel blockers and nitrates may have a role in some patients, side effects are common, and, in one series, pharmacologic therapy was ineffective in approximately 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, in patients at increased risk for post-ERCP pancreatitis, we suggest a trial of pharmacologic treatment; however, it is infrequently successful for long-term management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     Nifedipine",
"    </a>",
"    reduces basal SO pressure in volunteers without SOD, and has a more profound effect in patients with SOD who have elevated basal SO pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, results with nifedipine have been conflicting.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    was evaluated in a placebo-controlled crossover trial that included 28 patients with recurrent biliary pain thought to be related to SOD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/4\">",
"     4",
"    </a>",
"    ]. Nifedipine (given in the maximal tolerated dose) was associated with significant decreases in a cumulative pain score, number of pain episodes, oral analgesic tablets consumed, and emergency department visits. Responding patients were more likely to have predominant antegrade propagation of phasic contractions on post-treatment SO manometry (SOM), rather than abnormal propagation of phasic contractions. A response to nifedipine could not be predicted by any clinical, radiographic, or manometric criteria.",
"   </p>",
"   <p>",
"    However, in vivo studies in the Australian brush-tailed possum have shown that calcium channel blockers have greater effects on blood pressure at low doses than they do on sphincter of Oddi motility [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/5\">",
"     5",
"    </a>",
"    ]. A corresponding observation in humans was noted in a placebo-controlled crossover trial involving five patients who were randomly assigned to slow-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    or placebo during a six-month period [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/6\">",
"     6",
"    </a>",
"    ]. Active treatment was associated with frequent vascular side effects and was no more effective than placebo at controlling symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nitrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitrates can produce relaxation of the SO in animal models and in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/7\">",
"     7",
"    </a>",
"    ]. A potential role for nitrates in patients with SOD was suggested by a case report of a patient whose pain disappeared following nitrate administration; pain resolution was associated with a decrease in both basal and phasic SO activity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/8\">",
"     8",
"    </a>",
"    ]. However, the role of nitrates in the management of SOD has not yet been established by well-designed controlled trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ursodeoxycholic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have implicated biliary microlithiasis in the pathogenesis of postcholecystectomy pain. A randomized, crossover study involving 12 patients found to have microlithiasis (identified from a total of 118 patients with postcholecystectomy pain) reported significant improvement in pain after treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    (300 mg twice daily) compared with untreated controls [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/9\">",
"     9",
"    </a>",
"    ]. Treatment was continued for six months. During a mean of 29 months of follow-up, all patients except one continued to remain free of biliary pain after discontinuing therapy.",
"   </p>",
"   <p>",
"    This was a single center study involving a small number of patients. The accompanying editorial cautioned about the incorporation of this test into the diagnostic algorithm of postcholecystectomy pain evaluation based upon this study [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/10\">",
"     10",
"    </a>",
"    ]. Additional studies are needed to confirm these findings before a search for biliary microlithiasis can be recommended routinely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ENDOSCOPIC THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51501229\">",
"    <span class=\"h2\">",
"     Endoscopic sphincterotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biliary or pancreatic segment of the sphincter of Oddi can be severed using electrocautery during endoscopic retrograde cholangiopancreatography (ERCP). It should be performed by an experienced, capable endoscopist who has demonstrated good outcomes by sufficient patient follow-up.",
"   </p>",
"   <p>",
"    Multiple studies have evaluated the benefit of endoscopic sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/11-18\">",
"     11-18",
"    </a>",
"    ]. Although the duration of follow-up and inclusion criteria varied, improvement or elimination of pain occurred in approximately 30 to 90 percent of patients. The likelihood of success depends in part upon careful patient selection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Biliary pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with biliary pain, biliary sphincterotomy has the greatest benefit for those who have elevated basal SO pressures (greater than 40 mmHg). There is general consensus that patients with type I biliary SOD likely have papillary stenosis and benefit from endoscopic biliary sphincterotomy without the need for preceding SOM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=see_link&amp;anchor=H51500136#H51500136\">",
"     \"Clinical manifestations and diagnosis of sphincter of Oddi dysfunction\", section on 'Classification of pancreatic SOD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Type II patients generally undergo SOM and those with elevated basal biliary sphincter pressures undergo endoscopic sphincterotomy. Observational studies have not shown a benefit for this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/13,18-20\">",
"     13,18-20",
"    </a>",
"    ], but at least two randomized controlled trials support this practice [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/1,16\">",
"     1,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 47 patients thought to have type II biliary SOD based upon clinical findings were included; all the patients were presumed to have biliary pain and had previously undergone cholecystectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/16\">",
"       16",
"      </a>",
"      ]. Before undergoing manometry, the patients were randomly assigned to sphincterotomy or sham sphincterotomy. At one-year follow-up, biliary sphincterotomy improved pain scores and objective parameters in significantly more patients who had elevated basal sphincter pressures compared to those who underwent sham sphincterotomy (90 versus 25 percent, respectively). In contrast, pain scores were similar in patients without elevated pressures, regardless of treatment. Subsequent sphincterotomy benefited the majority of patients with elevated basal pressures who initially underwent sham sphincterotomy.",
"     </li>",
"     <li>",
"      A second trial of 81 patients supported the results of the earlier randomized trial [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/1\">",
"       1",
"      </a>",
"      ]. In that trial, the effects of sphincterotomy were evaluated in patients with types I, II, and III biliary SOD. The patients were randomly assigned to endoscopic sphincterotomy or sham sphincterotomy based on a SO biliary manometric pressure measurement. The manometric record was categorized as: (1) normal, (2) stenosis, or (3) dyskinesia.",
"      <br/>",
"      <br/>",
"      Twenty-six patients (32 percent) had SO stenosis based on the manometric results. Thirteen of these patients underwent sphincterotomy and thirteen underwent sham sphincterotomy. Patients in the sphincterotomy group showed significantly higher rates of long-term improvement compared to those in the sham group (85 versus 30 percent, respectively). There was no significant difference between patients who underwent sphincterotomy and those who underwent sham sphincterotomy when the manometry was normal or showed dyskinesia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other experts advocate performing endoscopic sphincterotomy without prior SOM for type II SOD patients, citing favorable clinical responses and low complication rates [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. However, data are lacking to support this practice.",
"   </p>",
"   <p>",
"    Type III biliary SOD patients are the most difficult to diagnose and manage. Due to a lack of objective findings, it is difficult to differentiate type III SOD from disorders that are unrelated to the sphincter of Oddi, such as irritable bowel syndrome and chronic functional abdominal pain. Thus, type III patients are best managed by gastroenterologists with expertise in SOD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Recurrent pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic pancreatic sphincterotomy may benefit patients with pancreatitis thought to be due to SOD. In a series of 160 patients with recurrent pancreatitis, endoscopic sphincterotomy resulted in complete and long-lasting resolution of symptoms in 64 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/25\">",
"     25",
"    </a>",
"    ]. However, some patients required repeat sphincterotomy for recurrent SO stenosis.",
"   </p>",
"   <p>",
"    Pancreatitis is also a potential complication of sphincterotomy. The risk may be greater after pancreatic than after biliary sphincterotomy and most often occurs in patients with pancreatic sphincter hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/26\">",
"     26",
"    </a>",
"    ]. Placement of a pancreatic stent following biliary sphincterotomy may reduce the incidence of pancreatitis in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=see_link\">",
"     \"Post-ERCP pancreatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22983?source=see_link\">",
"     \"Prophylactic pancreatic stents to prevent ERCP-induced pancreatitis: When do you use them?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A problem with pancreatic duct stenting is the requirement for another procedure to remove the stent. Nasopancreatic drainage may be an alternative, permitting noninvasive removal of the drain following recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Botulinum toxin injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic injection of botulinum toxin for biliary sphincter of Oddi dysfunction has been used successfully by some groups to determine if a symptomatic response might predict a successful outcome to subsequent sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/27\">",
"     27",
"    </a>",
"    ]. The influence of botulinum toxin on the pancreatic segment of the SO is unknown. Whether this material could be injected successfully into the pancreatic segment without a preceding biliary sphincterotomy is also not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biliary and pancreatic sphincterotomy can also be accomplished by a transduodenal surgical approach. Surgical sphincterotomy has two potential advantages compared to standard endoscopic approaches:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgery allows for greater precision in performing the sphincterotomy. With endoscopic sphincterotomy it is difficult to sever the transampullary septum without risking duodenal perforation. As a result, endoscopic sphincterotomy may not completely relieve pancreatic duct obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/28\">",
"       28",
"      </a>",
"      ]. Endoscopic sphincterotomy of the biliary segment of the SO also may not affect the pancreatic duct segment at all [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/29\">",
"       29",
"      </a>",
"      ]. These problems are both overcome by performing the sphincterotomy surgically.",
"     </li>",
"     <li>",
"      Surgery may reduce the chance of recurrent stenosis due to scarring.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Improvement in biliary pain and recurrent pancreatitis has been demonstrated in approximately 50 to 60 percent of patients treated by surgical sphincterotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/30-36\">",
"     30-36",
"    </a>",
"    ]. However, surgical sphincterotomy and septoplasty for pancreatitis may be associated with worse outcomes than for recurrent biliary pain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/36\">",
"     36",
"    </a>",
"    ]. One possible explanation is that some patients have unappreciated pancreatic parenchymal disease that continues to be the source of pain following surgery. For similar reasons, patients with acute recurrent pancreatitis may have better results than those with chronic pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these potential advantages, endoscopic therapy is less invasive, has similar outcomes, and is the preferred approach at most centers with experience in this technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     OTHER APPROACHES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Electroacupuncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential therapeutic role for electroacupuncture was suggested in a pilot study in which an acupoint on the right lateral tibia (GB34) was stimulated, resulting in a significant decrease in basal pressure, amplitude, duration, and frequency of phasic contractions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29126/abstract/37\">",
"     37",
"    </a>",
"    ]. The inhibition of SO contractility was accompanied by an increase in plasma CCK levels. All changes reverted to baseline upon discontinuation of stimulation. The clinical relevance of these observations remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of sphincter of Oddi dysfunction (SOD) varies depending on whether the patient has type I, II, or III SOD (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sphincter of Oddi dysfunction\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type I SOD: biliary-type pain, abnormal liver tests, and a dilated common bile duct",
"     </li>",
"     <li>",
"      Type II SOD: biliary-type pain and either abnormal liver tests or a dilated common bile duct",
"     </li>",
"     <li>",
"      Type III SOD: biliary-type pain but normal liver tests and common bile duct diameter",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Endoscopic therapy is preferred for patients with type I SOD, and many patients with type II SOD. Patients with type III SOD are more often managed without endoscopic intervention.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that patients with type I SOD be referred directly for endoscopic sphincterotomy, without preprocedure manometry (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Biliary pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with type II SOD be referred for sphincter of Oddi manometry and that an endoscopic sphincterotomy be performed if there is evidence of sphincter of Oddi stenosis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Biliary pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that endoscopic sphincterotomy be avoided in patients with type III SOD (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). These patients should be managed by gastroenterologists familiar with SOD. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Biliary pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest patients with recurrent pancreatitis be evaluated for SOD with manometry and that those with elevated sphincter pressures undergo endoscopic sphincterotomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Recurrent pancreatitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/1\">",
"      Toouli J, Roberts-Thomson IC, Kellow J, et al. Manometry based randomised trial of endoscopic sphincterotomy for sphincter of Oddi dysfunction. Gut 2000; 46:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/2\">",
"      D&ouml;br&ouml;nte Z, Simon L, Patai A. [Management of Oddi sphincter dyskinesis. Results of drug therapy and sphincterotomy]. Orv Hetil 1995; 136:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/3\">",
"      Guelrud M, Mendoza S, Rossiter G, et al. Effect of nifedipine on sphincter of Oddi motor activity: studies in healthy volunteers and patients with biliary dyskinesia. Gastroenterology 1988; 95:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/4\">",
"      Khuroo MS, Zargar SA, Yattoo GN. Efficacy of nifedipine therapy in patients with sphincter of Oddi dysfunction: a prospective, double-blind, randomized, placebo-controlled, cross over trial. Br J Clin Pharmacol 1992; 33:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/5\">",
"      Craig AG, Tottrup A, Toouli J, Saccone GT. Relative effects of dihydropyridine L-type calcium channel antagonism on biliary, duodenal, and vascular tissues: an in vivo and in vitro analysis in Australian brush-tailed possum. Dig Dis Sci 2002; 47:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/6\">",
"      Craig AG, Toouli J. Slow release nifedipine for patients with sphincter of Oddi dyskinesia: results of a pilot study. Intern Med J 2002; 32:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/7\">",
"      Brandst&auml;tter G, Schinzel S, Wurzer H. Influence of spasmolytic analgesics on motility of sphincter of Oddi. Dig Dis Sci 1996; 41:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/8\">",
"      Bar-Meir S, Halpern Z, Bardan E. Nitrate therapy in a patient with papillary dysfunction. Am J Gastroenterol 1983; 78:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/9\">",
"      Okoro N, Patel A, Goldstein M, et al. Ursodeoxycholic acid treatment for patients with postcholecystectomy pain and bile microlithiasis. Gastrointest Endosc 2008; 68:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/10\">",
"      Ahmed F, Sherman S. Should patients with biliary-type pain after cholecystectomy be evaluated for microlithiasis? Gastrointest Endosc 2008; 68:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/11\">",
"      Riemann JF, Lux G, F&ouml;rster P, Altendorf A. Long-term results after endoscopic papillotomy. Endoscopy 1983; 15 Suppl 1:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/12\">",
"      Meshkinpour H, Mollot M. Sphincter of Oddi dysfunction and unexplained abdominal pain: clinical and manometric study. Dig Dis Sci 1992; 37:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/13\">",
"      Thatcher BS, Sivak MV Jr, Tedesco FJ, et al. Endoscopic sphincterotomy for suspected dysfunction of the sphincter of Oddi. Gastrointest Endosc 1987; 33:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/14\">",
"      Neoptolemos JP, Bailey IS, Carr-Locke DL. Sphincter of Oddi dysfunction: results of treatment by endoscopic sphincterotomy. Br J Surg 1988; 75:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/15\">",
"      Seifert E. Long-term follow-up after endoscopic sphincterotomy (EST). Endoscopy 1988; 20 Suppl 1:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/16\">",
"      Geenen JE, Hogan WJ, Dodds WJ, et al. The efficacy of endoscopic sphincterotomy after cholecystectomy in patients with sphincter-of-Oddi dysfunction. N Engl J Med 1989; 320:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/17\">",
"      Bozkurt T, Orth KH, Butsch B, Lux G. Long-term clinical outcome of post-cholecystectomy patients with biliary-type pain: results of manometry, non-invasive techniques and endoscopic sphincterotomy. Eur J Gastroenterol Hepatol 1996; 8:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/18\">",
"      Wehrmann T, Wiemer K, Lembcke B, et al. Do patients with sphincter of Oddi dysfunction benefit from endoscopic sphincterotomy? A 5-year prospective trial. Eur J Gastroenterol Hepatol 1996; 8:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/19\">",
"      Roberts-Thomson IC, Toouli J. Is endoscopic sphincterotomy for disabling biliary-type pain after cholecystectomy effective? Gastrointest Endosc 1985; 31:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/20\">",
"      Botoman VA, Kozarek RA, Novell LA, et al. Long-term outcome after endoscopic sphincterotomy in patients with biliary colic and suspected sphincter of Oddi dysfunction. Gastrointest Endosc 1994; 40:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/21\">",
"      Lawrence C, Howell, Conklin D, et al. ERCP sphincterotomy without initial manometry for type II sphincter of Oddi dysfunction patients: a safe and effective strategy. Gastrointest Endosc 2004; 59:P99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/22\">",
"      Lin OS, Soetikno RM, Young HS. The utility of liver function test abnormalities concomitant with biliary symptoms in predicting a favorable response to endoscopic sphincterotomy in patients with presumed sphincter of Oddi dysfunction. Am J Gastroenterol 1998; 93:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/23\">",
"      Petersen BT. An evidence-based review of sphincter of Oddi dysfunction: part I, presentations with \"objective\" biliary findings (types I and II). Gastrointest Endosc 2004; 59:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/24\">",
"      Petersen BT. Sphincter of Oddi dysfunction, part 2: Evidence-based review of the presentations, with \"objective\" pancreatic findings (types I and II) and of presumptive type III. Gastrointest Endosc 2004; 59:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/25\">",
"      Elton E, Howell DA, Parsons WG, et al. Endoscopic pancreatic sphincterotomy: indications, outcome, and a safe stentless technique. Gastrointest Endosc 1998; 47:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/26\">",
"      Tarnasky P, Cunningham J, Cotton P, et al. Pancreatic sphincter hypertension increases the risk of post-ERCP pancreatitis. Endoscopy 1997; 29:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/27\">",
"      Wehrmann T, Seifert H, Seipp M, et al. Endoscopic injection of botulinum toxin for biliary sphincter of Oddi dysfunction. Endoscopy 1998; 30:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/28\">",
"      Funch-Jensen P, Kruse A. Manometric activity of the pancreatic duct sphincter in patients with total bile duct sphincterotomy for sphincter of Oddi dyskinesia. Scand J Gastroenterol 1987; 22:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/29\">",
"      Ugljesi�� M, Bulaji�� M, Milosavljevi�� T, Stimec B. Endoscopic manometry of the sphincter of Oddi in sphincterotomized patients. Hepatogastroenterology 1995; 42:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/30\">",
"      Toouli J, Di Francesco V, Saccone G, et al. Division of the sphincter of Oddi for treatment of dysfunction associated with recurrent pancreatitis. Br J Surg 1996; 83:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/31\">",
"      Moody FG, Becker JM, Potts JR. Transduodenal sphincteroplasty and transampullary septectomy for postcholecystectomy pain. Ann Surg 1983; 197:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/32\">",
"      Nardi GL, Michelassi F, Zannini P. Transduodenal sphincteroplasty. 5-25 year follow-up of 89 patients. Ann Surg 1983; 198:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/33\">",
"      Anderson TM, Pitt HA, Longmire WP Jr. Experience with sphincteroplasty and sphincterotomy in pancreatobiliary surgery. Ann Surg 1985; 201:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/34\">",
"      Stephens RV, Burdick GE. Microscopic transduodenal sphincteroplasty and transampullary septoplasty for papillary stenosis. Am J Surg 1986; 152:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/35\">",
"      H&auml;stbacka J, J&auml;rvinen H, Kivilaakso E, Turunen MT. Results of sphincteroplasty in patients with spastic sphincter of Oddi. Predictive value of operative biliary manometry and provocation tests. Scand J Gastroenterol 1986; 21:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/36\">",
"      Nussbaum MS, Warner BW, Sax HC, Fischer JE. Transduodenal sphincteroplasty and transampullary septotomy for primary sphincter of Oddi dysfunction. Am J Surg 1989; 157:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29126/abstract/37\">",
"      Lee SK, Kim MH, Kim HJ, et al. Electroacupuncture may relax the sphincter of Oddi in humans. Gastrointest Endosc 2001; 53:211.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5656 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.65.66-BC5B390E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_28_29126=[""].join("\n");
var outline_f28_28_29126=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H51501198\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT GOALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOLOGIC TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nitrates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ursodeoxycholic acid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ENDOSCOPIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51501229\">",
"      Endoscopic sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Biliary pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Recurrent pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Botulinum toxin injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      OTHER APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Electroacupuncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/5656\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5656|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/17/27924\" title=\"figure 1\">",
"      Sphincter of Oddi",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=related_link\">",
"      Clinical manifestations and diagnosis of sphincter of Oddi dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=related_link\">",
"      Post-ERCP pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22983?source=related_link\">",
"      Prophylactic pancreatic stents to prevent ERCP-induced pancreatitis: When do you use them?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_28_29127="Prognosis of diffuse large B cell lymphoma";
var content_f28_28_29127=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prognosis of diffuse large B cell lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/28/29127/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/28/29127/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/28/29127/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/28/29127/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/28/29127/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/28/29127/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/28/29127/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/28/29127/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H17220637\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL) accounting for approximately 25 percent of NHL cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is increasingly appreciated that the diagnostic category of \"DLBCL\" is quite heterogeneous in terms of morphology, genetics, and biologic behavior. A number of clinicopathologic entities are now recognized that are sufficiently distinct to be considered separate diagnostic categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T cell histiocyte rich large B cell lymphoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link&amp;anchor=H21#H21\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'T cell histiocyte rich large B cell lymphoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary DLBCL of the mediastinum, also called primary mediastinal large B cell lymphoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9238?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of primary mediastinal large B-cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intravascular lymphoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13511?source=see_link\">",
"       \"Intravascular large cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lymphomatoid granulomatosis, an Epstein-Barr virus positive large B cell lymphoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41287?source=see_link\">",
"       \"Pulmonary lymphomatoid granulomatosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link&amp;anchor=H763094#H763094\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'Lymphomatoid granulomatosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these is discussed separately in the sections that follow the general discussion of DLBCL, or in their own topics. In addition, the 2008 version of the World Health Organization (WHO) classification system provides two overlap categories termed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"B cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma\". Some tumors in this group were previously classified as \"Burkitt-like\" lymphoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link&amp;anchor=H16#H16\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'Burkitt lymphoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      \"B cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma\". (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link&amp;anchor=H18#H18\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'Hodgkin lymphoma'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognosis of nodal DLBCL will be reviewed here. The pathobiology, staging, diagnosis, and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38329?source=see_link\">",
"     \"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18634?source=see_link\">",
"     \"Initial treatment of limited stage diffuse large B cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17219010\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prognosis in DLBCL is highly associated with the International Prognostic Index (IPI) score, which was proposed in 1993 to assign prognosis to patients with aggressive non-Hodgkin lymphoma undergoing treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -containing chemotherapeutic regimens (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"     table 1",
"    </a>",
"    ). These findings have been confirmed in many series of patients with DLBCL.",
"   </p>",
"   <p>",
"    Other factors associated with a poor prognosis have been described that appear to either complement or outperform the IPI in patients with DLBCL [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. As an example, immunoblastic morphology, which defined a special category of particularly aggressive large cell lymphomas in the original Working Formulation classification system [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/5\">",
"     5",
"    </a>",
"    ], has been associated with a worse outcome in patients treated with R-CHOP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/6\">",
"     6",
"    </a>",
"    ]. However, the immunoblastic category was deleted from the subsequent REAL and WHO classification systems due to generally high intraobserver and interobserver diagnostic variability, and the role of morphologic subclassification of tumors in stratification of patients remains unsettled. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'Morphology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17219017\">",
"    <span class=\"h1\">",
"     INTERNATIONAL PROGNOSTIC INDEX",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Prognostic Index (IPI) and its variants are the main prognostic tools used in patients with DLBCL (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"     table 1",
"    </a>",
"    ). These indices are significantly more accurate than the Ann Arbor classification (which they incorporate) in predicting long-term survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17219024\">",
"    <span class=\"h2\">",
"     Original IPI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Institutions in the United States, Canada, and Europe participated in an International non-Hodgkin lymphoma Prognostic Factors Project, which developed the International Prognostic Index (IPI) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/7\">",
"     7",
"    </a>",
"    ]. Patients with aggressive non-Hodgkin lymphoma (eg, DLBCL) were evaluated for pretreatment features that predicted for survival following treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -containing chemotherapy regimens. The following factors were found to correlate significantly with shorter overall or relapse-free survival:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &gt;60",
"     </li>",
"     <li>",
"      Serum lactate dehydrogenase (LDH) concentration greater than normal",
"     </li>",
"     <li>",
"      ECOG performance status &ge;2 (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ann Arbor clinical stage III or IV (",
"      <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Number of involved extranodal disease sites &gt;1",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this system, one point is given for each of the above characteristics present in the patient, for a total score ranging from zero to five, representing increasing degrees of risk (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low risk &mdash; IPI score of zero or one",
"     </li>",
"     <li>",
"      Low intermediate risk &mdash; IPI score of two",
"     </li>",
"     <li>",
"      High intermediate risk &mdash; IPI score of three",
"     </li>",
"     <li>",
"      High risk &mdash; IPI score of four or five",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When applied to the initial group of 2031 patients with aggressive non-Hodgkin lymphoma treated with anthracycline-based regimens that did not include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , five-year overall survival rates for patients with scores of zero to one, two, three, and four to five were 73, 51, 43, and 26 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17219031\">",
"    <span class=\"h2\">",
"     Use of IPI for patients receiving rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to standard chemotherapy has resulted in significant improvements in the overall survival (OS) rates of CD-20 positive tumors. Specifically, the combination of rituximab plus CHOP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) or CHOP-like regimens is the most commonly employed treatment for DLBCL. The original IPI scoring system has been validated in this patient group [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H4#H4\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Rituximab containing regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An analysis of 1063 patients with aggressive B cell lymphoma who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    plus CHOP or CHOP-like chemotherapy in the context of three prospective trials analyzed the prognostic value of the original IPI [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/8\">",
"     8",
"    </a>",
"    ]. At a median observation time exceeding 30 months, three-year estimates for event-free (EFS), progression-free (PFS), and overall (OS) survival as divided by IPI score were (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      IPI score zero or one &mdash; rates of 81, 87, and 91 percent, respectively",
"     </li>",
"     <li>",
"      IPI score two &mdash; rates of 69, 75, and 81 percent, respectively",
"     </li>",
"     <li>",
"      IPI score three &mdash; rates of 53, 59, and 65 percent, respectively",
"     </li>",
"     <li>",
"      IPI score four or five &mdash; rates of 50, 56, and 59 percent, respectively",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When patients from all three trials were analyzed as a single set, these four IPI groups differed significantly from each other in their estimates of EFS, PFS, and OS. These results support the use of the original IPI, rather than a revised IPI [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], for stratifying patients in and reporting data from clinical trials of DLBCL using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17219038\">",
"    <span class=\"h2\">",
"     Age adjusted IPI",
"    </span>",
"    &nbsp;&mdash;&nbsp;An age-adjusted IPI was evaluated for the 1274 patients &le;60 years of age in the original study group [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/7\">",
"     7",
"    </a>",
"    ]. For this score, all of the prognostic factors listed above, with the exception of age and number of extranodal sites, were given one point, for a score ranging from zero to three (",
"    <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"     table 1",
"    </a>",
"    ), representing increased degrees of risk:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low risk &mdash; age-adjusted IPI score of zero",
"     </li>",
"     <li>",
"      Low intermediate risk &mdash; age-adjusted IPI score of one",
"     </li>",
"     <li>",
"      High intermediate risk &mdash; age-adjusted IPI score of two",
"     </li>",
"     <li>",
"      High risk &mdash; age-adjusted IPI score of three",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Five-year survival rates for patients &le;60 with age-adjusted scores of zero, one, two, and three were 83, 69, 46, and 32 percent, respectively. Survival rates for those &gt;60 with the same scores were 56, 44, 37, and 21 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17219045\">",
"    <span class=\"h2\">",
"     Stage adjusted IPI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modifications of the IPI have been made for patients with stage I or II aggressive non-Hodgkin lymphoma (\"stage-adjusted\" or \"stage-modified\" IPI) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], since there are marked differences in prognosis among such patients. In one proposed scoring system, one point was given for each of the following pre-treatment variables:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &gt;60",
"     </li>",
"     <li>",
"      Increased serum lactate dehydrogenase levels",
"     </li>",
"     <li>",
"      Stage II or stage IIE disease (",
"      <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Performance status &ge;2 (",
"      <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example of the variability in prognosis among patients with stage I or II aggressive non-Hodgkin lymphoma undergoing similar treatment (ie, three courses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -containing chemotherapy plus involved region radiation therapy), patients with scores on the stage-modified IPI from zero to four had the following 10-year overall survival rates [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Score zero &mdash; 90 percent",
"     </li>",
"     <li>",
"      Score one or two &mdash; 56 percent",
"     </li>",
"     <li>",
"      Score three or four &mdash; 48 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognostic utility of this stage-modified IPI has also been shown for primary gastric and intestinal diffuse large B cell lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. It has been further noted that patients with bulky stage II aggressive NHL have an estimated five-year overall survival of 49 percent, similar to that of patients with stage III or IV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\", section on 'Gastric lymphoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of gastrointestinal lymphomas\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14049196\">",
"    <span class=\"h1\">",
"     MOLECULAR GENETICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17219052\">",
"    <span class=\"h2\">",
"     Gene expression profiling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene expression profiling (GEP) by means of DNA microarrays is an evolving approach to classification and diagnosis of non-Hodgkin lymphoma and other malignancies. DLBCL is a heterogeneous group of tumors that are diverse in terms of their underlying molecular pathogenesis and their clinical outcome. A number of studies have subclassified DLBCL based on GEP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/18-28\">",
"     18-28",
"    </a>",
"    ]. Several different classifications have been generated; the most widely used separates DLBCL into two major groups (",
"    <a class=\"graphic graphic_figure graphicRef63638 \" href=\"UTD.htm?29/30/30189\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One group of DLBCLs (the germinal center type, GC) has a GEP that resembles a normal germinal center B cell. GC tumors frequently demonstrate t(14;18) translocations and a have a superior rate of five-year survival with current therapy (CHOP or R-CHOP).",
"     </li>",
"     <li>",
"      A second group of DLBCL (the activated B cell type, ABC) has a GEP that resembles an activated B cell. These tumors are likely derived from a post-germinal-center B cell that has commenced early stages of plasmacytic differentiation. ABC tumors frequently demonstrate trisomy 3, deletion of the inhibitor of kinase 4A-alternative reading frame",
"      <span class=\"nowrap\">",
"       (INK4A/ARF),",
"      </span>",
"      and constitutive activation of the antiapoptotic nuclear factor kappa B pathway. When compared with GC tumors, ABC tumors are associated with inferior rates of five-year survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional profiling studies suggest that signatures of the surrounding stromal-cells also influence outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role that GEP plays in the diagnosis and treatment of DLBCL is a matter of ongoing research. The poor outcome of the ABC type persists with the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    to CHOP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/29\">",
"     29",
"    </a>",
"    ]. This has stimulated interest in the development of new therapies targeted at this type of DLBCL. One approach that is being explored is the treatment of the ABC type with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    , a proteasome inhibitor that can interfere with NF-kappaB pathway signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/31\">",
"     31",
"    </a>",
"    ]. Studies relating outcomes following autologous hematopoietic cell transplantation (HCT) at relapse have had mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=see_link\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H468538\">",
"    <span class=\"h2\">",
"     Deep sequencing of DLBCL genomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep sequencing of DLBCL genomes has confirmed that heterogeneity in DLBCL extends to the tumor cell genome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. The relationship between various mutations and prognosis is an area of ongoing investigation.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14049240\">",
"    <span class=\"h2\">",
"     \"Double-hit\" lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;double-hit&rdquo; lymphoma is used colloquially to refer to cases of lymphoma that contain translocations of both the c-MYC gene at 8q24 and a second site, often the BCL-2 gene at 18q21 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. When treated with CHOP chemotherapy, &ldquo;double-hit&rdquo;",
"    <span class=\"nowrap\">",
"     c-MYC/BCL-2",
"    </span>",
"    lymphomas identified by genetic testing have a worse prognosis than other DLBCL [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/39\">",
"     39",
"    </a>",
"    ]. Initial studies also suggest that DLBCL with c-MYC and BCL-2 overexpression identified by immunohistochemistry may also predict worse survival [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Many of these cases would be best considered \"B cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma\" according to the 2008 version of the WHO classification system [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Translocations involving the c-MYC gene are seen in 5 to 15 percent of cases of DLBCL and confer a worse prognosis following treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -based combination chemotherapy (eg, CHOP) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In comparison, translocations involving the BCL-2 gene are seen in approximately 30 percent of cases of DLBCL and do not appear to impact survival when present as the sole genetic abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. The approximately half of patients with c-MYC translocation that also contain a BCL-2 translocation have an even worse prognosis with an estimated median survival times of 6 to 18 months with doxorubicin-based chemotherapy regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While all patients with c-MYC translocation will demonstrate increased c-MYC expression, there are additional patients that have overexpression of c-MYC due to other mechanisms (eg, amplifications). Overexpression of c-MYC and BCL-2 can be identified with immunohistochemistry. In two independent studies, coexpression of c-MYC and BCL-2 was seen in 21 to 29 percent of cases of DLBCL and predicted a lower complete response rate and shorter progression-free and overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29127/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. However, while the presence of a c-MYC translocation conferred a poor prognosis independent of BCL-2, c-MYC protein expression was only associated with worse outcome when accompanied by BCL-2 expression. Further studies are needed to clarify the prognosis of lymphomas that overexpress BCL-2 and c-MYC based on immunohistochemistry. For now, cases with c-MYC overexpression identified by immunohistochemistry should be considered for genetic testing for c-MYC translocations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17221149\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL) accounting for approximately 25 percent of NHL cases.",
"     </li>",
"     <li>",
"      It is increasingly appreciated that the diagnostic category of \"DLBCL\" is quite heterogeneous in terms of morphology, genetics, and biologic behavior. A number of clinicopathologic entities are now recognized that are sufficiently distinct to be considered separate diagnostic categories (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link&amp;anchor=H20#H20\">",
"       \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'Distinctive clinicopathologic subtypes of DLBCL'",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      T cell rich large B cell lymphoma",
"     </li>",
"     <li>",
"      Primary mediastinal large B cell lymphoma",
"     </li>",
"     <li>",
"      Intravascular lymphoma",
"     </li>",
"     <li>",
"      Lymphomatoid granulomatosis and EBV-positive DLBCL of the elderly",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The International Prognostic Index (IPI) and its variants are the main prognostic tools used in patients with DLBCL (",
"      <a class=\"graphic graphic_table graphicRef70850 \" href=\"UTD.htm?17/21/17757\">",
"       table 1",
"      </a>",
"      ). The IPI uses information regarding patient age, performance status, serum lactate dehydrogenase level, disease stage, and degree of extranodal involvement to determine a score that correlates with progression-free and overall survival after standard therapy. (See",
"      <a class=\"local\" href=\"#H17219024\">",
"       'Original IPI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gene expression profiling (GEP) by means of DNA microarrays is an evolving approach to classification and diagnosis of non-Hodgkin lymphoma and other malignancies. While a number of studies have subclassified DLBCL based on GEP, the role that GEP plays in the diagnosis and treatment of DLBCL is a matter of ongoing research. (See",
"      <a class=\"local\" href=\"#H17219052\">",
"       'Gene expression profiling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The relationship between the mutational landscape of DLBCL and prognosis is an area of ongoing investigation.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/2\">",
"      Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/3\">",
"      Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006; 24:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/4\">",
"      Wu G, Keating A. Biomarkers of potential prognostic significance in diffuse large B-cell lymphoma. Cancer 2006; 106:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/5\">",
"      National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49:2112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/6\">",
"      Ott G, Ziepert M, Klapper W, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010; 116:4916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/7\">",
"      A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/8\">",
"      Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28:2373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/9\">",
"      Salles G, de Jong D, Xie W, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011; 117:7070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/10\">",
"      Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/11\">",
"      Bari A, Marcheselli L, Sacchi S, et al. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol 2010; 21:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/12\">",
"      Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998; 339:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/13\">",
"      M&oslash;ller MB, Pedersen NT, Christensen BE. Factors predicting long-term survival in low-risk diffuse large B-cell lymphoma. Am J Hematol 2003; 74:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/14\">",
"      Shenkier TN, Voss N, Fairey R, et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 2002; 20:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/15\">",
"      Cortelazzo S, Rossi A, Roggero F, et al. Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG). Ann Oncol 1999; 10:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/16\">",
"      Cortelazzo S, Rossi A, Oldani E, et al. The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies. Br J Haematol 2002; 118:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/17\">",
"      Miller TP. The limits of limited stage lymphoma. J Clin Oncol 2004; 22:2982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/18\">",
"      Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/19\">",
"      Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/20\">",
"      Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/21\">",
"      Staudt LM. Molecular diagnosis of the hematologic cancers. N Engl J Med 2003; 348:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/22\">",
"      Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/23\">",
"      Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/24\">",
"      Malumbres R, Chen J, Tibshirani R, et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood 2008; 111:5509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/25\">",
"      Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008; 26:4587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/26\">",
"      Guti&eacute;rrez-Garc&iacute;a G, Cardesa-Salzmann T, Climent F, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 2011; 117:4836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/27\">",
"      Alizadeh AA, Gentles AJ, Alencar AJ, et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood 2011; 118:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/28\">",
"      Thieblemont C, Briere J, Mounier N, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 2011; 29:4079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/29\">",
"      Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/30\">",
"      Perry AM, Cardesa-Salzmann TM, Meyer PN, et al. A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. Blood 2012; 120:2290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/31\">",
"      Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009; 113:6069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/32\">",
"      Costa LJ, Feldman AL, Micallef IN, et al. Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation. Br J Haematol 2008; 142:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/33\">",
"      van Imhoff GW, Boerma EJ, van der Holt B, et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006; 24:4135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/34\">",
"      Zinzani PL, Broccoli A, Stefoni V, et al. Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. Cancer 2010; 116:5667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/35\">",
"      Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011; 471:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/36\">",
"      Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/37\">",
"      Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 2012; 109:3879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/38\">",
"      Friedberg JW. Double-hit diffuse large B-cell lymphoma. J Clin Oncol 2012; 30:3439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/39\">",
"      Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood 2011; 117:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/40\">",
"      Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30:3452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/41\">",
"      Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30:3460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/42\">",
"      Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009; 114:3533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/43\">",
"      Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010; 28:3360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/44\">",
"      Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29127/abstract/45\">",
"      Papakonstantinou G, Verbeke C, Hastka J, et al. bcl-2 expression in non-Hodgkin's lymphomas is not associated with bcl-2 gene rearrangements. Br J Haematol 2001; 113:383.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83821 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-04D01F2D42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_28_29127=[""].join("\n");
var outline_f28_28_29127=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17221149\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17220637\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17219010\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17219017\">",
"      INTERNATIONAL PROGNOSTIC INDEX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17219024\">",
"      Original IPI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17219031\">",
"      Use of IPI for patients receiving rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17219038\">",
"      Age adjusted IPI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17219045\">",
"      Stage adjusted IPI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14049196\">",
"      MOLECULAR GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17219052\">",
"      Gene expression profiling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H468538\">",
"      Deep sequencing of DLBCL genomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14049240\">",
"      \"Double-hit\" lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17221149\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/83821\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/83821|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/30/30189\" title=\"figure 1\">",
"      Survival DLBCL gene profiling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/83821|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/21/17757\" title=\"table 1\">",
"      Int prognostic index NHL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 2\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/59/37819\" title=\"table 3\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9238?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of primary mediastinal large B-cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=related_link\">",
"      Clinical presentation and diagnosis of primary gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=related_link\">",
"      Initial treatment of advanced stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18634?source=related_link\">",
"      Initial treatment of limited stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13511?source=related_link\">",
"      Intravascular large cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=related_link\">",
"      Management of gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38329?source=related_link\">",
"      Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41287?source=related_link\">",
"      Pulmonary lymphomatoid granulomatosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_28_29128="Complications of contact lenses";
var content_f28_28_29128=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of contact lenses",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/28/29128/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/28/29128/contributors\">",
"     Russell M LeBoyer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/28/29128/contributors\">",
"     Karen S. DeLoss, OD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/28/29128/contributors\">",
"     H Kaz Soong, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/28/29128/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/28/29128/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/28/29128/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/28/29128/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/28/29128/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Millions of people worldwide wear contact lenses. Noninfectious and infectious complications of contact lenses are therefore common and vary in severity from clinically inconsequential to potentially vision-threatening.",
"   </p>",
"   <p>",
"    Primary care and emergency department clinicians are often the first to evaluate patients with contact lens&ndash;related problems. Although many of these conditions necessitate referral to an eye care specialist, familiarity with these complications by the frontline clinician will allow prompt diagnosis, treatment, and appropriate triage.",
"   </p>",
"   <p>",
"    The presentation and management of complications associated with contact lenses will be reviewed here. An overview of contact lenses and specific microbial infections related to contact lens wear are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18183?source=see_link\">",
"     \"Overview of contact lenses\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10712?source=see_link&amp;anchor=H773301007#H773301007\">",
"     \"Clinical manifestations and diagnosis of Fusarium infection\", section on 'Keratitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4762?source=see_link&amp;anchor=H13571795#H13571795\">",
"     \"Free-living amebas\", section on 'Keratitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NONINFECTIOUS COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maintenance of a smooth and transparent anterior refractive surface is critical to good vision. A complex interplay between the corneal and conjunctival epithelium, the tear film, and the overlying eyelids provides protection against infection and scarring. Noninfectious complications are minimized with a well-fit contact lens that both rests on the pre-corneal tear film and moves only enough to allow good fluid and gas exchange, thereby functioning as a de facto extension of the ocular surface.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1572295\">",
"    <span class=\"h2\">",
"     Dryness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contact lens related dryness is commonly encountered and is the most frequent reason for contact lens discontinuation. Dryness can be caused by poor tear film, oxygen deprivation, lens deposits, and contact lens solution incompatibility [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Treatment includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    with and without contact lenses, topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    0.05%, and management of blepharitis and meibomian gland dysfunction when applicable. Patients may benefit from refitting with a higher oxygen permeable lens material or switching contact lens care solutions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=see_link\">",
"     \"Blepharitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Sterile corneal infiltrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple small infiltrates containing inflammatory cells (polymorphonuclear leukocytes and mononuclear cells) may accumulate within the collagen matrix of the corneal stroma in people who wear contact lenses [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/3\">",
"     3",
"    </a>",
"    ]. These infiltrates appear white and are located in the anterior stroma, usually in the peripheral cornea near the limbus (",
"    <a class=\"graphic graphic_picture graphicRef52402 \" href=\"UTD.htm?36/7/36990\">",
"     picture 1",
"    </a>",
"    ). They can occur singly or in clusters and are usually 0.1 to 1.0 mm in size. The infiltrates may be difficult to see without slit lamp biomicroscopy.",
"   </p>",
"   <p>",
"    Sterile infiltrates are usually asymptomatic but can cause pain, discomfort, tearing, or photophobia if they are severe or numerous. In most cases, the diagnosis is made during routine eye examination in contact lens wearers.",
"   </p>",
"   <p>",
"    The infiltrates are believed to result from a number of insults associated with contact lens wear: accumulated debris, chemical toxicity, hypoxia, and hypersensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/4\">",
"     4",
"    </a>",
"    ]. The infiltrates may also represent an immune reaction to exotoxins from staphylococci colonizing the sebaceous gland openings of the eyelid margins (staphylococcal marginal keratitis).",
"   </p>",
"   <p>",
"    Sterile infiltrates respond well to a short course of topical glucocorticoids or, in many patients, temporary elimination of contact lens wear. Concomitant control of the ocular surface and eyelid bacterial flora over a course of weeks may also be beneficial. This may involve eyelid hygiene, topical antibiotics, or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    100 mg once or twice daily. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=see_link&amp;anchor=H21#H21\">",
"     \"Blepharitis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ophthalmology consultation is appropriate to distinguish these infiltrates from infection and to initiate topical glucocorticoids when indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Corneal epithelial problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contact lenses may cause defects of the corneal epithelium through mechanical trauma, oxygen deprivation, nutrient starvation, metabolic injury, hypersensitivity, drying, or chemical toxicity. Epithelial defects of the cornea can be seen by staining the eye with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    dye. The dye is taken up by discontinuity of the epithelial surface related to cell damage or death.",
"   </p>",
"   <p>",
"    Mild staining of the epithelium is common, usually asymptomatic, and of little clinical consequence. Larger defects may cause pain, tearing, red eyes (conjunctival injection), photophobia, and blurred vision.",
"   </p>",
"   <p>",
"    Superficial punctate staining of the epithelium may be caused by a poorly-fit lens (eg, too steep or flat), hypoxia, chemical toxicity from storage or cleaning solutions, lens deposits, blepharitis, dry eyes, or desiccation from poor eyelid closure. Significant defects are usually the result of mechanical trauma in the form of an abrasion to the epithelial surface that is rendered more susceptible to denudation by the overall stress of contact lens wear.",
"   </p>",
"   <p>",
"    Microcysts in the epithelial layer may result from pockets of dead cellular debris associated with hypoxia in extended wear contact lens users [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/5\">",
"     5",
"    </a>",
"    ]. These microcysts appear as small, scattered, white dots by slit-lamp biomicroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/5\">",
"     5",
"    </a>",
"    ]. Although treatment is not indicated in most patients, severe or persistent cases may necessitate switching to daily wear contact lenses or to eliminating contact lens wear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Mechanical corneal abrasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The contact lens is essentially a foreign body that is retained in the eye for hours or weeks with repetitive pressing and sliding on the cornea with each blink. Mechanical abrasions can result from traumatic insertion and removal of the lens, tears, scratches, or chips in the lens; or foreign debris trapped under the lens. Abrasions are typically very painful, because the superficial cornea is replete with sensory nerve endings.",
"   </p>",
"   <p>",
"    Corneal abrasions related to contact lens wear pose a risk for bacterial ulcerative keratitis. As a result, preventive therapy is indicated with antibiotics effective against Pseudomonas, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/57/33680?source=see_link\">",
"     Sulfacetamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    are not satisfactory choices because they do not provide adequate Pseudomonas coverage. The antibiotics should be provided as eye drops used four times daily. More frequent instillation may delay healing through toxic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lens wear should be discontinued and the patient advised to use cold compresses and oral nonsteroidal antiinflammatory drugs for pain management. Cycloplegia may also provide pain relief [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/7\">",
"     7",
"    </a>",
"    ]. Close follow-up should be provided at 24 hours and through five days after the injury.",
"   </p>",
"   <p>",
"    Patching should be",
"    <strong>",
"     avoided",
"    </strong>",
"    . A meta-analysis of 11 randomized trials of patients with simple corneal abrasions (less than 10 mm diameter and not all related to contact lens wear) found that patching did not hasten the epithelialization process or improve patient comfort [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, patching worsens the condition if an apparent contact lens&ndash;related corneal abrasion actually represents an early Pseudomonas ulcer prior to development of clinically visible infectious infiltrates [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34600?source=see_link&amp;anchor=H17#H17\">",
"     \"Corneal abrasions and corneal foreign bodies\", section on 'Contact lens related abrasions'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H21\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hypoxic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cornea derives its oxygen by direct diffusion from the ocular surface. The presence of a contact lens, if not freely permeable to gas, may reduce access to oxygen. Hypoxia is worse at night under the closed eyelids in extended wear contact lens wearers.",
"   </p>",
"   <p>",
"    Hypoxia results in microcystic edema and punctate staining of the corneal epithelium, stromal edema (manifested by a steamy, cloudy, and thickened cornea with striae or folds in Descemet's membrane), decreased visual acuity, photophobia, and conjunctival hyperemia. Chronic hypoxia may lead to superficial, and rarely deep, corneal neovascularization, especially at the superior limbus [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Toxic and/or immune reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemicals in contact lens solutions may produce toxic or immune reactions on the corneal epithelium in susceptible individuals. Such reactions may result in severe, diffuse superficial punctate epitheliopathy (",
"    <a class=\"graphic graphic_picture graphicRef60904 \" href=\"UTD.htm?42/29/43486\">",
"     picture 2",
"    </a>",
"    ), frank epithelial erosion and defects, pseudodendrites, and conjunctival hyperemia. The multiple, small subepithelial corneal infiltrates resulting from chemical toxicity may be mistaken for viral infiltrates.",
"   </p>",
"   <p>",
"    Preservatives, surfactant cleaning agents, and disinfecting chemicals have been implicated. The preservative thimerosal, now rarely used, was at one time frequently responsible for toxic and immune keratoconjunctivitis.",
"   </p>",
"   <p>",
"    Undiluted enzyme cleaner and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    disinfectant may cause a severe acute keratitis. Solutions with hydrogen peroxide may cause gas bubble formation in the epithelium and cause temporary loss of vision. Current commercial multipurpose contact lens solutions contain more dilute concentrations of enzyme and hydrogen peroxide and are therefore safer than older preparations.",
"   </p>",
"   <p>",
"    Central toxic keratopathy, seen in patients after refractive surgery, has been reported in patients after extended contact lens wear. Central toxic keratopathy is characterized by central corneal opacification, thinning, and hyperopic shift. Confocal microscopy shows edema and re-arrangement of collagen fibrils with cellular infiltration and interspersed refractile elements [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/10\">",
"     10",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Superior limbic keratoconjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A condition resembling superior limbic keratoconjunctivitis (SLK) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/11\">",
"     11",
"    </a>",
"    ] may be seen in some contact lens wearers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Classic SLK, associated with dry eye syndrome or autoimmune thyroid disease, presents as tearing, burning, a foreign body sensation, mild photophobia, and mucous discharge. There is a thickened, keratinized, and hyperemic superior bulbar and palpebral conjunctiva (",
"    <a class=\"graphic graphic_picture graphicRef51836 \" href=\"UTD.htm?42/20/43343\">",
"     picture 3",
"    </a>",
"    ). Rose-Bengal or lissamine green dye staining reveals superior corneal and conjunctival punctate staining. The central cornea is not involved. Superior filamentary keratitis and papillary keratopathy are also commonly seen.",
"   </p>",
"   <p>",
"    Contact lens wear (almost exclusively with soft lenses) may result in many of the manifestations of SLK. However, filamentary keratitis is absent and the keratitis may extend to the central cornea, resulting in decreased visual acuity. The symptoms resolve upon cessation of contact lens wear, but the corneal and conjunctival changes may persist for months to years. Treatment consists of eliminating lens wear until the ocular surface returns to normal or switching to rigid gas-permeable lenses. Glucocorticoid treatment is of minimal benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Tight lens syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contact lenses normally ride on a layer of tears that allows adequate lens movement and oxygen diffusion. A lens that adheres too tightly to the corneal surface functions like a suction cup and may cause severe pain, blurred vision, redness, and photophobia. The contact lens is immobile and difficult to remove.",
"   </p>",
"   <p>",
"    The tight lens syndrome may cause corneal epithelial staining, marked corneal stromal edema with small peripheral infiltrates, an anterior chamber inflammatory reaction, and severe conjunctival hyperemia. The signs and symptoms resolve within a few days of removal of the contact lens. A short course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    and topical glucocorticoids may hasten resolution of the clinical manifestations.",
"   </p>",
"   <p>",
"    Contact lens removal may be facilitated by applying a topical anesthetic and contact lens saline solution before attempting to slide the lens off to the side or by using a suction-plunger lens remover designed for removal of rigid lenses (",
"    <a class=\"graphic graphic_picture graphicRef65740 \" href=\"UTD.htm?32/13/32990\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Dislocated contact lens",
"    </span>",
"    &nbsp;&mdash;&nbsp;A contact lens may become dislodged from the cornea, migrate under the upper eyelid, and become embedded in the tissues of the superior cul-de-sac (fornix), causing pain, irritation, redness, and eyelid swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/14\">",
"     14",
"    </a>",
"    ]. This condition occurs almost exclusively with rigid contact lenses.",
"   </p>",
"   <p>",
"    Chronic dislocation (over weeks to months) occasionally produces sterile abscesses, cysts, eyelid retraction, orbital masses, foreign body granulomas, ptosis, and subconjunctival embedding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Extreme (\"double\") eversion of the upper eyelid may be necessary to locate and remove the problematic lens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Giant papillary conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giant papillary conjunctivitis is a noninfectious inflammatory disorder that represents a reaction to lid movement over a foreign substance, such as contact lenses. It can occur in both soft and rigid gas permeable contact lens wearers and is characterized by foreign-body sensation on the upper eyelid, associated with formation of \"giant\" (&gt;1 mm) papillae (",
"    <a class=\"graphic graphic_picture graphicRef74752 \" href=\"UTD.htm?16/32/16896\">",
"     picture 5",
"    </a>",
"    ). Giant papillary conjunctivitis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5062?source=see_link\">",
"     \"Giant papillary conjunctivitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1584969542\">",
"    <span class=\"h2\">",
"     Subconjunctival hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subconjunctival hemorrhage is a benign disorder characterized by the acute appearance of a flat area of bleeding under the conjunctiva (",
"    <a class=\"graphic graphic_picture graphicRef51578 \" href=\"UTD.htm?4/24/4495\">",
"     picture 6",
"    </a>",
"    ). Subconjunctival hemorrhage can be a complication of contact lens use, occurring in approximately 5 percent of contact lens wearers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Endothelial complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic hypoxia and acidosis in long-term contact lens wearers may cause permanent morphological changes, including reduced density of the endothelial cells that line the innermost surface of the cornea [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. These cells pump excess fluid out of the stroma and are crucial in maintaining corneal clarity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CONTACT LENS&ndash;RELATED INFECTIOUS KERATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;With an incidence of 1 to 20 per 10,000 users per year, infectious keratitis is the most serious complication of contact lens use. By type of contact lens, annual incidence rates of infectious keratitis have been reported as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rigid lenses &mdash; 0.02 percent",
"     </li>",
"     <li>",
"      Daily soft wear lenses &mdash; 0.02 to 0.04 percent",
"     </li>",
"     <li>",
"      Extended-wear soft lenses &mdash; 0.1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Contact lens wear may increase the risk of infectious keratitis by several mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Altering and causing a breakdown of the natural protective barriers of the ocular surface and tear film (eg, hypoxia, epithelial abrasions, and tear stagnation)",
"     </li>",
"     <li>",
"      Providing a nidus for entrapment of microorganisms within the micropores of the oxygen-permeable polymers and the formation of microbial biofilms on the lens surfaces",
"     </li>",
"     <li>",
"      Contact lenses, storage cases, and disinfecting solutions may become contaminated through careless handling and poor hygienic habits of the user.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Worldwide contact lens-related epidemics of the filamentous fungus Fusarium and protozoan Acanthamoeba were reported in 2006 and 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/23\">",
"     23",
"    </a>",
"    ]. Epidemiological studies implicated specific brands of multipurpose disinfecting contact lens saline solution in each of these outbreaks and the offending solutions were subsequently withdrawn from the market. Although no organisms per se were isolated from these solutions, the particular formulation in each implicated brand may have promoted infection by altering the microbial biofilm on the lens surfaces. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10712?source=see_link&amp;anchor=H773301007#H773301007\">",
"     \"Clinical manifestations and diagnosis of Fusarium infection\", section on 'Keratitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4762?source=see_link&amp;anchor=H13571795#H13571795\">",
"     \"Free-living amebas\", section on 'Keratitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type of contact lens &mdash; Overnight or extended wear of contact lenses may be associated with a 6- to 15-fold increase in the risk of infectious keratitis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/24\">",
"       24",
"      </a>",
"      ]. Infectious keratitis is less frequent with daily-wear lenses and least common in those who wear rigid gas permeable lenses [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lens hygiene &mdash; Improper maintenance and wear behaviors by users contribute to the risk of infectious keratitis. Examples of poor contact lens practices include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Wetting the lens in saliva",
"     </li>",
"     <li>",
"      Reusing multipurpose saline solution",
"     </li>",
"     <li>",
"      Preparing solution using saline tablets reconstituted with store-bought distilled water",
"     </li>",
"     <li>",
"      Not regularly cleaning or replacing the lens storage case",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recommendations from the US Food and Drug Administration for proper management of contact lenses to reduce infection risk are shown in a table (",
"    <a class=\"graphic graphic_table graphicRef50775 \" href=\"UTD.htm?13/59/14267\">",
"     table 1",
"    </a>",
"    ). Additionally, contact lens cases rapidly become a depot and breeding ground for microorganisms. Daily rinsing and air-drying the case, alcohol swabbing, or heat sterilization will reduce the growth and attachment of microbial flora. A more complete discussion of contact lens care is available separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18183?source=see_link\">",
"     \"Overview of contact lenses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Demographics &mdash; Demographic factors associated with a higher risk of contact lens-related corneal infections are male gender, low socioeconomic status, young age, and smoking [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fungal infections are more frequent in tropical and semitropical regions than in temperate regions of the world. Corneal trauma from vegetable matter, such as wood, is a well-known risk factor for fungal keratitis. Altered host immunity from topical or systemic corticosteroids or from underlying systemic disease may increase the susceptibility to fungal infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial keratitis comprises 95 percent of all contact lens infections. In referral-based institutions, bacterial infections are predominantly due to Gram-negative organisms, such as Pseudomonas, followed by Gram-positive bacteria (Staphylococcus and Streptococcus) that constitute the normal ocular surface flora [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fungi and Acanthamoeba are a less common cause of contact lens keratitis than bacteria but may lead to severe infection and poor vision outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10712?source=see_link&amp;anchor=H773301007#H773301007\">",
"     \"Clinical manifestations and diagnosis of Fusarium infection\", section on 'Keratitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4762?source=see_link&amp;anchor=H13571795#H13571795\">",
"     \"Free-living amebas\", section on 'Keratitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Clinical diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms and signs of infectious keratitis usually begin within 24 hours of infection. The most common presenting features include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Red eye (conjunctival vascular injection)",
"     </li>",
"     <li>",
"      Reduced visual acuity (especially if the central cornea is involved)",
"     </li>",
"     <li>",
"      Pain",
"     </li>",
"     <li>",
"      Eyelid swelling",
"     </li>",
"     <li>",
"      Photophobia",
"     </li>",
"     <li>",
"      Corneal epithelial defect highlighted by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      staining",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following signs and symptoms also may be present:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Yellow or white stromal infiltrates",
"     </li>",
"     <li>",
"      Corneal edema",
"     </li>",
"     <li>",
"      Stromal loss and thinning &nbsp;",
"     </li>",
"     <li>",
"      Hypopyon (layering of white blood cells in the anterior chamber) (",
"      <a class=\"graphic graphic_picture graphicRef62192 \" href=\"UTD.htm?34/50/35630\">",
"       picture 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fibrin (proteinaceous exudation) in the anterior chamber",
"     </li>",
"     <li>",
"      Wessely ring infiltrate (sterile immune infiltrate in the corneal stroma) (",
"      <a class=\"graphic graphic_picture graphicRef80699 \" href=\"UTD.htm?20/25/20895\">",
"       picture 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Flat anterior chamber, if the cornea is perforated",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stromal infiltrates result from both the infection itself and the secondary host immune response. Bacterial keratitis is associated with yellow infiltrates while fungal keratitis tends to have white infiltrates, often with feathery borders, spreading branches, and multiple smaller satellite infiltrates (",
"    <a class=\"graphic graphic_picture graphicRef77231 \" href=\"UTD.htm?5/62/6112\">",
"     picture 9",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Stromal loss represents necrotic ulceration and focal thinning of the cornea. This results from collagenases produced by both the organism and the host response.",
"   </p>",
"   <p>",
"    Hypopyon usually represents a sterile inflammatory reaction in the anterior chamber to the overlying corneal infection, but may contain organisms if there is a perforated corneal ulcer. Hypopyon, as well as fibrinous anterior chamber reactions, occur more frequently with fungal keratitis.",
"   </p>",
"   <p>",
"    An endophytic fungal plaque on the endothelial surface may sometimes be diagnostic of fungal keratitis (",
"    <a class=\"graphic graphic_picture graphicRef64228 \" href=\"UTD.htm?41/34/42542\">",
"     picture 10",
"    </a>",
"    ). Unlike bacteria, fungi are capable of crossing an intact Descemet's membrane barrier.",
"   </p>",
"   <p>",
"    Corneal perforation is a serious complication that may potentially lead to endophthalmitis and intraocular damage and may warrant immediate surgical intervention (",
"    <a class=\"graphic graphic_picture graphicRef53729 \" href=\"UTD.htm?21/48/22287\">",
"     picture 11",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Microbial culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric treatment with topical wide-spectrum antibiotic eye drops is an accepted community standard for contact lens keratitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/29\">",
"     29",
"    </a>",
"    ]. Many argue that obtaining corneal cultures may not be cost-effective for the initial treatment of infectious keratitis. However, if the infection is particularly severe at the time of initial presentation, or if the infection does not respond to the initial antibacterial therapy, cultures must be obtained.",
"   </p>",
"   <p>",
"    Swab cultures obtained with cotton-tipped applicators are often inadequate and are not recommended unless there is no other recourse. Corneal scrapings for culture and Gram stain can be important in microbial identification of unusual bacteria, drug-resistant bacteria (eg, methicillin-resistant Staphylococcus aureus), or non-bacterial organisms, such as fungi and Acanthamoeba. Chronic or atypical corneal infections may eventually require deeper lamellar excisional biopsies for identification.",
"   </p>",
"   <p>",
"    Preferably, cultures should be performed by an ophthalmologist in a referral-based practice. Specimens from the infected cornea may be obtained by scraping with a Kimura spatula (",
"    <a class=\"graphic graphic_picture graphicRef71814 \" href=\"UTD.htm?22/10/22690\">",
"     picture 12",
"    </a>",
"    ) or a disposable sterile scalpel blade. The peripheral borders of the infiltrate, often the leading edge of infection, may contain the most active organisms and therefore yield the most productive cultures.",
"   </p>",
"   <p>",
"    Specimens should be cultured for bacteria and fungus; special media are required when nontuberculous mycobacterial or amebic infections are suspected. Routine and immunofluorescent stains may be helpful, but cultures are the top priority when there is limited sample.",
"   </p>",
"   <p>",
"    Contact lenses, cases, and lens care systems may provide an alternative source for culture, but they often harbor a wide spectrum of microorganisms, and culture results may be misleading or confusing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Impression cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to obtaining specimens by scraping is impression cytology, in which a cellulose acetate filter is placed on the ocular surface [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/23\">",
"     23",
"    </a>",
"    ]. When removed, the filter pulls up superficial layers of the ocular surface epithelium, and these cells can then be examined histologically or by molecular analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Confocal microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vivo microscopic examination of the cornea using confocal microscopy can reveal Acanthamoeba cysts and filamentous fungi in the corneal stroma. A more sophisticated tandem confocal microscope and Heidelberg retina tomograph (HRT-II) can identify necrotic inflammatory cells in the corneal stroma and anterior chamber patients with bacterial ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     General recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infected corneas should not be patched, because the darkness, warmth, and humidity underneath a covered eye may be conducive to enhanced growth of microorganisms. Even clean-appearing contact-lens related corneal abrasions, without infiltrates, should not be patched because such abrasions may occasionally be infections [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/6\">",
"     6",
"    </a>",
"    ]. A full-blown corneal infiltrate may not be manifested in the first few hours of infection.",
"   </p>",
"   <p>",
"    Antibiotic therapy should be empirically started at initial presentation of suspected abrasions and an examination by slit-lamp biomicroscopy performed within 24 hours. If the cornea is deeply ulcerated or perforated, a protective metal or plastic eye shield should be applied before urgent referral to an ophthalmologist.",
"   </p>",
"   <p>",
"    Concurrent cycloplegic eye drops may be used to reduce photophobia from ciliary spasm and to reduce the formation of pupillary adhesions to the lens (posterior synechia).",
"   </p>",
"   <p>",
"    The use of concurrent glucocorticoid eye drops should be avoided in the acute phase of the keratitis. Glucocorticoid adjunctive treatment may be indicated for selected patients (visually significant central corneal inflammation or a severe anterior segment inflammatory response) but there are no good quality randomized trials to evaluate this use [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/32\">",
"     32",
"    </a>",
"    ]. Topical glucocorticoids may be cautiously used together with the antimicrobial drugs only after the infection is under good control. The decision to start glucocorticoid therapy is best left to the ophthalmologist.",
"   </p>",
"   <p>",
"    Corneal surgery may be indicated for extirpation of recalcitrant infectious foci, improvement of drug penetration, and corneal perforation. A conjunctival flap over the cornea may sometimes be required to arrest a persistent corneal ulcer.",
"   </p>",
"   <p>",
"    Decisions about when and if contact lens wear may safely be resumed following resolution of infection are best left to the treating ophthalmologist and should take into account factors such as patient hygiene, compliance, coexisting ocular surface problems, and infection sequelae. For some patients, a type of lens other than the one worn prior to the infection may be indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Bacterial keratitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For suspected bacterial keratitis, broad-spectrum topical antibiotic eye drops should be instilled as often as every hour around the clock. Ointments have poor corneal bioavailability and drops are preferred in the acute therapy of infectious keratitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/33\">",
"     33",
"    </a>",
"    ]. Ointments may be used at bedtime to allow the patient to sleep through the night, but only after a positive response has been demonstrated to the initial intensive eyedrop treatment.",
"   </p>",
"   <p>",
"    Options for treatment of bacterial keratitis are fluoroquinolone monotherapy or a combination of fortified topical antibiotics (eg, a cephalosporin and an aminoglycoside) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/34\">",
"     34",
"    </a>",
"    ]. Topical antibiotics are fortified by adding a highly-concentrated saline solution of the intravenously-formulated antibiotic powder to commercially available antibiotic eyedrops. Fortified antibiotics present problems in preparation and storage, while fluoroquinolones may be associated with corneal precipitates and poor epithelial wound healing.",
"   </p>",
"   <p>",
"    In one trial, the fourth-generation",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/46/4836?source=see_link\">",
"     gatifloxacin",
"    </a>",
"    was more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    in the treatment of bacterial keratitis due to Gram-positive cocci [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/35\">",
"     35",
"    </a>",
"    ]. In vitro studies and in vivo animal studies suggest greater potency for the fourth-generation fluoroquinolones compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/36\">",
"     36",
"    </a>",
"    ]. Most bacterial infections respond to single-drug therapy with fourth-generation fluoroquinolone eye drops, such as gatifloxacin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    , or to alternating hourly doses of fortified",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/ml)",
"    </span>",
"    and fortified",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    (14",
"    <span class=\"nowrap\">",
"     mg/ml)",
"    </span>",
"    eye drops staggered 30 minutes apart from each other. We generally initiate treatment with gatifloxacin or moxifloxacin, although these agents are expensive. Severe infections may benefit from subconjunctival antibiotic injections in addition to the eyedrop therapy.",
"   </p>",
"   <p>",
"    Second generation (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    ) and third generation (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ) eye drops are also effective, and are available in generic formulation. Some antibiotic resistance has emerged to these medications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29128/abstract/36\">",
"     36",
"    </a>",
"    ], but they may be used as alternatives to the more expensive fourth generation medications when cost concerns do not permit use of the newer drugs.",
"   </p>",
"   <p>",
"    For bacterial keratitis, several weeks to months of treatment may be necessary. For most patients, intense hourly treatment is indicated for the first 24 to 48 hours, until some response is apparent, when applications can be tapered to every two and then every four hours and continued for a minimum of two weeks. Some patients with more severe infection will require ongoing antibiotic treatment for several months.",
"   </p>",
"   <p>",
"    If the keratitis does not respond to initial treatment, cultures may be invaluable in the identification and antibiotic sensitivities of the resistant organisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Fungal and protozoan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although fungi and Acanthamoeba are less common than bacteria in contact-lens infections, they can potentially lead to equally severe, if not graver consequences. Diagnosis and treatment in these uncommon infections are often delayed, because of lower indices of suspicion, relative unfamiliarity, and clinical signs that masquerade as viral or bacterial infection. Response to antimicrobial treatment may also be slow, in part due to the presence of protective cell walls or cysts, and in part due to difficult penetration of topical drug into deep cornea. Treatment may require prolonged use of medications for many months.",
"   </p>",
"   <p>",
"    Amebic and fungal keratitis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41640?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology and clinical manifestations of Scedosporium infection\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10712?source=see_link&amp;anchor=H773301000#H773301000\">",
"     \"Clinical manifestations and diagnosis of Fusarium infection\", section on 'Immunocompetent patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/42/3753?source=see_link&amp;anchor=H346085004#H346085004\">",
"     \"Treatment and prevention of Fusarium infection\", section on 'Keratitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4762?source=see_link&amp;anchor=H13571795#H13571795\">",
"     \"Free-living amebas\", section on 'Keratitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;If appropriate treatment is delayed, infectious keratitis may lead to serious, blinding complications including corneal scarring (leukoma), vascularization (",
"    <a class=\"graphic graphic_picture graphicRef53579 \" href=\"UTD.htm?32/40/33423\">",
"     picture 13",
"    </a>",
"    ), perforation, and irregular astigmatism. Intraocular complications may include cataract, glaucoma, endophthalmitis, and phthisis bulbi (endstage blind eye with low intraocular pressure, often resulting in shrinkage of the globe), which may necessitate enucleation of the eyeball.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Noninfectious complications of contact lens wear are minimized with a well-fitted lens that rests on the pre-corneal tear film and moves only enough to allow good fluid and gas exchange. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Noninfectious complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sterile corneal infiltrates are collections of inflammatory cells that appear as white lesions in the anterior stroma. They are usually asymptomatic and respond to topical glucocorticoids and eye hygiene measures. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Sterile corneal infiltrates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Corneal epithelial problems are diagnosed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      dye staining. Punctate staining is common and are caused by a number of mild insults related to contact lens wear; larger defects are due to mechanical trauma. Corneal abrasions should be treated with topical antibiotics with pseudomonal coverage and removal of the contact lens. We recommend not patching the eye for small (&lt;10 mm) corneal abrasions (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Corneal epithelial problems'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other noninfectious contact lens&ndash;related complications may result from hypoxic, toxic or immune reactions, a poorly-fit tight contact lens, or a dislocated lens. Giant papillary conjunctivitis represents a hypersensitivity reaction to antigens coating the contact lens. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Noninfectious complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Contact lens wear increases the risk of infectious keratitis, with heightened risk in extended wear lenses and in users with poor technique for contact lens preparation or disinfection. Microbial culture, involving corneal scraping, is indicated for patients with suspected severe infectious keratitis and for those who do not respond to empiric antibiotic treatment. Swab cultures are not adequate. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Contact lens&ndash;related infectious keratitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with suspected bacterial keratitis should be promptly and empirically treated with an antibiotic and referred to an ophthalmologist. We suggest empiric treatment with either a fourth-generation fluoroquinolone (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/46/4836?source=see_link\">",
"       gatifloxacin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Alternatively, a combination fortified",
"      <span class=\"nowrap\">",
"       aminoglycoside/fortified",
"      </span>",
"      cephalosporin eye drop instilled hourly is an acceptable choice. Patients should have close follow-up at 24 hours. Cycloplegia may reduce photophobia, and patching should be strictly avoided.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/1\">",
"      Sindt CW, Longmuir RA. Contact lens strategies for the patient with dry eye. Ocul Surf 2007; 5:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/2\">",
"      The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/3\">",
"      Bates AK, Morris RJ, Stapleton F, et al. 'Sterile' corneal infiltrates in contact lens wearers. Eye (Lond) 1989; 3 ( Pt 6):803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/4\">",
"      Gordon A, Kracher GP. Corneal infiltrates and extended-wear contact lenses. J Am Optom Assoc 1985; 56:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/5\">",
"      Zantos SG. Cystic formation in the corneal epithelium during extended wear of contact lenses. Int Contact Lens Clin 1983; 10:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/6\">",
"      Clemons CS, Cohen EJ, Arentsen JJ, et al. Pseudomonas ulcers following patching of corneal abrasions associated with contact lens wear. CLAO J 1987; 13:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/7\">",
"      Catania LJ. Management of corneal abrasions in an extended-wear patient population. Optom Clin 1991; 1:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/8\">",
"      Turner A, Rabiu M. Patching for corneal abrasion. Cochrane Database Syst Rev 2006; :CD004764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/9\">",
"      McMonnies CW. Contact-lens induced corneal vascularization. Int Contact Lens Clin 1983; 10:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/10\">",
"      Hsu M, Tu E, Bouchard C. Confocal microscopy of contact lens keratitis presenting as central toxic keratopathy. Eye Contact Lens 2011; 37:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/11\">",
"      Theodore FH. Superior limbic keratoconjunctivitis. Arch Ophthalmol 1983; 101:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/12\">",
"      Fuerst DJ, Sugar J, Worobec S. Superior limbic keratoconjunctivitis associated with cosmetic soft contact lens wear. Arch Ophthalmol 1983; 101:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/13\">",
"      Miller RA, Brightbill FS, Slama SL. Superior limbic keratoconjunctivitis in soft contact lens wearers. Cornea 1982; 1:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/14\">",
"      Burns JA, Cahill KV. Long-term dislocation of a hard contact lens. Ophthalmic Surg 1986; 17:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/15\">",
"      Weinstein GS, Myers BB. Eyelid retraction as a complication of an embedded hard contact lens. Am J Ophthalmol 1993; 116:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/16\">",
"      Nicolitz E, Flanagan JC. Orbital mass as a complication of contact lens wear. Arch Ophthalmol 1978; 96:2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/17\">",
"      Sebag J, Albert DM. Pseudochalazion of the upper lid due to hard contact lens embedding -- case reports and literature review. Ophthalmic Surg 1982; 13:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/18\">",
"      Mimura T, Yamagami S, Mori M, et al. Contact lens-induced subconjunctival hemorrhage. Am J Ophthalmol 2010; 150:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/19\">",
"      Bourne WM, Hodge DO, McLaren JW. Estimation of corneal endothelial pump function in long-term contact lens wearers. Invest Ophthalmol Vis Sci 1999; 40:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/20\">",
"      Bourne WM, Holtan SB, Hodge DO. Morphologic changes in corneal endothelial cells during 3 years of fluorocarbon contact lens wear. Cornea 1999; 18:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/21\">",
"      MacRae SM, Matsuda M, Phillips DS. The long-term effects of polymethylmethacrylate contact lens wear on the corneal endothelium. Ophthalmology 1994; 101:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/22\">",
"      Liesegang TJ. Contact lens-related microbial keratitis: Part I: Epidemiology. Cornea 1997; 16:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/23\">",
"      Thomas PA, Geraldine P. Infectious keratitis. Curr Opin Infect Dis 2007; 20:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/24\">",
"      Schein OD, Buehler PO, Stamler JF, et al. The impact of overnight wear on the risk of contact lens-associated ulcerative keratitis. Arch Ophthalmol 1994; 112:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/25\">",
"      Keay L, Stapleton F, Schein O. Epidemiology of contact lens-related inflammation and microbial keratitis: a 20-year perspective. Eye Contact Lens 2007; 33:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/26\">",
"      Keay L, Edwards K, Naduvilath T, et al. Microbial keratitis predisposing factors and morbidity. Ophthalmology 2006; 113:109.",
"     </a>",
"    </li>",
"    <li>",
"     Huang AJ, Wichiensin P, Yang M. Bacterial keratitis. In: Cornea, 2nd ed, Krachmer JH, McMannis MJ, Holland EJ (Eds), Elseverier Mosby, Philadelphia 2005. Vol 1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/28\">",
"      Mondino BJ, Weissman BA, Farb MD, Pettit TH. Corneal ulcers associated with daily-wear and extended-wear contact lenses. Am J Ophthalmol 1986; 102:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/29\">",
"      McDonnell PJ, Nobe J, Gauderman WJ, et al. Community care of corneal ulcers. Am J Ophthalmol 1992; 114:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/30\">",
"      Donzis PB, Mondino BJ, Weissman BA, Bruckner DA. Microbial analysis of contact lens care systems contaminated with Acanthamoeba. Am J Ophthalmol 1989; 108:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/31\">",
"      Donzis PB, Mondino BJ, Weissman BA, Bruckner DA. Microbial contamination of contact lens care systems. Am J Ophthalmol 1987; 104:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/32\">",
"      Suwan-Apichon O, Reyes JM, Herretes S, et al. Topical corticosteroids as adjunctive therapy for bacterial keratitis. Cochrane Database Syst Rev 2007; :CD005430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/33\">",
"      Robin JS, Ellis PP. Ophthalmic ointments. Surv Ophthalmol 1978; 22:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/34\">",
"      Ly CN, Pham JN, Badenoch PR, et al. Bacteria commonly isolated from keratitis specimens retain antibiotic susceptibility to fluoroquinolones and gentamicin plus cephalothin. Clin Experiment Ophthalmol 2006; 34:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/35\">",
"      Parmar P, Salman A, Kalavathy CM, et al. Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis. Am J Ophthalmol 2006; 141:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29128/abstract/36\">",
"      Scoper SV. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy. Adv Ther 2008; 25:979.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6913 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-64F316EBC0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_28_29128=[""].join("\n");
var outline_f28_28_29128=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NONINFECTIOUS COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1572295\">",
"      Dryness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Sterile corneal infiltrates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Corneal epithelial problems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Mechanical corneal abrasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hypoxic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Toxic and/or immune reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Superior limbic keratoconjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Tight lens syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Dislocated contact lens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Giant papillary conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1584969542\">",
"      Subconjunctival hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Endothelial complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CONTACT LENS&ndash;RELATED INFECTIOUS KERATITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Clinical diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Microbial culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Impression cytology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Confocal microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - General recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Bacterial keratitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Fungal and protozoan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6913\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6913|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/7/36990\" title=\"picture 1\">",
"      Mult sterile corneal infil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/29/43486\" title=\"picture 2\">",
"      Superfic puncuate keratitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/20/43343\" title=\"picture 3\">",
"      Limbic keratoconjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/13/32990\" title=\"picture 4\">",
"      Suction device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/32/16896\" title=\"picture 5\">",
"      Giant papillae in giant papillary conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/24/4495\" title=\"picture 6\">",
"      Subconjunctival hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/50/35630\" title=\"picture 7\">",
"      Pseudomonas corneal ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/25/20895\" title=\"picture 8\">",
"      Wessley immune ring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/62/6112\" title=\"picture 9\">",
"      Fungal keratitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/34/42542\" title=\"picture 10\">",
"      Fungal endothelial plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/48/22287\" title=\"picture 11\">",
"      Corneal perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/10/22690\" title=\"picture 12\">",
"      Instruments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/40/33423\" title=\"picture 13\">",
"      Endstage corneal scarring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6913|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/59/14267\" title=\"table 1\">",
"      Contact lens care tips",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=related_link\">",
"      Blepharitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10712?source=related_link\">",
"      Clinical manifestations and diagnosis of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34600?source=related_link\">",
"      Corneal abrasions and corneal foreign bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41640?source=related_link\">",
"      Epidemiology and clinical manifestations of Scedosporium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4762?source=related_link\">",
"      Free-living amebas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5062?source=related_link\">",
"      Giant papillary conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18183?source=related_link\">",
"      Overview of contact lenses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/42/3753?source=related_link\">",
"      Treatment and prevention of Fusarium infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_28_29129="Exercise ECG testing to determine prognosis of coronary heart disease";
var content_f28_28_29129=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Exercise ECG testing to determine prognosis of coronary heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/28/29129/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/28/29129/contributors\">",
"     Frank G Yanowitz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/28/29129/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/28/29129/contributors\">",
"     Patricia A Pellikka, MD, FACC, FAHA, FASE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/28/29129/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/28/29129/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/28/29129/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exercise ECG test is a well-established, inexpensive procedure for answering important clinical questions related to exercise tolerance and heart disease. It indirectly detects myocardial ischemia, which is the physiologic consequence of coronary obstruction.",
"   </p>",
"   <p>",
"    Exercise ECG testing is primarily performed in patients who are able to attain a sufficient level of exercise and who do not have baseline ECG abnormalities that can interfere with interpretation. These abnormalities include preexcitation (Wolff-Parkinson-White) syndrome, more than 1 mm of ST depression at rest, and patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    or with ECG criteria for left ventricular hypertrophy, even if they have less than 1 mm of baseline ST depression. Patients with one or more of these abnormalities should be tested with echocardiography or radionuclide myocardial perfusion imaging; pharmacologic stress is warranted in patients who are unable to exercise. (",
"    <a class=\"graphic graphic_table graphicRef64807 graphicRef74428 \" href=\"UTD.htm?31/62/32749\">",
"     table 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Stress testing in patients with LBBB or with a paced ventricular rhythm is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=see_link\">",
"     \"Stress testing in patients with left bundle branch block or a paced ventricular rhythm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sensitivity and specificity of exercise ECG testing have been derived from studies correlating the ECG response to exercise with coronary angiographic data (to document the anatomic abnormality). Patient gender, age, coronary risk factors, and the characteristics of the chest pain are also important determinants of the pretest probability of coronary heart disease (CHD) and therefore of the diagnostic accuracy of exercise ECG testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link&amp;anchor=H2#H2\">",
"     \"Stress testing for the diagnosis of coronary heart disease\", section on 'Pretest probability'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of exercise ECG testing to estimate prognosis in patients with known or suspected CHD will be reviewed here. The methodology, indications, and contraindications of this test, including exercise testing protocols (",
"    <a class=\"graphic graphic_table graphicRef70044 \" href=\"UTD.htm?12/51/13118\">",
"     table 2",
"    </a>",
"    ) the endpoints of exercise ECG testing (",
"    <a class=\"graphic graphic_table graphicRef77689 \" href=\"UTD.htm?14/28/14796\">",
"     table 3",
"    </a>",
"    ), the electrocardiographic manifestations of exercise-induced ischemia, and an overview of the role of stress testing in general to estimate prognosis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link\">",
"     \"Performance of exercise ECG testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11017?source=see_link\">",
"     \"Electrocardiographic changes during exercise ECG testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=see_link\">",
"     \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ADVERSE PREDICTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who undergo exercise stress, a number of variables, either alone or in combination, are associated with an increased risk of an adverse outcome in patients with CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/1-9\">",
"     1-9",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poor exercise capacity (&lt;5 METs)",
"     </li>",
"     <li>",
"      Exercise-induced angina, particularly that which is exercise-limiting or occurs at a low workload",
"     </li>",
"     <li>",
"      Abnormally low peak systolic blood pressure (&lt;130 mmHg) or a fall in systolic blood pressure below baseline during exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Chronotropic incompetence (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Heart rate response to exercise'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are also a number of ECG findings during exercise that are important. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &ge;1 mm of downsloping or flat ST segment depression during exercise or recovery",
"     </li>",
"     <li>",
"      &ge;2 mm of ischemic ST depression at a low workload (stage 2 or less or &le;130",
"      <span class=\"nowrap\">",
"       beats/min)",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef70044 \" href=\"UTD.htm?12/51/13118\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Early onset (stage 1) or prolonged duration (&gt;5 min) of ST depression",
"     </li>",
"     <li>",
"      Multiple leads (&gt;5) with ST depression",
"     </li>",
"     <li>",
"      ST segment elevation (in leads without pathological Q waves and not in aVR)",
"     </li>",
"     <li>",
"      Ventricular couplets or tachycardia at a low workload or during recovery",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       ST/HR",
"      </span>",
"      slope (6",
"      <span class=\"nowrap\">",
"       microV/beat",
"      </span>",
"      per min)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11017?source=see_link\">",
"     \"Electrocardiographic changes during exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognosis after exercise ECG testing may be better predicted with the use of treadmill scores that take into account multiple variables. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Duke treadmill score'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Flat or downsloping ST depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a positive exercise ECG test is defined as &ge;1 mm horizontal (flat) or downsloping ST segment depression measured at 80 msec after the end of the QRS complex, as recommended by the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/10\">",
"     10",
"    </a>",
"    ], the mean sensitivity and specificity are approximately 60 and 90 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/11\">",
"     11",
"    </a>",
"    ]. Upsloping ST depression may increase sensitivity at the price of reduced specificity and is not recommended as a criterion by the guidelines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11017?source=see_link&amp;anchor=H4#H4\">",
"     \"Electrocardiographic changes during exercise ECG testing\", section on 'ST segment depression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link\">",
"     \"Performance of exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Flat or downsloping ST depression can occur during exercise and during recovery and has prognostic significance at both time periods. The predictive value during exercise testing was illustrated in two studies of patients with known or suspected CHD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report evaluated 1472 patients who also underwent coronary angiography [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/4\">",
"       4",
"      </a>",
"      ]. Patients who developed &ge;1 mm ST depression in stage 1 or 2 of the Bruce protocol (",
"      <a class=\"graphic graphic_table graphicRef70044 \" href=\"UTD.htm?12/51/13118\">",
"       table 2",
"      </a>",
"      ) or at heart rates less than 120",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      had a poor prognosis (12 month survival of less than 85 percent) and a high probability of significant left main (25 percent) or three vessel disease (more than 60 percent). In contrast, the ability to exercise into stage 4 (&gt;10 METs) or to achieve a maximal heart rate greater than 160 beats per min with &lt;1 mm ST depression was associated with an excellent prognosis (12 month survival more than 99 percent) and a low probability of significant left main (less than 1 percent) or three vessel disease (less than 15 percent). The intermediate group fell between these two extremes.",
"     </li>",
"     <li>",
"      Similar findings were noted in a review from the Coronary Artery Surgery Study (CASS) Registry of 4083 medically treated patients with stable angina [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/2\">",
"       2",
"      </a>",
"      ]. The 12 percent of patients with &ge;1 mm exercise-induced ST depression and final stage &le;1 of the Bruce protocol (",
"      <a class=\"graphic graphic_table graphicRef70044 \" href=\"UTD.htm?12/51/13118\">",
"       table 2",
"      </a>",
"      ) were at high risk with an average annual mortality rate of approximately 5 percent per year. In contrast, the 34 percent of patients who had &lt;1 mm ST depression and final exercise stage &ge;3 were at low risk with an annual mortality of less than 1 percent per year. An intermediate risk group with some ischemia but preserved exercise tolerance (&ge;1 mm of ST depression and final exercise stage &ge;2) had an annual mortality of approximately 2 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of such stratification is that it identifies patients who are likely to benefit from coronary intervention compared to medical therapy. At least four studies have reported improved survival following coronary artery bypass graft surgery in patients with an abnormal exercise test prior to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/3,6,12,13\">",
"     3,6,12,13",
"    </a>",
"    ]. By comparison, survival was similar with surgical and medical therapy among patients with a more normal presurgery exercise test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=see_link\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These differences were illustrated in a later report from the CASS registry [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/12\">",
"     12",
"    </a>",
"    ]. The benefit from CABG was greatest in high risk patients with &ge;1 mm exercise-induced ST depression and final stage &le;1 of the Bruce protocol (seven year survival 81 versus 58 percent for medical therapy). In contrast, there was no difference in survival among low risk patients with &lt;1 mm ST depression and final exercise stage &ge;3.",
"   </p>",
"   <p>",
"    Although typically occurring during exercise, ST depression develops in some patients (approximately 8 percent in two reports) only during recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The positive predictive value of ST depression occurring during recovery for significant angiographic disease is not significantly different from that occurring during exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/14\">",
"     14",
"    </a>",
"    ]. The prognostic significance also may be similar [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Flat or downsloping ST segment depression during exercise or recovery is also an adverse predictor in apparently healthy individuals. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Asymptomatic patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Heart rate response to exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;An impaired heart rate (HR) response to exercise, known as chronotropic incompetence, is generally defined as failure to achieve 85 percent of the age-predicted maximum heart rate. Chronotropic incompetence may be predictive of all-cause mortality and CHD risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/8,16-18\">",
"     8,16-18",
"    </a>",
"    ]. The following reports illustrate the potential prognostic value of this abnormality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective cohort study evaluated 2953 patients referred for exercise ECG testing with thallium imaging [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/17\">",
"       17",
"      </a>",
"      ]. Eleven percent failed to achieve at least 85 percent of the age-predicted maximal heart rate. At a mean follow-up of two years, chronotropic incompetence was associated with a significant increase in mortality after adjusting for age, sex, thallium perfusion defects, and other confounders (absolute increase 4 percent, adjusted relative risk 1.84) (",
"      <a class=\"graphic graphic_figure graphicRef70339 \" href=\"UTD.htm?15/3/15421\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Similar findings were noted in a report of 3221 patients undergoing treadmill exercise echocardiography in which 495 patients (15 percent) failed to achieve at least 85 percent of the age-predicted maximal heart rate [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/18\">",
"       18",
"      </a>",
"      ]. At a median follow-up of 3.2 years, these patients had significant increases in all-cause and cardiac mortality after adjusting for clinical parameters, left ventricular ejection fraction (LVEF), and the severity of ischemic wall motion abnormalities on echocardiography (adjusted risk 1.5 and 2.1).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, in a prospective cohort study that evaluated all-cause mortality in 5437 asymptomatic females 35 years or older without active cardiovascular disease who were followed for 16 years, there was no significant change in all-cause mortality in those who failed to achieve 85 percent of maximal HR (hazard ratio 1.17, 95% CI 0.89-1.56) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/19\">",
"     19",
"    </a>",
"    ]. As opposed to the studies of symptomatic patients described above, this study enrolled healthy asymptomatic women expected to have a lower event rate, which may have limited the ability of the study to detect a significant difference in mortality. However, peak heart rate remains important as it was inversely associated with mortality. For each additional 1 bpm increase in overall HR with exercise, there was a 3 percent decrease in overall mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Heart rate recovery after exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed return of the heart rate to the normal range after exercise, probably a reflection of decreased vagal reactivation, provides important prognostic information. The definitions of abnormal heart rate recovery (HRR) have varied in different studies from &le;12 to &le;18",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    at one minute [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/20-23\">",
"     20-23",
"    </a>",
"    ] to &le;22 to &le;42",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    at two minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Late HRR (five minutes after the cessation of exercise) has also been defined and investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The predictive value of abnormal HRR following exercise stress testing has been evaluated in a variety of clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 2428 patients without heart failure or prior bypass surgery who were referred for exercise testing with radionuclide myocardial perfusion imaging, abnormal HRR (defined as &le;12",
"      <span class=\"nowrap\">",
"       beats/min)",
"      </span>",
"      while the patient was exercising lightly during the one minute \"cool down phase\" was associated with an increase in overall mortality at six-year follow-up (",
"      <a class=\"graphic graphic_figure graphicRef57524 \" href=\"UTD.htm?30/56/31629\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/20\">",
"       20",
"      </a>",
"      ]. This relationship persisted after adjustment for standard cardiovascular risk factors, changes in heart rate during exercise, the use of medications, exercise capacity, and the presence or absence of myocardial perfusion defects.",
"     </li>",
"     <li>",
"      In a follow-up study of 9454 subjects at the same institution, mortality at five years was independently predicted by both abnormal HRR and an intermediate or high Duke treadmill score (eight versus two percent in those with a low score) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/21\">",
"       21",
"      </a>",
"      ]. There was no interaction between these two predictors. The predictive value of abnormal HRR persisted after the angiographic severity of coronary disease was taken into account [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Duke treadmill score'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In patients who undergo exercise echocardiography requiring them to lie down immediately (rather than having a cool down phase) after exercise cessation, abnormal HRR (&le;18",
"      <span class=\"nowrap\">",
"       beats/min)",
"      </span>",
"      independently predicts increased mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A similar increase in overall mortality has been seen in octogenarians with abnormal HRR [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Late HRR at five minutes post-exercise appears to provide additional prognostic information beyond that acquired with abnormal HRR at one minute. In a cohort of 2082 patients who underwent exercise testing and were followed for an average of 10 years, patients with impaired late HRR at five minutes had significantly higher all-cause mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although routine screening for coronary heart disease in asymptomatic patients is not recommended, studies in which this has been performed have found that HRR is predictive of long-term outcomes in both men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/26,29,30\">",
"     26,29,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=see_link&amp;anchor=H10#H10\">",
"     \"Screening for coronary heart disease\", section on 'High-risk patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 5713 asymptomatic men, subjects in the lowest quintile of HRR (&lt;25",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      reduction in the first minute after exercise) had a significantly higher incidence of sudden death (adjusted relative risk 2.1) compared to those in the highest quintile (&gt;40",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      reduction) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/30\">",
"       30",
"      </a>",
"      ]. However, in this population, the strongest heart rate predictor of sudden death was a lower increase in heart rate with exercise (adjusted relative risk 4.0 for increase in heart rate with exercise &lt;89",
"      <span class=\"nowrap\">",
"       beats/min).",
"      </span>",
"     </li>",
"     <li>",
"      In a report from the Lipid Clinics Research Study of asymptomatic women, the cardiovascular mortality was highest in women who were below the median for both heart rate recovery and exercise capacity (multivariable-adjusted hazard ratio 3.5 compared to those above the median for both variables) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/29\">",
"       29",
"      </a>",
"      ]. At 20-year follow-up, for every 10 beats per minute decrement in heart rate recovery at two minutes post-exercise while seated in a chair, the hazard ratio for cardiovascular death was 1.36 (95% CI 1.19-1.55).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     BP recovery after exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise is associated with an increase in systolic pressure, while the diastolic pressure is stable or falls. In an initial observation in which exercise test results were correlated with angiographic findings, a delayed decline of systolic pressure after exercise, defined as a ratio of systolic blood pressure at three minutes of recovery to systolic pressure at one minute of recovery &gt;1, was associated with a greater likelihood of severe coronary artery disease (defined as left main or three vessel disease or two-vessel disease with proximal left anterior descending artery involvement) (34 versus 17 percent in those with a normal decline in systolic pressure) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link&amp;anchor=H20#H20\">",
"     \"Performance of exercise ECG testing\", section on 'BP measurements'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ventricular arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise-induced ventricular ectopy occurs in 7 to 20 percent of patients undergoing exercise ECG testing for known or suspected coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/32-36\">",
"     32-36",
"    </a>",
"    ] and in 2 to 8 percent of asymptomatic men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/29,37\">",
"     29,37",
"    </a>",
"    ]. The clinical significance of exercise-induced ventricular premature beats (VPBs) in patients without known or suspected heart disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical significance and treatment of ventricular premature beats\", section on 'Exercise-induced'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most studies in patients with known or suspected CHD have noted an association between exercise-induced ventricular arrhythmia and increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. However, it remains uncertain whether ventricular arrhythmia is an independent risk factor or a marker for more severe underlying disease.",
"   </p>",
"   <p>",
"    The frequency of VPBs was evaluated in 1293 consecutive nonsurgically treated patients with suspected CHD who underwent an exercise test within six weeks of coronary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/34\">",
"     34",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At least one VPB (but without paired complexes or ventricular tachycardia) occurred in association with exercise testing in 18 percent of patients.",
"     </li>",
"     <li>",
"      The development of VPBs was more common in patients with significant three-vessel coronary artery disease, reduced left ventricular function, more segmental wall motion abnormalities, and a greater degree of ST segment depression during exercise.",
"     </li>",
"     <li>",
"      VPBs added independent prognostic value to noninvasive evaluation, but provided no independent information once the results of coronary angiography were known. There was no relationship between VPBs and survival in patients without significant CHD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the largest study, the importance of frequent ventricular ectopy (defined as &ge;7 VPBs per minute, ventricular bigeminy or trigeminy, or more marked ventricular arrhythmia) was evaluated in 29,244 patients referred for symptom-limited exercise testing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/32\">",
"     32",
"    </a>",
"    ]. Frequent ventricular ectopy developed during exercise alone in 3 percent, during recovery alone in 2 percent, and during both exercise and recovery in 2 percent. The following findings were noted at a mean follow-up of 5.3 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frequent ventricular ectopy during exercise was associated with an increase in mortality and with an LVEF less than 40 percent and with echocardiographic evidence of ischemia. However, the increase in mortality did not persist after adjustment for confounding variables (adjusted hazard ratio 1.1).",
"     </li>",
"     <li>",
"      Frequent ventricular ectopy during recovery which, as noted above, is a period of rapid vagal reactivation, was associated with an increase in mortality and with an LVEF less than 40 percent. The increase in mortality risk remained significant after adjustment for confounding variables (11 versus 5 percent, adjusted hazard ratio 1.5). The association with a low LVEF, which was also an independent predictor of mortality, suggests that measurement of LVEF may be warranted in such patients, since effective therapy to prevent progression of left ventricular dysfunction is available. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=see_link\">",
"       \"Evaluation and management of asymptomatic left ventricular systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Atrial arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial arrhythmias also occur during exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In a report of 5375 patients with known or suspected CHD, atrial premature beats occurred in 24 percent, supraventricular tachycardia in 3.4 percent, and atrial",
"    <span class=\"nowrap\">",
"     fibrillation/flutter",
"    </span>",
"    in 0.8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/38\">",
"     38",
"    </a>",
"    ]. In contrast to exercise-induced ventricular arrhythmias, the development of atrial arrhythmias during exercise was not predictive of long-term rates of cardiac death or revascularization after adjustment for clinical and exercise variables.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Exercise-induced LBBB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left bundle branch block (LBBB) masks the ability to identify ischemia during exercise because of the associated ST and T wave abnormalities. Stress testing in patients with LBBB or with a paced ventricular rhythm is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=see_link\">",
"     \"Stress testing in patients with left bundle branch block or a paced ventricular rhythm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A separate issue is the development of transient LBBB during exercise testing. In a review of 17,277 exercise tests, transient LBBB was noted in 70 (0.4 percent): 40 had a history of CHD and, among the 43 patients in whom angiography was performed, 35 had significant CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/40\">",
"     40",
"    </a>",
"    ]. The development of LBBB was an independent predictor of death and major cardiac events at four years (adjusted relative risk 2.78 compared to 70 matched controls) (",
"    <a class=\"graphic graphic_figure graphicRef55830 \" href=\"UTD.htm?41/60/42957\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Exercise capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Independent of past history, patients with poor exercise capacity are at increased cardiovascular risk, while those with excellent exercise capacity (a measure of fitness) are at reduced risk. This section will emphasize studies evaluating the importance of exercise capacity when exercise testing in performed in patients with known or suspected coronary heart disease. The relationship between fitness and long-term outcomes in asymptomatic individuals is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=see_link&amp;anchor=H11#H11\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\", section on 'Relation to fitness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of exercise capacity was illustrated in a report of 6213 consecutive men referred for exercise testing who were then followed for a mean of 6.2 years: 59 percent had an abnormal exercise test",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a history of cardiovascular disease, while 41 percent had a normal exercise test and no history of cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/1\">",
"     1",
"    </a>",
"    ]. After adjustment for age, peak exercise capacity, measured in metabolic equivalents (METs), was the strongest predictor of mortality among men with and without cardiovascular disease. One MET is defined as 3.5 mL O2",
"    <span class=\"nowrap\">",
"     uptake/kg",
"    </span>",
"    per min, which is the resting oxygen uptake in a sitting position. For each 1 MET increase in exercise capacity there was a 12 percent improvement in survival.",
"   </p>",
"   <p>",
"    In other studies, workload was the major or only treadmill exercise test variable significantly associated with all-cause mortality and cardiac events, particularly in elderly patients. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Elderly'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DUKE TREADMILL SCORE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most popular validated treadmill score comes from Duke University and is based upon data from 2758 consecutive patients seen from 1969 through 1980 with a median age of 49 who had chest pain and underwent both exercise treadmill testing and coronary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/5\">",
"     5",
"    </a>",
"    ]. Testing in a subsequent sample of 467 patients seen from 1984 through 1990 was used to validate the results.",
"   </p>",
"   <p>",
"    There were a number of important exclusions in this study. Excluded were patients who were asymptomatic, had significant valvular or congenital heart disease, an uninterpretable ECG, a surgical or percutaneous revascularization procedure performed in the past or within three months after the exercise test, or a recent myocardial infarction.",
"   </p>",
"   <p>",
"    A possible limitation to the survival rates in studies utilizing the Duke treadmill score is that the results were obtained before the use of current medical therapies that significantly improve patient outcomes such as statin therapy to appropriate LDL-cholesterol goals and perhaps lower blood pressure goals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Duke treadmill score uses three exercise parameters:",
"   </p>",
"   <p>",
"    &nbsp;Duke prognostic treadmill score =",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Exercise time (minutes based on the Bruce protocol) -",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;(5 x maximum ST segment deviation in mm) - (4 x exercise angina [0 = none,1 = nonlimiting, and 2 = exercise limiting])",
"   </p>",
"   <p>",
"    Patients are classified as low, moderate, or high risk according to the score:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low risk &ndash; score &ge;+5",
"     </li>",
"     <li>",
"      Moderate risk &ndash; score from -10 to +4",
"     </li>",
"     <li>",
"      High risk &ndash; score &le;-11",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsequent reports have confirmed the utility of the Duke treadmill score in different groups [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. As an example, the following findings were noted in the different risk groups in an analysis of the original Duke cohort of 2758 medically treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 36 percent of patients categorized as low-risk, 60 percent had no coronary stenosis &ge;75 percent, 16 percent had single vessel disease, and 9 percent had three vessel or left main disease; five-year survival was above 97 percent.",
"     </li>",
"     <li>",
"      Among the 9 percent of patients categorized as high-risk, 74 percent had three vessel or left main disease and five-year survival was 65 percent.",
"     </li>",
"     <li>",
"      Among the 55 percent of patients categorized as moderate risk, the frequency of three vessel or left main disease (31 percent) and five-year survival (90 percent) were intermediate between the other two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Within each risk class, the prognosis was better in women than men [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Women'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The Duke treadmill score added independent prognostic information to that provided by clinical data, coronary anatomy, and left ventricular function. As an example, subset analysis in the original study revealed that, among patients with three vessel disease, those with an abnormal exercise score had a five year survival rate of 67 percent compared with 93 percent for those with a normal exercise score [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Duke treadmill score retains its predictive value in patients with baseline nonspecific ST-T abnormalities. This was illustrated in a report that compared the outcomes in 1466 symptomatic patients with a normal resting ECG and 939 with nonspecific ST-T abnormalities at rest [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/44\">",
"     44",
"    </a>",
"    ]. The latter group did not include patients with identifiable causes of such abnormalities such as left ventricular hypertrophy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    therapy, left or right bundle branch block, preexcitation syndrome, permanent pacing, valvular, congenital or cardiomyopathic heart disease, or previous cardiac surgery or percutaneous coronary intervention. The group with nonspecific ST-T abnormalities had fewer low-risk patients (45 versus 55 percent) and a significantly lower seven-year survival (94 versus 98 percent). Despite these findings, the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines concluded that there were not enough data to recommend exercise ECG testing alone in patients with baseline ST depression of 1.0 to 1.9 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Interaction with imaging modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;At a given Duke treadmill score on exercise ECG testing, the prognosis can be further stratified by the findings on concurrently performed exercise echocardiography or radionuclide myocardial perfusion imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/45,46\">",
"     45,46",
"    </a>",
"    ] and by a clinical determination of risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/47\">",
"     47",
"    </a>",
"    ]. The interaction of the Duke treadmill score with these parameters is discussed separately, but a review of one reports illustrates the potential magnitude of this effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=see_link&amp;anchor=H12#H12\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\", section on 'With other exercise data'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=see_link&amp;anchor=H19#H19\">",
"     \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\", section on 'Exercise rMPI for prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The combined utility of the Duke treadmill score and exercise echocardiography was illustrated in a study of 5375 patients with known or suspected CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/45\">",
"     45",
"    </a>",
"    ]. At a mean follow-up of 5.5 years, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with a low-risk Duke treadmill score, the yearly mortality in those with a normal rest echo study or evidence of disease in a single or multivessel territory was 0.7, 1.8, and 3 percent, respectively. However, although multivessel territory disease on echocardiography was associated with increased risk, it was present in only 1.4 percent of patients with a low risk Duke treadmill score.",
"     </li>",
"     <li>",
"      Among patients with a moderate-risk Duke treadmill score, the yearly mortality in the three echocardiographic groups was 2.4, 3.7, and 7 percent, respectively.",
"     </li>",
"     <li>",
"      Among patients with a high-risk Duke treadmill score, the yearly mortality in the three echocardiographic groups was 4.6, 5, and 12 percent, respectively.",
"     </li>",
"     <li>",
"      Among patients with a normal echocardiographic study, the yearly mortality was 1 percent overall, and 0.7, 2.4, and 4.6 percent, respectively, in patients with a low, moderate, and high-risk Duke treadmill score.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OTHER RISK SCORES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other treadmill scores have also been devised [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/2,48\">",
"     2,48",
"    </a>",
"    ]. One model used exercise testing data from 4083 patients from the Coronary Artery Surgery Study (CASS) registry who were treated medically and followed prospectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/2\">",
"     2",
"    </a>",
"    ]. The presence of significant (&ge;1 mm) exercise-induced ST depression, the stage of exercise completed, and the extent of left ventricular dysfunction were important determinants of one year mortality and of the likelihood of three vessel or left main disease. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Flat or downsloping ST depression'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The Cleveland Clinic nomogram-illustrated model was developed from the results of ECG exercise testing in 30,000 patients referred for suspected coronary heart disease, all of whom had normal baseline ECGs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/49\">",
"     49",
"    </a>",
"    ]. It was validated in a separate group of over 5000 patients. The Cleveland Clinic model was better able to predict all-cause mortality over three years than the Duke score. However, the Cleveland Clinic model is more difficult to use due to the inclusion of multiple clinical variables such as age, sex, and presence of risk factors, as well as more exercise variables.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SPECIFIC PATIENT GROUPS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with chest pain, compared to men, have a lower rate of CHD and a higher rate of false positive results on exercise ECG testing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Duke treadmill score appears to perform better in women than men for excluding disease. This was illustrated in a report of 976 women and 2249 men with chest pain and suspected CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/43\">",
"     43",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fewer low-risk women had any coronary artery with &ge;75 percent stenosis (19 versus 47 percent in men) or three vessel or left main disease (3.5 versus 11.4 percent).",
"     </li>",
"     <li>",
"      The risk of coronary artery disease increased in women with higher risk scores. The frequency of three vessel or left main disease was 12 percent with moderate-risk scores and 46 percent with high-risk scores.",
"     </li>",
"     <li>",
"      The treadmill score was of limited value for predicting short-term prognosis. At two years, the mortality rate was 1.0, 2.2, and 3.6 percent in women at low, moderate, and high risk. Comparable values in men were 1.7, 5.8, and 16.6 percent, indicating substantial prognostic stratification.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A possible explanation for the inability to identify different risk groups in women in this study is that the mean age was 51 years, an age at which there is a low frequency of clinically important CHD in women. Only 32 percent of the women had a coronary stenosis &ge;75 percent, compared to 72 percent of men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treadmill exercise ECG testing in older adults provides prognostic information that is incremental to clinical data. Workload may be the most important determinant of risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. This was illustrated in a study of 514 elderly men (&ge;65 years of age) who were compared to 2593 younger men [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/52\">",
"     52",
"    </a>",
"    ]. The older patients had more comorbid conditions, achieved a lower workload (mean 6.0 versus 10.7 METs), and had a greater likelihood of a positive exercise test (28 versus 9 percent).",
"   </p>",
"   <p>",
"    After a median follow-up of six years, both overall survival (63 versus 92 percent) and cardiac event-free survival (66 versus 95 percent) were significantly lower in older adults. A positive exercise ECG was associated with cardiac events only in the younger patients. After adjustment for clinical variables, workload was the only treadmill exercise test variable associated with all-cause mortality and cardiac events in both age groups. In this and another cohort study, each one MET increase in exercise capacity was associated with an 11 to 18 percent reduction in annual mortality in older adults and 11 to 14 percent in younger subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Exercise capacity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Given the apparent limited predictive value from exercise ECG findings in older adults, it is not surprising that the Duke treadmill score, which was derived from patients with a median age of 49 years, does not identify a truly low-risk group in older adults. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Duke treadmill score'",
"    </a>",
"    above.) One report evaluated the Duke treadmill score in 247 patients &ge;75 years of age: 26, 68, and 6 percent of patients were stratified into low, intermediate, or high risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/55\">",
"     55",
"    </a>",
"    ]. The seven year cardiac survival in the three groups was 86, 85, and 69 percent respectively. Thus, elderly patients who were considered to be low risk still had an annual cardiac mortality of 2 percent.",
"   </p>",
"   <p>",
"    A different score has been reported to be more predictive than the Duke treadmill score in elderly men [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/54\">",
"     54",
"    </a>",
"    ]. However, prospective validation is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abnormal exercise ECG in an asymptomatic person appears to predict increased cardiovascular risk. In asymptomatic women undergoing treadmill exercise testing, exercise capacity, rather than ST segment changes, was the best predictor of outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/56\">",
"     56",
"    </a>",
"    ]. However, this does not mean that exercise testing reduces mortality or is cost-effective in unselected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=see_link&amp;anchor=H2#H2\">",
"     \"Screening for coronary heart disease\", section on 'Rationale for screening'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=see_link&amp;anchor=H8#H8\">",
"     \"Screening for coronary heart disease\", section on 'Clinical studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with coronary heart disease who can exercise and have an interpretable ECG, the presence or absence of a number of findings described above on exercise ECG testing has prognostic value. The concurrent performance of echocardiography or radionuclide myocardial perfusion imaging appears to provide additional risk stratification [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29129/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Issues related to the choice of stress test are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=see_link\">",
"     \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following points should be kept in mind when ordering or evaluating the results of an exercise ECG:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Due to the possibility of electrocardiographic false positive results, patients with one or more of the following abnormalities should be tested with echocardiography or radionuclide myocardial perfusion imaging: preexcitation (Wolff-Parkinson-White) syndrome, more than 1 mm of ST depression at rest, and patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      or with ECG criteria for left ventricular hypertrophy, even if they have less than 1 mm of baseline ST depression.",
"     </li>",
"     <li>",
"      Exercise stress testing alone in patients with LBBB or with a paced ventricular rhythm is nondiagnostic, and these patients require additional noninvasive imaging. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=see_link\">",
"       \"Stress testing in patients with left bundle branch block or a paced ventricular rhythm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Multiple non-ECG exercise variables such as the exercise capacity, the heart rate and blood pressure responses during exercise and recovery, the presence of chest pain and ventricular arrhythmias are very important to assess the risk of patients with CAD or those at high likelihood of having the disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Adverse predictors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two exercise scores, from Duke and the Cleveland Clinic, utilizing multiple clinical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      exercise variables have been validated as providing important prognostic information. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Duke treadmill score'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Other risk scores'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with chest pain, compared to men, have a lower rate of CHD and a higher rate of false positive results on exercise ECG testing. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Women'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H218184284\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to thank Dr. Donald Weiner, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/1\">",
"      Myers J, Prakash M, Froelicher V, et al. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002; 346:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/2\">",
"      Weiner DA, Ryan TJ, McCabe CH, et al. Prognostic importance of a clinical profile and exercise test in medically treated patients with coronary artery disease. J Am Coll Cardiol 1984; 3:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/3\">",
"      Bruce RA, DeRouen TA, Hammermeister KE. Noninvasive screening criteria for enhanced 4-year survival after aortocoronary bypass surgery. Circulation 1979; 60:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/4\">",
"      McNeer JF, Margolis JR, Lee KL, et al. The role of the exercise test in the evaluation of patients for ischemic heart disease. Circulation 1978; 57:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/5\">",
"      Mark DB, Hlatky MA, Harrell FE Jr, et al. Exercise treadmill score for predicting prognosis in coronary artery disease. Ann Intern Med 1987; 106:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/6\">",
"      Peduzzi P, Hultgren H, Thomsen J, Angell W. Veterans Administration Cooperative Study of medical versus surgical treatment for stable angina--progress report. Section 8. Prognostic value of baseline exercise tests. Prog Cardiovasc Dis 1986; 28:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/7\">",
"      Forslund L, Hjemdahl P, Held C, et al. Prognostic implications of results from exercise testing in patients with chronic stable angina pectoris treated with metoprolol or verapamil. A report from the Angina Prognosis Study In Stockholm (APSIS). Eur Heart J 2000; 21:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/8\">",
"      Lauer MS, Okin PM, Larson MG, et al. Impaired heart rate response to graded exercise. Prognostic implications of chronotropic incompetence in the Framingham Heart Study. Circulation 1996; 93:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/9\">",
"      Dubach P, Froelicher VF, Klein J, et al. Exercise-induced hypotension in a male population. Criteria, causes, and prognosis. Circulation 1988; 78:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/10\">",
"      Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/11\">",
"      Gianrossi R, Detrano R, Mulvihill D, et al. Exercise-induced ST depression in the diagnosis of coronary artery disease. A meta-analysis. Circulation 1989; 80:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/12\">",
"      Weiner DA, Ryan TJ, McCabe CH, et al. The role of exercise testing in identifying patients with improved survival after coronary artery bypass surgery. J Am Coll Cardiol 1986; 8:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/13\">",
"      Varnauskas E. Twelve-year follow-up of survival in the randomized European Coronary Surgery Study. N Engl J Med 1988; 319:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/14\">",
"      Lachterman B, Lehmann KG, Abrahamson D, Froelicher VF. \"Recovery only\" ST-segment depression and the predictive accuracy of the exercise test. Ann Intern Med 1990; 112:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/15\">",
"      Rywik TM, Zink RC, Gittings NS, et al. Independent prognostic significance of ischemic ST-segment response limited to recovery from treadmill exercise in asymptomatic subjects. Circulation 1998; 97:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/16\">",
"      Lauer MS, Mehta R, Pashkow FJ, et al. Association of chronotropic incompetence with echocardiographic ischemia and prognosis. J Am Coll Cardiol 1998; 32:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/17\">",
"      Lauer MS, Francis GS, Okin PM, et al. Impaired chronotropic response to exercise stress testing as a predictor of mortality. JAMA 1999; 281:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/18\">",
"      Elhendy A, Mahoney DW, Khandheria BK, et al. Prognostic significance of impairment of heart rate response to exercise: impact of left ventricular function and myocardial ischemia. J Am Coll Cardiol 2003; 42:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/19\">",
"      Gulati M, Shaw LJ, Thisted RA, et al. Heart rate response to exercise stress testing in asymptomatic women: the st. James women take heart project. Circulation 2010; 122:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/20\">",
"      Cole CR, Blackstone EH, Pashkow FJ, et al. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med 1999; 341:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/21\">",
"      Nishime EO, Cole CR, Blackstone EH, et al. Heart rate recovery and treadmill exercise score as predictors of mortality in patients referred for exercise ECG. JAMA 2000; 284:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/22\">",
"      Vivekananthan DP, Blackstone EH, Pothier CE, Lauer MS. Heart rate recovery after exercise is a predictor of mortality, independent of the angiographic severity of coronary disease. J Am Coll Cardiol 2003; 42:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/23\">",
"      Watanabe J, Thamilarasan M, Blackstone EH, et al. Heart rate recovery immediately after treadmill exercise and left ventricular systolic dysfunction as predictors of mortality: the case of stress echocardiography. Circulation 2001; 104:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/24\">",
"      Shetler K, Marcus R, Froelicher VF, et al. Heart rate recovery: validation and methodologic issues. J Am Coll Cardiol 2001; 38:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/25\">",
"      Cole CR, Foody JM, Blackstone EH, Lauer MS. Heart rate recovery after submaximal exercise testing as a predictor of mortality in a cardiovascularly healthy cohort. Ann Intern Med 2000; 132:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/26\">",
"      Mora S, Redberg RF, Sharrett AR, Blumenthal RS. Enhanced risk assessment in asymptomatic individuals with exercise testing and Framingham risk scores. Circulation 2005; 112:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/27\">",
"      Johnson NP, Goldberger JJ. Prognostic value of late heart rate recovery after treadmill exercise. Am J Cardiol 2012; 110:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/28\">",
"      Yanagisawa S, Miki K, Yasuda N, et al. The prognostic value of treadmill exercise testing in very elderly patients: heart rate recovery as a predictor of mortality in octogenarians. Europace 2011; 13:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/29\">",
"      Mora S, Redberg RF, Cui Y, et al. Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study. JAMA 2003; 290:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/30\">",
"      Jouven X, Empana JP, Schwartz PJ, et al. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005; 352:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/31\">",
"      McHam SA, Marwick TH, Pashkow FJ, Lauer MS. Delayed systolic blood pressure recovery after graded exercise: an independent correlate of angiographic coronary disease. J Am Coll Cardiol 1999; 34:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/32\">",
"      Frolkis JP, Pothier CE, Blackstone EH, Lauer MS. Frequent ventricular ectopy after exercise as a predictor of death. N Engl J Med 2003; 348:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/33\">",
"      Udall JA, Ellestad MH. Predictive implications of ventricular premature contractions associated with treadmill stress testing. Circulation 1977; 56:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/34\">",
"      Califf RM, McKinnis RA, McNeer JF, et al. Prognostic value of ventricular arrhythmias associated with treadmill exercise testing in patients studied with cardiac catheterization for suspected ischemic heart disease. J Am Coll Cardiol 1983; 2:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/35\">",
"      Sami M, Chaitman B, Fisher L, et al. Significance of exercise-induced ventricular arrhythmia in stable coronary artery disease: a coronary artery surgery study project. Am J Cardiol 1984; 54:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/36\">",
"      Elhendy A, Chandrasekaran K, Gersh BJ, et al. Functional and prognostic significance of exercise-induced ventricular arrhythmias in patients with suspected coronary artery disease. Am J Cardiol 2002; 90:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/37\">",
"      Jouven X, Zureik M, Desnos M, et al. Long-term outcome in asymptomatic men with exercise-induced premature ventricular depolarizations. N Engl J Med 2000; 343:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/38\">",
"      Bunch TJ, Chandrasekaran K, Gersh BJ, et al. The prognostic significance of exercise-induced atrial arrhythmias. J Am Coll Cardiol 2004; 43:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/39\">",
"      Jelinek MV, Lown B. Exercise stress testing for exposure of cardiac arrhythmia. Prog Cardiovasc Dis 1974; 16:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/40\">",
"      Grady TA, Chiu AC, Snader CE, et al. Prognostic significance of exercise-induced left bundle-branch block. JAMA 1998; 279:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/41\">",
"      Mark DB, Shaw L, Harrell FE Jr, et al. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med 1991; 325:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/42\">",
"      Shaw LJ, Peterson ED, Shaw LK, et al. Use of a prognostic treadmill score in identifying diagnostic coronary disease subgroups. Circulation 1998; 98:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/43\">",
"      Alexander KP, Shaw LJ, Shaw LK, et al. Value of exercise treadmill testing in women. J Am Coll Cardiol 1998; 32:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/44\">",
"      Kwok JM, Miller TD, Christian TF, et al. Prognostic value of a treadmill exercise score in symptomatic patients with nonspecific ST-T abnormalities on resting ECG. JAMA 1999; 282:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/45\">",
"      Marwick TH, Case C, Vasey C, et al. Prediction of mortality by exercise echocardiography: a strategy for combination with the duke treadmill score. Circulation 2001; 103:2566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/46\">",
"      Gibbons RJ, Hodge DO, Berman DS, et al. Long-term outcome of patients with intermediate-risk exercise electrocardiograms who do not have myocardial perfusion defects on radionuclide imaging. Circulation 1999; 100:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/47\">",
"      Poornima IG, Miller TD, Christian TF, et al. Utility of myocardial perfusion imaging in patients with low-risk treadmill scores. J Am Coll Cardiol 2004; 43:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/48\">",
"      Morrow K, Morris CK, Froelicher VF, et al. Prediction of cardiovascular death in men undergoing noninvasive evaluation for coronary artery disease. Ann Intern Med 1993; 118:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/49\">",
"      Lauer MS, Pothier CE, Magid DJ, et al. An externally validated model for predicting long-term survival after exercise treadmill testing in patients with suspected coronary artery disease and a normal electrocardiogram. Ann Intern Med 2007; 147:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/50\">",
"      Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. N Engl J Med 1979; 300:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/51\">",
"      Weiner DA, Ryan TJ, McCabe CH, et al. Exercise stress testing. Correlations among history of angina, ST-segment response and prevalence of coronary-artery disease in the Coronary Artery Surgery Study (CASS). N Engl J Med 1979; 301:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/52\">",
"      Goraya TY, Jacobsen SJ, Pellikka PA, et al. Prognostic value of treadmill exercise testing in elderly persons. Ann Intern Med 2000; 132:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/53\">",
"      Spin JM, Prakash M, Froelicher VF, et al. The prognostic value of exercise testing in elderly men. Am J Med 2002; 112:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/54\">",
"      Lai S, Kaykha A, Yamazaki T, et al. Treadmill scores in elderly men. J Am Coll Cardiol 2004; 43:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/55\">",
"      Kwok JM, Miller TD, Hodge DO, Gibbons RJ. Prognostic value of the Duke treadmill score in the elderly. J Am Coll Cardiol 2002; 39:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29129/abstract/56\">",
"      Gulati M, Arnsdorf MF, Shaw LJ, et al. Prognostic value of the duke treadmill score in asymptomatic women. Am J Cardiol 2005; 96:369.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1548 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-D141E0F7E3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_28_29129=[""].join("\n");
var outline_f28_28_29129=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ADVERSE PREDICTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Flat or downsloping ST depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Heart rate response to exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Heart rate recovery after exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BP recovery after exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Atrial arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Exercise-induced LBBB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Exercise capacity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DUKE TREADMILL SCORE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Interaction with imaging modalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OTHER RISK SCORES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SPECIFIC PATIENT GROUPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Elderly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H218184284\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1548\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1548|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/3/15421\" title=\"figure 1\">",
"      ETT maximal HR outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/56/31629\" title=\"figure 2\">",
"      ETT HR recovery prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/60/42957\" title=\"figure 3\">",
"      Exercise-induced LBBB and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1548|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/11/15548\" title=\"table 1A\">",
"      ACC AHA ETT risk assess CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/46/33516\" title=\"table 1B\">",
"      ACC AHA choice imaging risk I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/51/13118\" title=\"table 2\">",
"      Exercise testing protocols",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/28/14796\" title=\"table 3\">",
"      Exercise test endpoints",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=related_link\">",
"      Clinical significance and treatment of ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11017?source=related_link\">",
"      Electrocardiographic changes during exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=related_link\">",
"      Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=related_link\">",
"      Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=related_link\">",
"      Performance of exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=related_link\">",
"      Screening for coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=related_link\">",
"      Stress echocardiography in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=related_link\">",
"      Stress testing for the diagnosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=related_link\">",
"      Stress testing in patients with left bundle branch block or a paced ventricular rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=related_link\">",
"      Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_28_29130="Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis";
var content_f28_28_29130=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/28/29130/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/28/29130/contributors\">",
"     Guy Rordorf, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/28/29130/contributors\">",
"     Colin McDonald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/28/29130/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/28/29130/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/28/29130/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/28/29130/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/28/29130/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracerebral hemorrhage (ICH) is the second most common cause of stroke, trailing only ischemic stroke in frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Estimates of the annual incidence range from 16 to 33 cases per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/3\">",
"     3",
"    </a>",
"    ]. There are many underlying pathological conditions associated with ICH; hypertension, amyloid angiopathy, ruptured saccular aneurysm, and vascular malformation account for the majority of cases.",
"   </p>",
"   <p>",
"    The pathogenesis, epidemiology, clinical features, and diagnosis of ICH will be reviewed here, with an emphasis upon hypertensive hemorrhage. The prognosis and treatment of ICH are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertensive vasculopathy is the most common etiology of spontaneous ICH. Cerebral amyloid angiopathy is the most common cause of nontraumatic lobar ICH in the elderly, while vascular malformations are the most common cause of ICH in children [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/4\">",
"     4",
"    </a>",
"    ]. Additional causes of nontraumatic ICH include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemorrhagic infarction (including venous sinus thrombosis).",
"     </li>",
"     <li>",
"      Septic embolism, mycotic aneurysm.",
"     </li>",
"     <li>",
"      Brain tumor.",
"     </li>",
"     <li>",
"      Bleeding disorders, anticoagulants, thrombolytic therapy.",
"     </li>",
"     <li>",
"      Central nervous system (CNS) infection (eg, herpes simplex encephalitis).",
"     </li>",
"     <li>",
"      Moyamoya.",
"     </li>",
"     <li>",
"      Vasculitis.",
"     </li>",
"     <li>",
"      Drugs (cocaine, amphetamines) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/5\">",
"       5",
"      </a>",
"      ]. Phenylpropanolamine in appetite suppressants, and possibly cold remedies, may be an independent risk factor for intracranial hemorrhage (including intracerebral hemorrhage and subarachnoid hemorrhage) in women [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These disorders are discussed elsewhere in appropriate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37001?source=see_link\">",
"     \"Cerebral amyloid angiopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18584?source=see_link\">",
"     \"Vascular malformations of the central nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypertensive hemorrhages occur in the territory of penetrator arteries that branch off major intracerebral arteries, often at 90&ordm; angles with the parent vessel. These small penetrating arteries may be particularly susceptible to the effects of hypertension, as they are directly exposed to the pressure of the much larger parent vessel, without the protection of a preceding gradual decrease in vessel caliber [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The blood vessels that give rise to hypertensive hemorrhage generally are the same as those affected by hypertensive occlusive disease and diabetic vasculopathy, which cause lacunar strokes. These vessels supply the pons and midbrain (penetrators off the basilar artery), thalamus (thalamostriate penetrators off the P1 and P2 segments of the posterior cerebral arteries), and putamen and caudate (lenticulostriate penetrators off the M1 segment of the middle cerebral artery). One exception is hypertensive cerebellar hemorrhage; lacunar infarctions are uncommon in the deep cerebellar nuclei, while hypertensive cerebellar hemorrhages occur more frequently.",
"   </p>",
"   <p>",
"    Pathologic examination of the blood vessels in patients with chronic hypertension and in those with intracerebral hemorrhage (ICH) has led to a theory of how hypertensive hemorrhage occurs. The penetrator vessels in patients with chronic hypertension develop intimal hyperplasia with hyalinosis in the vessel wall; this predisposes to focal necrosis, causing breaks in the wall of the vessel. These \"pseudoaneurysms\" have been associated with small amounts of blood outside their walls. Pseudoaneurysm formation with subclinical leaks of blood may be relatively common; massive hemorrhage can occur when the clotting system is unable to compensate for the disruption in the vessel wall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cerebral microbleeds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroimaging data suggest that pseudoaneurysm formation with subclinical leaks of blood is relatively common in patients with spontaneous ICH. Gradient echo and T2*-weighted MRI can detect small regions of focal or multifocal hemosiderin deposition in these patients that represent remnants of clinically silent cerebral microbleeds [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/9\">",
"     9",
"    </a>",
"    ]. These microbleeds (also known as microhemorrhages) may be a marker of bleeding-prone microangiopathy due to hyalinosis (chronic hypertension) or amyloid deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/10\">",
"     10",
"    </a>",
"    ]. These have also been described in patients with infective endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic review, the prevalence of microbleeds visible on MRI was 5 percent in healthy adults, 34 percent in patients with ischemic stroke, and 60 percent in patients with nontraumatic ICH [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/12\">",
"     12",
"    </a>",
"    ]. In a memory disorders clinic population, the prevalence was 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/13\">",
"     13",
"    </a>",
"    ]. In a population-based cohort from the Framingham study, microbleeds were more prevalent with advanced age and male sex [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/14\">",
"     14",
"    </a>",
"    ]. A population-based study from Iceland reported similar findings [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/15\">",
"     15",
"    </a>",
"    ]. Pathologic examination may show a somewhat higher prevalence of microbleeds; in one cohort of elderly patients (ages 71 to 105 years), these were found in 22 of 33 individuals and appeared to arise at the capillary level in many cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In different populations, microbleeds have been associated with hypertension (odds ratio [OR] 3.9), diabetes mellitus (OR 2.2), and cigarette smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/12,13,17,18\">",
"     12,13,17,18",
"    </a>",
"    ]. In the Framingham study, blood pressure was associated with the presence of microbleeds in the crude analysis, but the relationship was not significant after adjustment for age and sex [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/14\">",
"     14",
"    </a>",
"    ]. One explanation for this result is that a higher percentage (73 percent) of cerebral microbleeds were found in",
"    <span class=\"nowrap\">",
"     cortical/subcortical",
"    </span>",
"    regions in the Framingham study population than in other studies (55 to 57 percent) of healthy volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], and lesions in the",
"    <span class=\"nowrap\">",
"     cortical/subcortical",
"    </span>",
"    region are more likely to be related to cerebral amyloid angiopathy (CAA) than to hypertensive microangiopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37001?source=see_link&amp;anchor=H9#H9\">",
"     \"Cerebral amyloid angiopathy\", section on 'Microhemorrhages'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Microbleeds have also been found to be more common in patients who are on antithrombotic therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or antiplatelet agents) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/21\">",
"     21",
"    </a>",
"    ]. A few studies have found that microbleeds, particularly those with a lobar distribution, are more likely to occur in individuals with the APOE genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/13,18\">",
"     13,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Associations between the incidence of microbleeds and lacunar stroke and white matter hyperintensities have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/13,18\">",
"     13,18",
"    </a>",
"    ]. In one study, a lobar distribution of microbleeds consistent with CAA was predictive of subsequent stroke-related death, while nonlobar microbleeds were associated with cardiovascular mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/22\">",
"     22",
"    </a>",
"    ]. Another study found that the presence of microbleeds in older volunteers predicted subsequent ischemic stroke and intracerebral hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/23\">",
"     23",
"    </a>",
"    ]. All hemorrhages occurred in deep brain locations and were associated with microbleeds in that region as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mechanisms of brain injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several mechanisms of brain injury in ICH:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Primary direct mechanical injury to brain parenchyma by the expanding clot",
"     </li>",
"     <li>",
"      Increased intracranial pressure (ICP)",
"     </li>",
"     <li>",
"      Herniation secondary to mass effect",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both clot volume and secondary perilesional edema contribute to the mass effect and its secondary effects. In a cat model of ICH, edema surrounding the area of the hemorrhage contributed significantly to the increase in ICP and was a major cause of herniation leading to death [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Secondary brain injury after the initial hemorrhage is an important contributing process; however, the exact mechanism(s) underlying this remain uncertain. Neuroimaging and pathologic studies have yielded some insights. One study using 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) demonstrated a perihematomal region of increased glucose metabolism two to four days after ICH [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/25\">",
"     25",
"    </a>",
"    ]. Postcontrast enhancement may be noted in the perihematomal area on CT and MRI, representing blood-brain barrier disruption [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/26\">",
"     26",
"    </a>",
"    ]. One MRI study described a pattern of punctate areas of contrast enhancement in the sulcal areas both contiguous and remote from the hemorrhage in patients with acute primary ICH suggesting that ICH may be associated with more diffuse breakdown of the blood-cerebrospinal fluid barrier as well [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On CT and MRI, perihematomal edema is typically present when the patient is first imaged and progresses, reaching maximum volume 7 to 12 days after onset, with the most rapid expansion occurring in the first 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. A higher admission hematocrit and PTT appear to correlate with peak edema volume, at least in one study. The perihematomal region exhibits delayed perfusion and increased diffusivity, mixed with areas of reduced diffusion suggesting the presence of both vasogenic and cytotoxic edema [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/30\">",
"     30",
"    </a>",
"    ]. The latter may be related to ICH mass effect, local neuronal ischemia or the accumulation of cytotoxic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased blood flow to the area surrounding the clot causes local neuronal ischemia, which leads to further cytotoxic edema and the toxic release of excitatory amino acids and inflammatory mediators [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/32\">",
"       32",
"      </a>",
"      ]. This sequence of events is supported by studies in a rat model, which showed that the ischemic zone surrounding an ICH can be decreased by various neuroprotective treatments, including N-methyl-D-aspartate (NMDA) receptor antagonism (which blunts excitatory amino acid-mediated neuronal cell death) and immunosuppression (which diminishes microglia-mediated neuronal injury) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/33\">",
"       33",
"      </a>",
"      ]. These studies have also found that edema and ischemia persist after removal of the hematoma, emphasizing the major contribution of secondary ischemic injury in ICH and explaining in part why surgical evacuation of the hematoma often produces disappointing results. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link&amp;anchor=H21#H21\">",
"       \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Surgery'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thrombin-induced activation of the inflammatory cascade and overexpression of matrix metalloproteinases (MMPs) is an additional mechanism that contributes to breakdown of the blood brain barrier and edema formation in ICH [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/34-36\">",
"       34-36",
"      </a>",
"      ]. MMPs appear to promote extracellular matrix proteolysis, attack the basal lamina, and degrade cellular fibronectin (c-Fn), a glycoprotein that is important for hemostasis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/37\">",
"       37",
"      </a>",
"      ]. Elevated serum levels of MMP-9 have been associated with an increased volume of peripheral edema surrounding ICH [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/38,39\">",
"       38,39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of studies have found that a significant number of patients with ICH have acute ischemic lesions on diffusion-weighted MRI imaging that are not contiguous to the hematoma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The mechanism underlying this phenomenon and the implication of these findings for clinical brain injury and prognosis are as yet undefined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hemorrhage enlargement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial CT scans in patients with hypertensive hemorrhage have shown that the hemorrhage enlarges in the first six hours after presentation in a subset of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/31,42,43\">",
"     31,42,43",
"    </a>",
"    ]. In a prospective series of 103 patients with ICH, significant hematoma growth (a &gt;33 percent volume increase) occurred in 38 percent of patients over the first 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pathologic studies prior to CT scanning found that bleeding points occurred in the rim of the hemorrhage and postulated that this new recruitment of bleeding sites would lead to enlargement of the clot. As the clot expands, surrounding vessels are stretched, causing new sites of vessel rupture. Although the precise mechanism of hemorrhage enlargement is not yet defined and may be heterogeneous, blood brain barrier breakdown and dysregulation of hemostasis via inflammatory cascade activation and MMP overexpression, as discussed above, is probably one important pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/31\">",
"     31",
"    </a>",
"    ]. Elevated plasma concentrations of c-Fn and the inflammatory mediator interleukin-6 (IL-6) in the early acute phase of ICH have been associated with ICH enlargement [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/44\">",
"     44",
"    </a>",
"    ]. However, the clinical utility of MMP, c-Fn, or IL-6 blood levels in early ICH is not yet clear.",
"   </p>",
"   <p>",
"    Risk factors for hematoma expansion include antithrombotic therapy, sustained elevated blood pressure, large hematoma size, and evidence of contrast extravasation on initial CT imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The relationship of systemic blood pressure to hematoma enlargement is not clear [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/42,45,46\">",
"       42,45,46",
"      </a>",
"      ]. Some studies have found that systolic blood pressure at the time of hospital admission is associated with hematoma enlargement [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/47\">",
"       47",
"      </a>",
"      ], while others have not [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/43,48-50\">",
"       43,48-50",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Elevated or maximal systolic blood pressure (SBP) after admission may be a more important measure [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/48\">",
"       48",
"      </a>",
"      ]. This observation is supported by a retrospective observational study of 76 patients with hypertensive ICH [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/51\">",
"       51",
"      </a>",
"      ]. Hematoma enlargement occurred in 16 patients (21 percent) and was significantly and independently associated with the maximum SBP recorded between the first and second head CT scan. In addition, hematoma enlargement was significantly associated with treatment target SBPs of 160 mmHg or greater compared with target SBPs of 150 or 140 mmHg. These results must be interpreted cautiously because of small patient numbers and the retrospective observational nature of the study.",
"     </li>",
"     <li>",
"      Contrast extravasation within the hematoma on CT angiography (CTA &ldquo;spot sign&rdquo;) has been linked to hematoma expansion and poor outcomes in several studies [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/52-58\">",
"       52-58",
"      </a>",
"      ]. In a retrospective analysis of 367 patients with acute ICH, this was found in 19 percent of patients and was independently associated with hematoma expansion [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/52\">",
"       52",
"      </a>",
"      ]. Similar results were reported other retrospective and prospective series, which have also linked this finding to increased mortality and morbidity [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/53-58\">",
"       53-58",
"      </a>",
"      ]. In one case series, the spot sign was more likely to be present in patients with chronic hypertension, and less likely in those with probable cerebral amyloid angiopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/59\">",
"       59",
"      </a>",
"      ]. A \"spot sign\" score which grades the number of spot signs, their maximum dimension and attenuation, was found to be the strongest predictor of hematoma expansion among other clinical factors, but requires independent, prospective validation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/52\">",
"       52",
"      </a>",
"      ]. Similarly, accumulation of contrast extravasation within the hematoma on postcontrast CT also predicts subsequent hematoma expansion [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/60\">",
"       60",
"      </a>",
"      ]. In another series, large hematoma size and heterogeneity of hematoma density on the initial CT scan were independent predictors of hematoma growth [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The relationship of antiplatelet and anticoagulant therapy and hematoma expansion is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link&amp;anchor=H8#H8\">",
"       \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Preceding antithrombotic use'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Enlargement of the hematoma is associated with neurologic deterioration and worse outcomes. These observations indicate that significant improvements in patient outcome from ICH can be achieved by minimizing both secondary brain ischemia and hematoma enlargement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link&amp;anchor=H5#H5\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Hematoma growth'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link&amp;anchor=H13#H13\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontraumatic intracerebral hemorrhage (ICH) causes 8 to 15 percent of all first-ever strokes in Australia, England, and the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]; it accounts for 25 percent of strokes in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/64\">",
"     64",
"    </a>",
"    ]. The overall incidence of ICH ranges from 12 to 31 per 100,000 people, and it varies by race [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/65-68\">",
"     65-68",
"    </a>",
"    ]. The incidence of ICH increases with age, doubling every 10 years after age 35 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/2,69\">",
"     2,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of occurrence is highest in Asians, intermediate in blacks, and lowest in whites. The higher rate of ICH in black compared with white Americans is predominately attributable to excess ICH in deep cerebral and brainstem locations where hypertension is the major risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/66\">",
"     66",
"    </a>",
"    ]. Mexican Americans also have a higher incidence of ICH than non-Hispanic whites [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from the United Kingdom suggests that incidence of hypertensive ICH has declined since the early 1980s with improved control of hypertension, but overall rates of ICH have remained stable, in part due to an increase in ICH associated with antithrombotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/72\">",
"     72",
"    </a>",
"    ]. As the population ages, the incidence of ICH may rise in the future due to amyloid angiopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=see_link\">",
"     \"Risk of intracerebral hemorrhage in patients treated with warfarin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37001?source=see_link\">",
"     \"Cerebral amyloid angiopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gender does not appear to have a significant impact on risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is the most important risk factor for the development of intracerebral hemorrhage (ICH) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/73-76\">",
"     73-76",
"    </a>",
"    ]. In one study of 331 consecutive cases, hypertension more than doubled the risk of ICH [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative contribution of hypertension may be greater for deep than for lobar ICH [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/76\">",
"     76",
"    </a>",
"    ]. In a meta-analysis that pooled data from 28 studies, hypertension was twice as common in patients with deep ICH as in patients with lobar ICH (odds ratio [OR] 2.1, 95% CI 1.82-2.42) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/78\">",
"     78",
"    </a>",
"    ]. In data from a subset of three studies in the meta-analysis meeting more rigorous methodologic criteria, the association of hypertension with deep ICH remained significant (OR 1.5, 95% CI 1.09-2.07).",
"   </p>",
"   <p>",
"    Hypertension has also been shown to be a risk factor for ICH in the setting of other underlying etiologies for ICH (eg, cerebral amyloid angiopathy, antithrombotic-associated ICH) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37001?source=see_link\">",
"     \"Cerebral amyloid angiopathy\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H9\">",
"     'Antithrombotic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition to hypertension, a systematic review [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/81\">",
"     81",
"    </a>",
"    ] and a large population-based study [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/82\">",
"     82",
"    </a>",
"    ] identified the following risk factors for ICH:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Older age",
"     </li>",
"     <li>",
"      High alcohol intake",
"     </li>",
"     <li>",
"      Black ethnicity",
"     </li>",
"     <li>",
"      Lower cholesterol and lower LDL cholesterol",
"     </li>",
"     <li>",
"      Lower triglycerides",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of additional studies have found an inverse relationship between total and LDL-cholesterol and the risk of ICH [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/83-90\">",
"     83-90",
"    </a>",
"    ]. At least one study suggested that the association is stronger for subcortical or hypertensive ICH than lobar hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/87\">",
"     87",
"    </a>",
"    ]. However, treatment with statins does not appear to increase the risk of primary ICH or to negatively impact prognosis according to a number of studies and meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/91-96\">",
"     91-96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although data are limited, a population-based study cohort study with 4937 participants found that chronic kidney disease, defined by a decreased glomerular filtration rate, is a risk factor for ICH but not ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/97\">",
"     97",
"    </a>",
"    ]. This study should be interpreted cautiously, as there were relatively few hemorrhagic strokes (n = 88), and the study did not distinguish between ICH and subarachnoid hemorrhage. Nevertheless, it is plausible that a decreased glomerular filtration rate might be associated with ICH, since chronic kidney disease is associated with platelet dysfunction and a propensity to bleeding. An alternate explanation is that kidney disease, often attributed to renal small vessel disease, may simply be a marker of cerebrovascular small vessel disease, which is the major mechanism of hypertensive ICH. In another large cohort study in Japan, the observed excess risk of hemorrhagic stroke among patients with chronic kidney disease appeared to be confined to individuals who also regularly consumed alcohol [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/98\">",
"     98",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=see_link\">",
"     \"Platelet dysfunction in uremia\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Most cases of ICH are not believed to have a genetic component. One exception is cerebral amyloid angiopathy-related ICH which has been shown to have an association with APOE genotype. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37001?source=see_link&amp;anchor=H5#H5\">",
"     \"Cerebral amyloid angiopathy\", section on 'Apolipoprotein E'",
"    </a>",
"    .) However, a large-scale genetic association study of 2189 ICH cases and 4041 controls revealed that APOE allele &epsilon;4 was also associated with deep ICH (OR = 1.21), a location not typical for cerebral amyloid angiopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/99\">",
"     99",
"    </a>",
"    ]. Another study has implicated a rare mutation in the collagen IV gene COL4A1 in a small number of patients with ICH [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antithrombotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    increases the risk of ICH two- to fivefold, depending upon the intensity of anticoagulation. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=see_link\">",
"     \"Risk of intracerebral hemorrhage in patients treated with warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to an increased risk of ICH, retrospective evidence suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy with an international normalized ratio (INR) &gt;3 is a risk factor for larger initial hemorrhage volume [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is probably a very small absolute increased risk of primary ICH associated with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or antiplatelet agents, based on meta-analyses of randomized, controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/102,103\">",
"     102,103",
"    </a>",
"    ], although a case-control trial did not find increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/83\">",
"     83",
"    </a>",
"    ]. A subsequent review estimated the risk of ICH associated with the use of aspirin for primary and secondary prevention of coronary heart disease to be 0.2 events per 1000 patient years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, NSAIDs do not appear to increase the risk of ICH [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/105-108\">",
"     105-108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypertension is a risk factor for ICH among patients taking antithrombotic agents. In a cohort study of 4009 patients taking antiplatelet agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , the risk of ICH was associated with average systolic and diastolic BP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/109\">",
"     109",
"    </a>",
"    ]. The optimal cutoff BP level to predict ICH risk was",
"    <span class=\"nowrap\">",
"     &gt;130/81.",
"    </span>",
"   </p>",
"   <p>",
"    The presence of microbleeds on MRI is another risk factor for ICH among antithrombotic users (OR = 12.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of recurrent ICH associated with antiplatelet and anticoagulation therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8089?source=see_link\">",
"     \"Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link&amp;anchor=H23#H23\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Resumption of antiplatelet therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some hypertensive hemorrhages occur with exertion or intense emotional activity. However, most cases take place during routine activity. The neurologic symptoms usually increase gradually over minutes or a few hours (",
"    <a class=\"graphic graphic_figure graphicRef61491 \" href=\"UTD.htm?6/23/6526\">",
"     figure 1",
"    </a>",
"    ). In contrast to brain embolism and subarachnoid hemorrhage, the neurologic symptoms do not begin abruptly and are not maximal at onset.",
"   </p>",
"   <p>",
"    Headache, vomiting, and a decreased level of consciousness develop if the hematoma becomes sufficiently large. Headache and vomiting occur in approximately one-half of patients with intracerebral hemorrhage (ICH) (",
"    <a class=\"graphic graphic_figure graphicRef60831 \" href=\"UTD.htm?0/5/88\">",
"     figure 2",
"    </a>",
"    ). Headache may be due to traction on meningeal pain fibers, increased intracranial pressure (ICP), or blood in the cerebrospinal fluid (CSF); it is most common with cerebellar and lobar hemorrhages. These symptoms are absent with small hemorrhages; the clinical presentation in this setting is that of a gradually progressing stroke. Patients may complain of a stiff neck and have meningismus on physical examination, if there is intraventricular blood.",
"   </p>",
"   <p>",
"    Seizures in the first days after ICH occur in 4 to 29 percent of patients; they are more common in lobar hemorrhages (affecting cortical tissue) than in deep or cerebellar ICHs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/63,110-113\">",
"     63,110-113",
"    </a>",
"    ]. In a series of 63 patients with ICH in an intensive care unit who had continuous electroencephalogram monitoring, seizures within 72 hours of admission occurred in 29 percent and were often nonconvulsive [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/112\">",
"     112",
"    </a>",
"    ]. In addition, the presence of seizures was independently associated with midline brain shift and neurologic deterioration.",
"   </p>",
"   <p>",
"    Stupor or coma in ICH is an ominous sign. The only exception is patients with thalamic hemorrhage, in whom involvement of the reticular activating system is the cause of stupor rather than diffuse brain injury; these patients may recover after blood is reabsorbed.",
"   </p>",
"   <p>",
"    Some patients have abnormalities on the electrocardiogram (ECG), including a prolonged QT interval, depressed ST segment, flat or inverted T waves, U waves, and tall peaked T waves. These changes are predominately reflective of ischemia in the subendocardium of the left ventricle, which is most likely due to a centrally mediated release of catecholamines induced by hypoperfusion of the posterior hypothalamus. Mild elevations in serum myocardial enzymes often accompany the ECG changes, and ventricular arrhythmias may occur with brainstem compression [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neurologic signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic signs vary depending upon the location of the hemorrhage. Bleeding into the putamen occurs in approximately 35 percent of cases, subcortex in 30 percent, cerebellum in 16 percent, thalamus in 15 percent, and pons in 5 to 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Putamenal hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spread of hemorrhage into the putamen most commonly occurs along white matter fiber tracts, causing hemiplegia, hemisensory loss, homonymous hemianopsia, gaze palsy, stupor, and coma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Cerebellar hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebellar hemorrhages usually originate in the dentate nucleus, extend into the hemisphere and fourth ventricle, and possibly into the pontine tegmentum. These bleeds cause an inability to walk due to imbalance, vomiting, headache (which may be referred to the neck or shoulder, usually occipital), neck stiffness, gaze palsy, and facial weakness. There is notably no hemiparesis. The patient may become stuporous due to brainstem compression if the hemorrhage is unrecognized or untreated. Cerebellar hemorrhage is a crucial diagnosis to make since these patients frequently deteriorate and require surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Thalamic hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thalamic hemorrhage may extend in a transverse direction to the posterior limb of the internal capsule, downward to put pressure on the tectum of the midbrain, or may rupture into the third ventricle. Symptoms include hemiparesis, hemisensory loss, and occasionally transient homonymous hemianopsia. There may also be an upgaze palsy with miotic pupils that are unreactive, peering at the tip of the nose, skewed, or \"wrong way eyes\" toward the weak side (in contrast to hemispheric cortical injury in which the eyes are deviated away from the hemiparesis). Aphasia may occur if the bleed affects the dominant hemisphere or neglect in the nondominant hemisphere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Lobar hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lobar hemorrhages vary in their neurologic signs depending upon location. They most often affect the parietal and occipital lobes. These bleeds are associated with a higher incidence of seizures. Occipital hemorrhages frequently present with a very dense contralateral homonymous hemianopsia. Hemorrhages in the frontal region will bring about a contralateral plegia or paresis of the leg with relative sparing of the arm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Pontine hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pontine hemorrhage is characterized by a medial hematoma that extends into the base of the pons. These often lead to deep coma over the first few minutes following the hemorrhage, probably due to disruption of the reticular activating system. The motor examination is marked by total paralysis. The pupils are pinpoint and react to a strong light source. Horizontal eye movements are absent, and there may be ocular bobbing, facial palsy, deafness, and dysarthria when the patient is awake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ICH is a neurologic and medical emergency because it is associated with a high risk of ongoing bleeding, progressive neurologic deterioration, permanent disability, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The acute evaluation of patients with suspected stroke, including issues related to the history, physical examination, airway and breathing, and immediate laboratory studies, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical diagnosis of intracerebral hemorrhage (ICH) is based upon features such as gradually progressive worsening of symptoms and increasing neurologic deficit. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Clinical presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Neuroimaging with brain CT or MRI is essential to confirm the diagnosis of ICH and to exclude ischemic stroke and stroke mimics as possible causes. Both CT and MRI are considered first-choice imaging options for the emergency diagnosis and assessment of ICH [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/63,116\">",
"     63,116",
"    </a>",
"    ]. However, head CT should be obtained in patients with contraindications to MRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Head CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noncontrast cranial CT is the study most widely used to evaluate for the presence of acute ICH, which is evident almost immediately. CT can define the size and location of the hematoma. It also provides information about extension into the ventricular system, the presence of surrounding edema, and shifts in brain contents (herniation). Hyperacute blood will appear hyperdense unless the patient is severely anemic, in which case it might appear isodense. Over weeks, the blood will become isodense and may have a ring enhancement appearance. Chronically, the blood is hypodense.",
"   </p>",
"   <p>",
"    Primary ICH needs to be distinguished from hemorrhagic transformation of a cerebral infarction. While there are no defined radiologic criteria for this distinction, a patchy appearance of the hyperdensity within a larger area of low attenuation is an important feature, as is a wedge-shaped abnormality that extends to the cortex. A delay from stroke onset to CT examination, however, can be problematic in CT interpretation and has been shown to reduce inter-observer reliability [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/117\">",
"     117",
"    </a>",
"    ]. When an ICH clot retracts and surrounding edema develops, the appearance of a primary ICH can resemble that of a hemorrhagic cerebral infarction.",
"   </p>",
"   <p>",
"    An estimate of ICH volume is useful to communicate hemorrhage severity and make early assessments of prognosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link&amp;anchor=H4#H4\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Initial ICH volume and level of consciousness'",
"    </a>",
"    .) The formula is calculated using the centimeter scale on the CT (or MRI) images as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/118\">",
"     118",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A is the greatest hemorrhage diameter on the CT slice with the largest area of hemorrhage.",
"     </li>",
"     <li>",
"      B is the largest diameter 90 degrees to A on the same (index) CT slice.",
"     </li>",
"     <li>",
"      C is the approximate number of CT slices with hemorrhage multiplied by the slice thickness in centimeters. To calculate C, each CT slice with hemorrhage is visually compared with the index CT slice [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/118\">",
"       118",
"      </a>",
"      ]. An individual hemorrhage slice is counted as one full slice for determining C if the hemorrhage area is &gt;75 percent of the area on the slice with the largest hemorrhage. A slice is counted as one-half if the hemorrhage area is approximately 25 to 75 percent of the area on the largest hemorrhage slice. The slice is not counted if the area is &lt;25 percent of the largest hemorrhage slice.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       ABC/2",
"      </span>",
"      gives the ICH volume in cubic centimeters.",
"     </li>",
"     <li>",
"      In children, ICH volume may instead be measured as a percent of total brain volume as",
"      <span class=\"nowrap\">",
"       ABC/XYZ,",
"      </span>",
"      where X, Y, and Z are perpendicular measures of the supratentorial intracranial space [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/119\">",
"       119",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Contrast-enhanced CT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CT angiography (CTA) may reveal a focus of contrast extravasation (&ldquo;spot sign&rdquo;) that suggests that the patient is at risk for hematoma expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/120\">",
"     120",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link&amp;anchor=H5#H5\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Hematoma growth'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Brain MRI",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2513592\">",
"    <span class=\"h3\">",
"     Hemorrhage appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulating evidence has confirmed that hyperacute parenchymal hemorrhage can be accurately detected using MRI with T2-sensitive pulse sequences such as gradient echo (GRE) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/121-127\">",
"     121-127",
"    </a>",
"    ]. These sequences are highly sensitive to the nonuniform static magnetic fields produced by paramagnetic molecules such as deoxyhemoglobin. This property of paramagnetic molecules is termed the magnetic susceptibility effect; it results in rapid dephasing of proton spins causing signal loss (darkening or hypointensity) that is best seen in T2*-weighted images.",
"   </p>",
"   <p>",
"    Acute ICH can be diagnosed by MRI with up to 100 percent sensitivity and accuracy by experienced readers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/126\">",
"     126",
"    </a>",
"    ]. This was illustrated in the Hemorrhage and Early MRI Evaluation (HEME) study, a prospective two-center study that evaluated 200 patients presenting with focal stroke symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/127\">",
"     127",
"    </a>",
"    ]. All patients had MRI with gradient echo (GRE) and diffusion-weighted (DWI) sequences within six hours of symptom onset followed by CT. The study was stopped early because MRI was detecting cases of hemorrhagic transformation that CT did not reveal. MRI and CT were equivalent for the detection of acute ICH, and MRI was significantly more accurate than CT for the detection of chronic ICH.",
"   </p>",
"   <p>",
"    The appearance of blood on MRI images depends upon the paramagnetic properties of the various stages of hemoglobin and on the mode of imaging acquisition:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hyperacute hematoma. The ability of MRI to detect hyperacute ICH, within the first one to six hours, is based upon the magnetic susceptibility effect of deoxyhemoglobin [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/122\">",
"       122",
"      </a>",
"      ]. Hyperacute hematoma on MRI appears to be composed of three distinct areas (",
"      <a class=\"graphic graphic_picture graphicRef81767 \" href=\"UTD.htm?23/19/23864\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/124\">",
"       124",
"      </a>",
"      ]:",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A center that is isointense to hyperintense on susceptibility weighted and T2-weighted imaging. The center may be smaller or larger than the periphery and may be heterogeneous in appearance. It may be entirely absent by two hours as the periphery expands towards the center [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/124\">",
"       124",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A periphery that appears hypointense or dark on susceptibility weighted imaging due to deoxyhemoglobin. This signal loss gradually expands from the periphery toward the center. This effect is best seen on sequences that are T2* weighted, such as GRE.",
"     </li>",
"     <li>",
"      A rim that appears hypointense on T1-weighted imaging and hyperintense on T2-weighted imaging, representing vasogenic edema encasing the hematoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Subacute hematoma. ICH appears as high signal intensity on T1 due to the presence of methemoglobin, particularly in the periphery. The appearance on T2 is initially dark, then later becomes bright as the red blood cells lyse and methemoglobin becomes extracellular.",
"      <br/>",
"     </li>",
"     <li>",
"      Chronic hematoma. Hemosiderin is produced by phagocytes ingesting methemoglobin; this appears as a low signal on T2 and T1, enhanced by susceptibility weighted images such as GRE sequences.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Microbleeds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral microbleeds are small hemosiderin deposits that are best visualized as punctate areas of low signal on T2* weighted GRE sequences. Hypertension and cerebral amyloid angiopathy are the two most important pathologies associated with microbleeds. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Cerebral microbleeds'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The location of microbleeds is suggestive of the underlying pathology.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Microbleeds in deep gray and infratentorial brain regions such as the pons, thalamus, and basal ganglia, are characteristic of hypertensive bleeding prone microangiopathy",
"     </li>",
"     <li>",
"      Microbleeds in the cortical-subcortical junction (gray-white junction) are characteristic of cerebral amyloid angiopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37001?source=see_link\">",
"       \"Cerebral amyloid angiopathy\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2513599\">",
"    <span class=\"h3\">",
"     Underlying etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contrast-enhanced MRI (along with magnetic resonance angiography, magnetic resonance venography) can be useful to evaluated for underlying structural lesions (eg, vascular malformations, tumors), when there is clinical or radiologic suspicion for these [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The necessity for further evaluation to determine the cause of ICH varies with the clinical setting. In particular the patient's age, the",
"    <span class=\"nowrap\">",
"     presence/absence",
"    </span>",
"    of hypertension, and the hemorrhage location are primary considerations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/128\">",
"     128",
"    </a>",
"    ]. No further diagnostic tests are necessary in the severely hypertensive patient with a well-circumscribed and homogeneous hematoma that is located in a typical location for hypertensive ICH (eg,",
"    <span class=\"nowrap\">",
"     putamen/internal",
"    </span>",
"    capsule, caudate nucleus, thalamus, pons, or cerebellum); the clinician can be confident that such a patient has a hypertensive hemorrhage. Similarly, a traumatic etiology can be diagnosed with confidence in the patient who has had recent trauma and lesions in the location and with the appearance of contusion and traumatic hemorrhages (eg, anterior",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    orbital frontal lobes and temporal lobes at the surface).",
"   </p>",
"   <p>",
"    Evaluation for a bleeding disorder (platelet count, prothrombin time, and activated partial thromboplastin time) should be performed in every patient with an ICH, especially if the cause is not immediately clear. A bleeding tendency can cause or contribute to bleeding initiated by other etiologies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"     \"Approach to the adult patient with a bleeding diathesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Iatrogenic prescription of anticoagulants is the most common bleeding disorder leading to brain hemorrhages. In one series of 24 such patients, 18 were hypertensive, but only one had simultaneous bleeding in other organs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/129\">",
"     129",
"    </a>",
"    ]. These bleeds are most often lobar or cerebellar. Anticoagulant hemorrhages often develop gradually and may become progressively larger over hours or even a few days [",
"    <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/129,130\">",
"     129,130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amyloid angiopathy, bleeding into a tumor, and vascular malformations are likely etiologies of hemorrhages that are lobar or atypical in appearance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37001?source=see_link\">",
"     \"Cerebral amyloid angiopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18584?source=see_link\">",
"     \"Vascular malformations of the central nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemorrhages related to amyloid angiopathy are usually lobar, but they are occasionally cerebellar. They predominantly involve the posterior portions of the brain, including the parietal and occipital lobes. The hemorrhages are usually multiple; gradient-echo MRI may show the presence of old small hemorrhages. Patients with amyloid angiopathy are typically over the age of 65. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37001?source=see_link\">",
"       \"Cerebral amyloid angiopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other bleeding lesions should be excluded in patients under the age of 60 if the blood pressure is not sufficiently elevated to make a firm diagnosis of hypertensive lobar hemorrhage. A repeat MRI after the blood has been reabsorbed (four to eight weeks) may show residual vascular malformations or a brain tumor.",
"      <br/>",
"      <br/>",
"      Vascular imaging using contrast CT angiography (CTA) or magnetic resonance angiography (MRA) of the intracranial circulation are useful screening tests for vascular malformations and aneurysms [",
"      <a class=\"abstract\" href=\"UTD.htm?28/28/29130/abstract/131-134\">",
"       131-134",
"      </a>",
"      ]. Contrast angiography by arterial catheterization may be necessary in patients with a CTA or MRA suggestive of vascular malformation. A finding of a \"spot sign\" on CTA has been found to be associated with a high risk of hematoma expansion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"       \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18584?source=see_link\">",
"       \"Vascular malformations of the central nervous system\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32872?source=see_link\">",
"       \"Brain arteriovenous malformations\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link\">",
"       \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with ICH after cocaine use (but not amphetamines) have a relatively high incidence of underlying aneurysms and vascular malformations. They require vascular imaging tests (eg, CTA, MRA,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angiography).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/34/22050?source=see_link\">",
"       \"Patient information: Hemorrhagic stroke (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/42/26274?source=see_link\">",
"       \"Patient information: Arteriovenous malformations in the brain (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"       \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/63/8180?source=see_link\">",
"       \"Patient information: Hemorrhagic stroke treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H121289585\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertensive vasculopathy is the most common etiology of spontaneous intracerebral hemorrhage (ICH). Cerebral amyloid angiopathy is the most common cause of nontraumatic lobar ICH in the elderly, while vascular malformations are the most common cause of ICH in children. Additional causes include tumors, coagulopathies, and others. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiologies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to hypertension, older age, and antithrombotic therapy are risk factors. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients typically present with an acute onset of a focal neurologic deficit that corresponds to the part of the brain affected. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      With large hemorrhages, there is elevated intracranial pressure and suppressed level of consciousness.",
"      <br/>",
"      <br/>",
"      Seizures may complicate 5 to 30 percent of hemorrhages, particularly if the hematoma is more superficial than deep.",
"     </li>",
"     <li>",
"      A noncontrast head computed tomogram (CT) is ordered in all patients with this presentation and is reliable at demonstrating the hematoma, although the cause may remain obscure. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Head CT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A contrast enhanced magnetic resonance imaging (MRI) study is useful to detect underlying causative lesions such as a vascular malformation, tumor, and cerebral amyloid angiopathy and should be performed when these are suspected or the cause of ICH otherwise remains obscure. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Brain MRI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients without hypertension or other known etiology for the hemorrhage should have other studies to evaluate potential causes such as coagulation studies, toxicology screen, and other vascular imaging such as MR or CT angiography. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Other studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/1\">",
"      Mohr JP, Caplan LR, Melski JW, et al. The Harvard Cooperative Stroke Registry: a prospective registry. Neurology 1978; 28:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/2\">",
"      Broderick JP, Brott T, Tomsick T, et al. Intracerebral hemorrhage more than twice as common as subarachnoid hemorrhage. J Neurosurg 1993; 78:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/3\">",
"      Sacco S, Marini C, Toni D, et al. Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. Stroke 2009; 40:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/4\">",
"      Beslow LA, Licht DJ, Smith SE, et al. Predictors of outcome in childhood intracerebral hemorrhage: a prospective consecutive cohort study. Stroke 2010; 41:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/5\">",
"      Martin-Schild S, Albright KC, Hallevi H, et al. Intracerebral hemorrhage in cocaine users. Stroke 2010; 41:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/6\">",
"      Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/7\">",
"      Yoon BW, Bae HJ, Hong KS, et al. Phenylpropanolamine contained in cold remedies and risk of hemorrhagic stroke. Neurology 2007; 68:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/8\">",
"      Garcia JH, Ho KL. Pathology of hypertensive arteriopathy. Neurosurg Clin N Am 1992; 3:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/9\">",
"      Offenbacher H, Fazekas F, Schmidt R, et al. MR of cerebral abnormalities concomitant with primary intracerebral hematomas. AJNR Am J Neuroradiol 1996; 17:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/10\">",
"      Fazekas F, Kleinert R, Roob G, et al. Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol 1999; 20:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/11\">",
"      Klein I, Iung B, Labreuche J, et al. Cerebral microbleeds are frequent in infective endocarditis: a case-control study. Stroke 2009; 40:3461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/12\">",
"      Cordonnier C, Al-Shahi Salman R, Wardlaw J. Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting. Brain 2007; 130:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/13\">",
"      Goos JD, Henneman WJ, Sluimer JD, et al. Incidence of cerebral microbleeds: a longitudinal study in a memory clinic population. Neurology 2010; 74:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/14\">",
"      Jeerakathil T, Wolf PA, Beiser A, et al. Cerebral microbleeds: prevalence and associations with cardiovascular risk factors in the Framingham Study. Stroke 2004; 35:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/15\">",
"      Sveinbjornsdottir S, Sigurdsson S, Aspelund T, et al. Cerebral microbleeds in the population based AGES-Reykjavik study: prevalence and location. J Neurol Neurosurg Psychiatry 2008; 79:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/16\">",
"      Fisher M, French S, Ji P, Kim RC. Cerebral microbleeds in the elderly: a pathological analysis. Stroke 2010; 41:2782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/17\">",
"      Staals J, van Oostenbrugge RJ, Knottnerus IL, et al. Brain microbleeds relate to higher ambulatory blood pressure levels in first-ever lacunar stroke patients. Stroke 2009; 40:3264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/18\">",
"      Poels MM, Ikram MA, van der Lugt A, et al. Incidence of cerebral microbleeds in the general population: the Rotterdam Scan Study. Stroke 2011; 42:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/19\">",
"      Roob G, Schmidt R, Kapeller P, et al. MRI evidence of past cerebral microbleeds in a healthy elderly population. Neurology 1999; 52:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/20\">",
"      Tsushima Y, Tanizaki Y, Aoki J, Endo K. MR detection of microhemorrhages in neurologically healthy adults. Neuroradiology 2002; 44:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/21\">",
"      Lovelock CE, Cordonnier C, Naka H, et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies. Stroke 2010; 41:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/22\">",
"      Altmann-Schneider I, Trompet S, de Craen AJ, et al. Cerebral microbleeds are predictive of mortality in the elderly. Stroke 2011; 42:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/23\">",
"      Bokura H, Saika R, Yamaguchi T, et al. Microbleeds are associated with subsequent hemorrhagic and ischemic stroke in healthy elderly individuals. Stroke 2011; 42:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/24\">",
"      Xu BN, Yabuki A, Mishina H, et al. Pathophysiology of brain swelling after acute experimental brain compression and decompression. Neurosurgery 1993; 32:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/25\">",
"      Zazulia AR, Videen TO, Powers WJ. Transient focal increase in perihematomal glucose metabolism after acute human intracerebral hemorrhage. Stroke 2009; 40:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/26\">",
"      Murai Y, Ikeda Y, Teramoto A, Tsuji Y. Magnetic resonance imaging-documented extravasation as an indicator of acute hypertensive intracerebral hemorrhage. J Neurosurg 1998; 88:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/27\">",
"      Kidwell CS, Burgess R, Menon R, et al. Hyperacute injury marker (HARM) in primary hemorrhage: a distinct form of CNS barrier disruption. Neurology 2011; 77:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/28\">",
"      Venkatasubramanian C, Mlynash M, Finley-Caulfield A, et al. Natural history of perihematomal edema after intracerebral hemorrhage measured by serial magnetic resonance imaging. Stroke 2011; 42:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/29\">",
"      Staykov D, Wagner I, Volbers B, et al. Natural course of perihemorrhagic edema after intracerebral hemorrhage. Stroke 2011; 42:2625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/30\">",
"      Olivot JM, Mlynash M, Kleinman JT, et al. MRI profile of the perihematomal region in acute intracerebral hemorrhage. Stroke 2010; 41:2681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/31\">",
"      Balami JS, Buchan AM. Complications of intracerebral haemorrhage. Lancet Neurol 2012; 11:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/32\">",
"      Dearden NM. Mechanisms and prevention of secondary brain damage during intensive care. Clin Neuropathol 1998; 17:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/33\">",
"      Mendelow AD. Mechanisms of ischemic brain damage with intracerebral hemorrhage. Stroke 1993; 24:I115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/34\">",
"      Lee KR, Kawai N, Kim S, et al. Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model. J Neurosurg 1997; 86:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/35\">",
"      Rosenberg GA, Navratil M. Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat. Neurology 1997; 48:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/36\">",
"      Xi G, Wagner KR, Keep RF, et al. Role of blood clot formation on early edema development after experimental intracerebral hemorrhage. Stroke 1998; 29:2580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/37\">",
"      Makogonenko E, Tsurupa G, Ingham K, Medved L. Interaction of fibrin(ogen) with fibronectin: further characterization and localization of the fibronectin-binding site. Biochemistry 2002; 41:7907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/38\">",
"      Castillo J, D&aacute;valos A, Alvarez-Sab&iacute;n J, et al. Molecular signatures of brain injury after intracerebral hemorrhage. Neurology 2002; 58:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/39\">",
"      Abilleira S, Montaner J, Molina CA, et al. Matrix metalloproteinase-9 concentration after spontaneous intracerebral hemorrhage. J Neurosurg 2003; 99:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/40\">",
"      Menon RS, Burgess RE, Wing JJ, et al. Predictors of highly prevalent brain ischemia in intracerebral hemorrhage. Ann Neurol 2012; 71:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/41\">",
"      Garg RK, Liebling SM, Maas MB, et al. Blood pressure reduction, decreased diffusion on MRI, and outcomes after intracerebral hemorrhage. Stroke 2012; 43:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/42\">",
"      Broderick JP, Brott TG, Tomsick T, et al. Ultra-early evaluation of intracerebral hemorrhage. J Neurosurg 1990; 72:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/43\">",
"      Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/44\">",
"      Silva Y, Leira R, Tejada J, et al. Molecular signatures of vascular injury are associated with early growth of intracerebral hemorrhage. Stroke 2005; 36:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/45\">",
"      Chen ST, Chen SD, Hsu CY, Hogan EL. Progression of hypertensive intracerebral hemorrhage. Neurology 1989; 39:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/46\">",
"      Qureshi AI, Wilson DA, Hanley DF, Traystman RJ. Pharmacologic reduction of mean arterial pressure does not adversely affect regional cerebral blood flow and intracranial pressure in experimental intracerebral hemorrhage. Crit Care Med 1999; 27:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/47\">",
"      Kazui S, Minematsu K, Yamamoto H, et al. Predisposing factors to enlargement of spontaneous intracerebral hematoma. Stroke 1997; 28:2370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/48\">",
"      Fujii Y, Takeuchi S, Sasaki O, et al. Multivariate analysis of predictors of hematoma enlargement in spontaneous intracerebral hemorrhage. Stroke 1998; 29:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/49\">",
"      Jauch EC, Lindsell CJ, Adeoye O, et al. Lack of evidence for an association between hemodynamic variables and hematoma growth in spontaneous intracerebral hemorrhage. Stroke 2006; 37:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/50\">",
"      Broderick JP, Diringer MN, Hill MD, et al. Determinants of intracerebral hemorrhage growth: an exploratory analysis. Stroke 2007; 38:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/51\">",
"      Ohwaki K, Yano E, Nagashima H, et al. Blood pressure management in acute intracerebral hemorrhage: relationship between elevated blood pressure and hematoma enlargement. Stroke 2004; 35:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/52\">",
"      Delgado Almandoz JE, Yoo AJ, Stone MJ, et al. Systematic characterization of the computed tomography angiography spot sign in primary intracerebral hemorrhage identifies patients at highest risk for hematoma expansion: the spot sign score. Stroke 2009; 40:2994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/53\">",
"      Goldstein JN, Fazen LE, Snider R, et al. Contrast extravasation on CT angiography predicts hematoma expansion in intracerebral hemorrhage. Neurology 2007; 68:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/54\">",
"      Wada R, Aviv RI, Fox AJ, et al. CT angiography \"spot sign\" predicts hematoma expansion in acute intracerebral hemorrhage. Stroke 2007; 38:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/55\">",
"      Delgado Almandoz JE, Yoo AJ, Stone MJ, et al. The spot sign score in primary intracerebral hemorrhage identifies patients at highest risk of in-hospital mortality and poor outcome among survivors. Stroke 2010; 41:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/56\">",
"      Rodriguez-Luna D, Rubiera M, Ribo M, et al. Ultraearly hematoma growth predicts poor outcome after acute intracerebral hemorrhage. Neurology 2011; 77:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/57\">",
"      Li N, Wang Y, Wang W, et al. Contrast extravasation on computed tomography angiography predicts clinical outcome in primary intracerebral hemorrhage: a prospective study of 139 cases. Stroke 2011; 42:3441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/58\">",
"      Demchuk AM, Dowlatshahi D, Rodriguez-Luna D, et al. Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): a prospective observational study. Lancet Neurol 2012; 11:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/59\">",
"      Evans A, Demchuk A, Symons SP, et al. The spot sign is more common in the absence of multiple prior microbleeds. Stroke 2010; 41:2210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/60\">",
"      Ederies A, Demchuk A, Chia T, et al. Postcontrast CT extravasation is associated with hematoma expansion in CTA spot negative patients. Stroke 2009; 40:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/61\">",
"      Barras CD, Tress BM, Christensen S, et al. Density and shape as CT predictors of intracerebral hemorrhage growth. Stroke 2009; 40:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/62\">",
"      Kannel WB, Wolf PA, Verter J, McNamara PM. Epidemiologic assessment of the role of blood pressure in stroke: the Framingham Study. 1970. JAMA 1996; 276:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/63\">",
"      Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 2007; 38:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/64\">",
"      Kimura Y, Takishita S, Muratani H, et al. Demographic study of first-ever stroke and acute myocardial infarction in Okinawa, Japan. Intern Med 1998; 37:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/65\">",
"      Gebel JM, Broderick JP. Intracerebral hemorrhage. Neurol Clin 2000; 18:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/66\">",
"      Flaherty ML, Woo D, Haverbusch M, et al. Racial variations in location and risk of intracerebral hemorrhage. Stroke 2005; 36:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/67\">",
"      Labovitz DL, Halim A, Boden-Albala B, et al. The incidence of deep and lobar intracerebral hemorrhage in whites, blacks, and Hispanics. Neurology 2005; 65:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/68\">",
"      van Asch CJ, Luitse MJ, Rinkel GJ, et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 2010; 9:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/69\">",
"      Stein M, Misselwitz B, Hamann GF, et al. Intracerebral hemorrhage in the very old: future demographic trends of an aging population. Stroke 2012; 43:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/70\">",
"      Bruno A, Carter S, Qualls C, Nolte KB. Incidence of spontaneous intracerebral hemorrhage among Hispanics and non-Hispanic whites in New Mexico. Neurology 1996; 47:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/71\">",
"      Morgenstern LB, Smith MA, Lisabeth LD, et al. Excess stroke in Mexican Americans compared with non-Hispanic Whites: the Brain Attack Surveillance in Corpus Christi Project. Am J Epidemiol 2004; 160:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/72\">",
"      Lovelock CE, Molyneux AJ, Rothwell PM, Oxford Vascular Study. Change in incidence and aetiology of intracerebral haemorrhage in Oxfordshire, UK, between 1981 and 2006: a population-based study. Lancet Neurol 2007; 6:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/73\">",
"      Woo D, Sauerbeck LR, Kissela BM, et al. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke 2002; 33:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/74\">",
"      Woo D, Haverbusch M, Sekar P, et al. Effect of untreated hypertension on hemorrhagic stroke. Stroke 2004; 35:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/75\">",
"      Feldmann E, Broderick JP, Kernan WN, et al. Major risk factors for intracerebral hemorrhage in the young are modifiable. Stroke 2005; 36:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/76\">",
"      Zia E, Hedblad B, Pessah-Rasmussen H, et al. Blood pressure in relation to the incidence of cerebral infarction and intracerebral hemorrhage. Hypertensive hemorrhage: debated nomenclature is still relevant. Stroke 2007; 38:2681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/77\">",
"      Thrift AG, McNeil JJ, Forbes A, Donnan GA. Three important subgroups of hypertensive persons at greater risk of intracerebral hemorrhage. Melbourne Risk Factor Study Group. Hypertension 1998; 31:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/78\">",
"      Jackson CA, Sudlow CL. Is hypertension a more frequent risk factor for deep than for lobar supratentorial intracerebral haemorrhage? J Neurol Neurosurg Psychiatry 2006; 77:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/79\">",
"      Ritter MA, Droste DW, Heged&uuml;s K, et al. Role of cerebral amyloid angiopathy in intracerebral hemorrhage in hypertensive patients. Neurology 2005; 64:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/80\">",
"      Arima H, Tzourio C, Anderson C, et al. Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke 2010; 41:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/81\">",
"      Ariesen MJ, Claus SP, Rinkel GJ, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke 2003; 34:2060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/82\">",
"      Sturgeon JD, Folsom AR, Longstreth WT Jr, et al. Risk factors for intracerebral hemorrhage in a pooled prospective study. Stroke 2007; 38:2718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/83\">",
"      Thrift AG, McNeil JJ, Forbes A, Donnan GA. Risk factors for cerebral hemorrhage in the era of well-controlled hypertension. Melbourne Risk Factor Study (MERFS) Group. Stroke 1996; 27:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/84\">",
"      Giroud M, Creisson E, Fayolle H, et al. Risk factors for primary cerebral hemorrhage: a population-based study--the Stroke Registry of Dijon. Neuroepidemiology 1995; 14:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/85\">",
"      Iribarren C, Jacobs DR, Sadler M, et al. Low total serum cholesterol and intracerebral hemorrhagic stroke: is the association confined to elderly men? The Kaiser Permanente Medical Care Program. Stroke 1996; 27:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/86\">",
"      Gonz&aacute;lez-Duarte A, Cant&uacute; C, Ru&iacute;z-Sandoval JL, Barinagarrementeria F. Recurrent primary cerebral hemorrhage: frequency, mechanisms, and prognosis. Stroke 1998; 29:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/87\">",
"      Segal AZ, Chiu RI, Eggleston-Sexton PM, et al. Low cholesterol as a risk factor for primary intracerebral hemorrhage: A case-control study. Neuroepidemiology 1999; 18:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/88\">",
"      Yano K, Reed DM, MacLean CJ. Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke 1989; 20:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/89\">",
"      Shinkawa A, Ueda K, Hasuo Y, et al. Seasonal variation in stroke incidence in Hisayama, Japan. Stroke 1990; 21:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/90\">",
"      Noda H, Iso H, Irie F, et al. Low-density lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage: the Ibaraki Prefectural Health Study. Circulation 2009; 119:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/91\">",
"      Woo D, Kissela BM, Khoury JC, et al. Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study. Stroke 2004; 35:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/92\">",
"      Amarenco P, Labreuche J, Lavall&eacute;e P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004; 35:2902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/93\">",
"      Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/94\">",
"      Leker RR, Khoury ST, Rafaeli G, et al. Prior use of statins improves outcome in patients with intracerebral hemorrhage: prospective data from the National Acute Stroke Israeli Surveys (NASIS). Stroke 2009; 40:2581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/95\">",
"      Hackam DG, Austin PC, Huang A, et al. Statins and intracerebral hemorrhage: a retrospective cohort study. Arch Neurol 2012; 69:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/96\">",
"      Hackam DG, Woodward M, Newby LK, et al. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation 2011; 124:2233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/97\">",
"      Bos MJ, Koudstaal PJ, Hofman A, Breteler MM. Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam Study. Stroke 2007; 38:3127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/98\">",
"      Shimizu Y, Maeda K, Imano H, et al. Chronic kidney disease and drinking status in relation to risks of stroke and its subtypes: the Circulatory Risk in Communities Study (CIRCS). Stroke 2011; 42:2531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/99\">",
"      Biffi A, Sonni A, Anderson CD, et al. Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol 2010; 68:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/100\">",
"      Weng YC, Sonni A, Labelle-Dumais C, et al. COL4A1 mutations in patients with sporadic late-onset intracerebral hemorrhage. Ann Neurol 2012; 71:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/101\">",
"      Flaherty ML, Tao H, Haverbusch M, et al. Warfarin use leads to larger intracerebral hematomas. Neurology 2008; 71:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/102\">",
"      He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 1998; 280:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/103\">",
"      Hart RG, Halperin JL, McBride R, et al. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol 2000; 57:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/104\">",
"      Gorelick PB, Weisman SM. Risk of hemorrhagic stroke with aspirin use: an update. Stroke 2005; 36:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/105\">",
"      Thrift AG, McNeil JJ, Forbes A, Donnan GA. Risk of primary intracerebral haemorrhage associated with aspirin and non-steroidal anti-inflammatory drugs: case-control study. BMJ 1999; 318:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/106\">",
"      Bak S, Andersen M, Tsiropoulos I, et al. Risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nested case-control study. Stroke 2003; 34:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/107\">",
"      Johnsen SP, Pedersen L, Friis S, et al. Nonaspirin nonsteroidal anti-inflammatory drugs and risk of hospitalization for intracerebral hemorrhage: a population-based case-control study. Stroke 2003; 34:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/108\">",
"      Choi NK, Park BJ, Jeong SW, et al. Nonaspirin nonsteroidal anti-inflammatory drugs and hemorrhagic stroke risk: the Acute Brain Bleeding Analysis study. Stroke 2008; 39:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/109\">",
"      Toyoda K, Yasaka M, Uchiyama S, et al. Blood pressure levels and bleeding events during antithrombotic therapy: the Bleeding with Antithrombotic Therapy (BAT) Study. Stroke 2010; 41:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/110\">",
"      Faught E, Peters D, Bartolucci A, et al. Seizures after primary intracerebral hemorrhage. Neurology 1989; 39:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/111\">",
"      Passero S, Rocchi R, Rossi S, et al. Seizures after spontaneous supratentorial intracerebral hemorrhage. Epilepsia 2002; 43:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/112\">",
"      Vespa PM, O'Phelan K, Shah M, et al. Acute seizures after intracerebral hemorrhage: a factor in progressive midline shift and outcome. Neurology 2003; 60:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/113\">",
"      Claassen J, Jett&eacute; N, Chum F, et al. Electrographic seizures and periodic discharges after intracerebral hemorrhage. Neurology 2007; 69:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/114\">",
"      Davis AM, Natelson BH. Brain-heart interactions. The neurocardiology of arrhythmia and sudden cardiac death. Tex Heart Inst J 1993; 20:158.",
"     </a>",
"    </li>",
"    <li>",
"     Stroke pathophysiology, diagnosis, and management, Barnett HJ, Mohr JP, Stein BM (Eds), Churchill Livingstone, Philadelphia 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/116\">",
"      Kidwell CS, Wintermark M. Imaging of intracranial haemorrhage. Lancet Neurol 2008; 7:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/117\">",
"      Lovelock CE, Anslow P, Molyneux AJ, et al. Substantial observer variability in the differentiation between primary intracerebral hemorrhage and hemorrhagic transformation of infarction on CT brain imaging. Stroke 2009; 40:3763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/118\">",
"      Kothari RU, Brott T, Broderick JP, et al. The ABCs of measuring intracerebral hemorrhage volumes. Stroke 1996; 27:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/119\">",
"      Beslow LA, Ichord RN, Kasner SE, et al. ABC/XYZ estimates intracerebral hemorrhage volume as a percent of total brain volume in children. Stroke 2010; 41:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/120\">",
"      Morgenstern LB, Hemphill JC 3rd, Anderson C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010; 41:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/121\">",
"      Edelman RR, Johnson K, Buxton R, et al. MR of hemorrhage: a new approach. AJNR Am J Neuroradiol 1986; 7:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/122\">",
"      Patel MR, Edelman RR, Warach S. Detection of hyperacute primary intraparenchymal hemorrhage by magnetic resonance imaging. Stroke 1996; 27:2321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/123\">",
"      Schellinger PD, Jansen O, Fiebach JB, et al. A standardized MRI stroke protocol: comparison with CT in hyperacute intracerebral hemorrhage. Stroke 1999; 30:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/124\">",
"      Linfante I, Llinas RH, Caplan LR, Warach S. MRI features of intracerebral hemorrhage within 2 hours from symptom onset. Stroke 1999; 30:2263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/125\">",
"      Kidwell CS, Saver JL, Mattiello J, et al. Diffusion-perfusion MR evaluation of perihematomal injury in hyperacute intracerebral hemorrhage. Neurology 2001; 57:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/126\">",
"      Fiebach JB, Schellinger PD, Gass A, et al. Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage: a multicenter study on the validity of stroke imaging. Stroke 2004; 35:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/127\">",
"      Kidwell CS, Chalela JA, Saver JL, et al. Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA 2004; 292:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/128\">",
"      Cordonnier C, Klijn CJ, van Beijnum J, Al-Shahi Salman R. Radiological investigation of spontaneous intracerebral hemorrhage: systematic review and trinational survey. Stroke 2010; 41:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/129\">",
"      Kase CS, Robinson RK, Stein RW, et al. Anticoagulant-related intracerebral hemorrhage. Neurology 1985; 35:943.",
"     </a>",
"    </li>",
"    <li>",
"     Kase CS. Bleeding disorders. In: Intracerebral Hemorrhage, Kase CS, Caplan LR (Eds), Butterworth-Heinemann, Boston 1994. p.117.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/131\">",
"      Alberico RA, Patel M, Casey S, et al. Evaluation of the circle of Willis with three-dimensional CT angiography in patients with suspected intracranial aneurysms. AJNR Am J Neuroradiol 1995; 16:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/132\">",
"      Edelman RR, Mattle HP, Atkinson DJ, Hoogewoud HM. MR angiography. AJR Am J Roentgenol 1990; 154:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/133\">",
"      Oleinik A, Romero JM, Schwab K, et al. CT angiography for intracerebral hemorrhage does not increase risk of acute nephropathy. Stroke 2009; 40:2393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/28/29130/abstract/134\">",
"      Wong GK, Siu DY, Abrigo JM, et al. Computed tomographic angiography and venography for young or nonhypertensive patients with acute spontaneous intracerebral hemorrhage. Stroke 2011; 42:211.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1133 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.80.101-607E99995B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_28_29130=[""].join("\n");
var outline_f28_28_29130=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H121289585\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Etiologies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cerebral microbleeds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mechanisms of brain injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hemorrhage enlargement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antithrombotic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neurologic signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Putamenal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Cerebellar hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Thalamic hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Lobar hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Pontine hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Head CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Brain MRI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2513592\">",
"      - Hemorrhage appearance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Microbleeds",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2513599\">",
"      - Underlying etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Other studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H121289585\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1133\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1133|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/23/6526\" title=\"figure 1\">",
"      Time course cerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/5/88\" title=\"figure 2\">",
"      Headache and vomiting in stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1133|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/19/23864\" title=\"picture 1\">",
"      MRI of hyperacute ICH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8089?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32872?source=related_link\">",
"      Brain arteriovenous malformations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37001?source=related_link\">",
"      Cerebral amyloid angiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/42/26274?source=related_link\">",
"      Patient information: Arteriovenous malformations in the brain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/34/22050?source=related_link\">",
"      Patient information: Hemorrhagic stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/63/8180?source=related_link\">",
"      Patient information: Hemorrhagic stroke treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=related_link\">",
"      Platelet dysfunction in uremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=related_link\">",
"      Risk of intracerebral hemorrhage in patients treated with warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18584?source=related_link\">",
"      Vascular malformations of the central nervous system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_28_29131="Timing first exam for ROP";
var content_f28_28_29131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Timing of first eye examination for retinopathy of prematurity based upon gestational age at birth*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Gestational age at birth",
"        <br/>",
"        (weeks)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chronologic age at initial examination",
"        <br/>",
"        (weeks)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        22",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        23",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        24",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        25",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        26",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        27-30",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        31-32",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The above schedule detects prethreshold ROP with 99 percent confidence, usually well before any required treatment.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Because of the small numbers of survivors in these gestational categories, this guideline should be considered tentative rather than evidence based.",
"     <br/>",
"     &Delta; If necessary.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_28_29131=[""].join("\n");
var outline_f28_28_29131=null;
var title_f28_28_29132="Consensus statement ov ca";
var content_f28_28_29132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76135&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ovarian cancer symptoms consensus statement",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Historically, ovarian cancer was called the \"silent killer\" because symptoms were not thought to develop until the chance of cure was poor. However, recent studies have shown this term is untrue and that the following symptoms are much more likely to occur in women with ovarian cancer than in women in the general population.",
"        <strong>",
"         These symptoms include",
"        </strong>",
"        <sup>",
"         [1,2]",
"        </sup>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Bloating",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Pelvic or abdominal pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Difficulty eating or feeling full quickly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Urinary symptoms (urgency or frequency)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women with ovarian cancer report that symptoms are persistent and represent a change from normal for their bodies. The frequency and/or number of such symptoms are key factors in the diagnosis of ovarian cancer",
"        <sup>",
"         [3]",
"        </sup>",
"        . Several studies show that even early stage ovarian cancer can produce these symptoms",
"        <sup>",
"         [2-6]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women who have these symptoms almost daily for more than a few weeks should see their doctor, preferably a gynecologist. Prompt medical evaluation may lead to detection at the earliest possible stage of the disease. Early stage diagnosis is associated with an improved prognosis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Several other symptoms have been commonly reported by women with ovarian cancer",
"        <sup>",
"         [2-5]",
"        </sup>",
"        . These symptoms include fatigue, indigestion, back pain, pain with intercourse, constipation, and menstrual irregularities. However, these other symptoms are not as useful in identifying ovarian cancer because they are also found in equal frequency in women in the general population who do not have ovarian cancer",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gynecologic Cancer Foundation (",
"     <a href=\"file://www.wcn.org\" style=\"FONT-STYLE: italic\">",
"      www.wcn.org",
"     </a>",
"     ).",
"     <br>",
"      1. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care. JAMA 2004; 291:2705. Level II-2.",
"      <br>",
"       2. Olson SH, Mignone L, Nakaraseive C, et al. Symptoms of ovarian cancer. Obstet Gynecol 2001; 98:212. Level II-2.",
"       <br>",
"        3. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis: results of a national ovarian cancer survey. Cancer 2000; 89:2068. Level III.",
"        <br>",
"         4. Vine MF, Ness RB, Calingaert B, et al. Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor. Gynecol Oncol 2001; 83:466. Level III.",
"         <br>",
"          5. Yawn BP, Barrette BA, Wollan PC. Ovarian cancer: the neglected diagnosis. Mayo Clin Proc 2004; 79:1277. Level III.",
"          <br>",
"           6. Goff BA, Mandel L, Drescher CW, et al. Development of an ovarian cancer symptom index. Cancer 2007; 109:221. Level II-2.",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_28_29132=[""].join("\n");
var outline_f28_28_29132=null;
var title_f28_28_29133="Hyphema rapid overview";
var content_f28_28_29133=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Overview of traumatic hyphema",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        History",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Typically caused by blunt trauma to the orbit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Associated injuries: Head trauma, orbital fracture, posterior segment injury (vitreous, retina, choroid, and/or optic nerve), and open globe (rare)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risk factors for poor outcome: Sickle cell disease or trait, bleeding tendency (eg, hemophilia, von Willebrand disease, or anticoagulated)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Causes of spontaneous hyphema (rare): Diabetes mellitus, clotting disorder, or eye tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Signs of open globe:",
"        <span class=\"red\">",
"         Emergent ophthalmology consultation indicated if present!",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Markedly decreased visual acuity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Eccentric pupil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Markedly increased or decreased anterior chamber depth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Extrusion of ocular contents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Tenting of the sclera at site of globe puncture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Large circumferential subconjunctival hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Clinical findings of hyphema:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Decreased visual acuity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Eye pain with pupillary constriction to bright light (direct and consensual)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Blood in the anterior chamber either grossly visible (hyphema) or visible with slit lamp exam (microhyphema)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Damage to adjacent structures or abnormal IOP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull;",
"        <span class=\"red\">",
"         Caution! Only measure IOP once globe rupture is excluded",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnostic evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Comprehensive eye examination including intraocular pressure (if not contraindicated by concern for ruptured globe)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solubility testing (eg, Sickledex&reg;) or hemoglobin electrophoresis in patients of African or Mediterranean descent with uncertain sickle hemoglobin status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CBC, PT, PTT, INR for patients with bleeding dyscrasia. Other blood and urine studies based on presence and degree of other injuries.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Orbital computed tomography (CT) without contrast with 1 to 2 mm axial and coronal cuts through the orbits as indicated:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Concern for ruptured globe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Concern for intraocular foreign body",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Trauma patients undergoing cranial CT for other indications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Concern for orbital fracture (palpable step-off of inferior orbital ridge, limited extraocular movement, or significant periocular swelling)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Initial treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assess and treat life-threatening injuries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid succinylcholine if rapid sequence intubation is required and globe rupture is suspected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treat any underlying bleeding dyscrasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Place an eye shield over the affected eye and maintain except during eye examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevate the patient's head to 30 degrees and maintain the patient at bed rest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Instill cyclopentolate one percent (Cyclogyl&reg;), one drop, or scopolamine 0.25 percent, one drop; to dilate pupil for examination and for pain relief",
"        <span class=\"red\">",
"         (Caution! Only perform if globe rupture is excluded)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide additional pain control with proparacaine or tetracaine ophthalmic (1 drop to affected eye,",
"        <span class=\"red\">",
"         [Caution! Only perform if globe rupture is excluded]",
"        </span>",
"        ); oxycodone (0.15 mg/kg) with acetaminophen (15 mg/kg, maximum dose 1 gram); and/or IV morphine (0.1-0.15 mg/kg) or fentanyl (1 to 2 micrograms/kg), as needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do not give NSAIDs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administer high-dose ondansetron (0.15 mg/kg up to 12 mg) for nausea or vomiting*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ensure definitive management by an ophthalmologist",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IOP: intraocular pressure; NSAID: non-steroidal antiinflammatory drug (eg, ibuprofen, ketorolac).",
"     <br>",
"      * Ondansetron should be AVOIDED in patients with congenital long QT syndrome. ECG monitoring should be performed for patients receiving ondansetron who also have the following conditions: electrolyte abnormalities (eg, hypokalemia, hypomagnesemia), congestive heart failure, or bradyarrhythmias, or are taking medications that prolong the QT interval.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_28_29133=[""].join("\n");
var outline_f28_28_29133=null;
var title_f28_28_29134="Low dose E and BMD";
var content_f28_28_29134=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F50951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F50951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Effect of estrogen dose on change in bone mineral density (BMD) in postmenopausal women",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 322px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean percentage of change from baseline in lumbar spine (L1-4) BMD measured by dual x-ray absorptiometry (DXA). Placebo (diamonds), esterified estrogens: 0.3 mg (squares), 0.625 mg (triangles), 1.25 mg (circles). BMD changes at all timepoints and at all esterified estrogens doses were significantly different from those occurring with placebo use.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Genant HK, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group.&nbsp;Arch Intern Med 1997; 157:2609.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_28_29134=[""].join("\n");
var outline_f28_28_29134=null;
var title_f28_28_29135="Contents: Neuromuscular disease";
var content_f28_28_29135=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/63/1022\">",
"       Neurology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Neuromuscular disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Neuromuscular disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Acquired noninflammatory muscle disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/33/10777\">",
"           Causes of rhabdomyolysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/55/32632\">",
"           Clinical manifestations and diagnosis of rhabdomyolysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/31/1526\">",
"           Diabetic muscle infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/44/6856\">",
"           Drug-induced myopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/40/23173\">",
"           Glucocorticoid-induced myopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29093\">",
"           Hypothyroid myopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/9/2201\">",
"           Major causes of musculoskeletal chest pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/37/4695\">",
"           Muscle disease in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/53/22358\">",
"           Musculoskeletal complications in diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/12/23753\">",
"           Musculoskeletal manifestations of systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/51/14137\">",
"           Myopathies of systemic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/60/43976\">",
"           Neuromuscular weakness related to critical illness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/38/4711\">",
"           Nocturnal leg cramps",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/20/35142\">",
"           Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/0/33802\">",
"           Statin myopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/41/665\">",
"           Stiff-person syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Channnelopathies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/54/871\">",
"           Hyperkalemic periodic paralysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/62/9193\">",
"           Hypokalemic periodic paralysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/38/22119\">",
"           Thyrotoxic periodic paralysis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Clinical evaluation of neuromuscular disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/4/26694\">",
"           Approach to the patient with muscle weakness",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diagnostic methods",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/13/27863\">",
"           Clinical neurophysiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/33/30232\">",
"           Diagnostic ultrasound in neuromuscular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/40/13962\">",
"           Electrodiagnostic evaluation of the neuromuscular junction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/29/13785\">",
"           Motor unit number estimation (MUNE)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/56/36745\">",
"           Muscle enzymes in the evaluation of neuromuscular diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/24/29060\">",
"           Muscle examination in the evaluation of weakness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/21/39251\">",
"           Nerve conduction studies: Late responses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/46/1769\">",
"           Overview of electromyography",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/31/2554\">",
"           Overview of nerve conduction studies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Focal nerve syndromes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/14/14570\">",
"           Polyradiculopathy: spinal stenosis, infectious, carcinomatous, and inflammatory nerve root syndromes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Inflammatory myopathies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/4/27722\">",
"           Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/23/15735\">",
"           Clinical manifestations and diagnosis of inclusion body myositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/22/11626\">",
"           Initial treatment of dermatomyositis and polymyositis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/7/24697\">",
"           Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/42/38566\">",
"           Malignancy in dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/37/4695\">",
"           Muscle disease in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/43/29368\">",
"           Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/8/42121\">",
"           Pathogenesis of inflammatory myopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/11/32950\">",
"           Pyomyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/0/33802\">",
"           Statin myopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/30/28133\">",
"           Treatment and prognosis of inclusion body myositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/5/2138\">",
"           Treatment and prognosis of juvenile dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/48/13065\">",
"           Treatment of recurrent and resistant dermatomyositis and polymyositis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/41/9879\">",
"           Viral myositis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Inherited muscle disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/56/905\">",
"           Approach to the metabolic myopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/36/21065\">",
"           Causes of metabolic myopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/16/1290\">",
"           Clinical features and diagnosis of Duchenne and Becker muscular dystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/58/21415\">",
"           Emery-Dreifuss muscular dystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/63/6134\">",
"           Energy metabolism in muscle",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/34/26153\">",
"           Facioscapulohumeral muscular dystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/31/44530\">",
"           Lactate dehydrogenase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/32/15881\">",
"           Limb-girdle muscular dystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/20/17736\">",
"           Lysosomal acid maltase deficiency (glycogen storage disease II, Pompe disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/19/43315\">",
"           Lysosome-associated membrane protein 2 deficiency (glycogen storage disease IIb, Danon disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/12/7370\">",
"           Mitochondrial myopathies: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/30/2536\">",
"           Mitochondrial myopathies: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/35/12853\">",
"           Mitochondrial structure, function, and genetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/23/23928\">",
"           Muscle phosphorylase deficiency (glycogen storage disease V, McArdle disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/26/19882\">",
"           Myotonic dystrophy: Etiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/40/18057\">",
"           Myotonic dystrophy: Prognosis and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/14/41192\">",
"           Oculopharyngeal, distal, and congenital muscular dystrophies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/35/40500\">",
"           Other disorders of glycogen metabolism: GLUT2 deficiency and aldolase A deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/16/4356\">",
"           Overview of inherited disorders of glucose and glycogen metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/59/28596\">",
"           Phosphofructokinase deficiency (glycogen storage disease VII, Tarui disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/19/44341\">",
"           Phosphoglycerate kinase deficiency and phosphoglycerate mutase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/2/26666\">",
"           Treatment of Duchenne and Becker muscular dystrophy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Motor system diseases",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/21/40280\">",
"           Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/34/16938\">",
"           Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/44/23240\">",
"           Disease modifying treatment of amyotrophic lateral sclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/57/23450\">",
"           Epidemiology and pathogenesis of amyotrophic lateral sclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/48/16138\">",
"           Familial amyotrophic lateral sclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/44/36553\">",
"           Polio and infectious diseases of the anterior horn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/45/5849\">",
"           Post-polio syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/26/33193\">",
"           Symptom-based management of amyotrophic lateral sclerosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neuromuscular junction disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/17/11546\">",
"           Chronic immunomodulating therapies for myasthenia gravis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/9/35992\">",
"           Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/51/17206\">",
"           Clinical manifestations of myasthenia gravis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/12/32968\">",
"           Diagnosis of myasthenia gravis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/18/15654\">",
"           Differential diagnosis of myasthenia gravis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/45/36567\">",
"           Management of myasthenia gravis in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/10/6311\">",
"           Myasthenic crisis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/53/7001\">",
"           Ocular myasthenia gravis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/45/41688\">",
"           Overview of neuromuscular junction toxins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/35/31287\">",
"           Pathogenesis of myasthenia gravis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/59/41910\">",
"           Thymectomy for myasthenia gravis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/43/2744\">",
"           Treatment of Lambert-Eaton myasthenic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/57/7066\">",
"           Treatment of myasthenia gravis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neuropathies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/22/5481\">",
"           Clinical features and diagnosis of Guillain-Barr������ syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/32/8712\">",
"           Differential diagnosis of peripheral nerve and muscle disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/60/43976\">",
"           Neuromuscular weakness related to critical illness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/6/40038\">",
"           Pathogenesis of Guillain-Barr������ syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/14/14570\">",
"           Polyradiculopathy: spinal stenosis, infectious, carcinomatous, and inflammatory nerve root syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/16/265\">",
"           Treatment and prognosis of Guillain-Barr������ syndrome in adults",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-64C8D081E4-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f28_28_29135=[""].join("\n");
var outline_f28_28_29135=null;
